Onkološki inštitut Ljubljana
Institute of Oncology Ljubljana

EPIDEMIOLOGIJA IN REGISTER RAKA
EPIDEMIOLOGY AND CANCER REGISTRY

Rak v Sloveniji 2016

Cancer in Slovenia

Rak v Sloveniji 2016

Cancer in Slovenia

Naslov / Title
Rak v Sloveniji 2016 / Cancer in Slovenia 2016

Uredniški odbor / Editorial Board
Vesna Zadnik, glavna urednica / editor-in-chief
Gorana Gašljević, Marko Hočevar, Urška Ivanuš,
Katja Jarm, Vera Pompe-Kirn, Primož Strojan,
Sonja Tomšič, Branko Zakotnik in Tina Žagar

Računalniška obdelava / EDP analysis
Tina Žagar, Katarina Lokar in Miran Mlakar

Oblikovanje in priprava za tisk / Design & Typesetting
Studio N, studio za oblikovanje in grafično pripravo, Ljubljana

Tisk / Printing
GRAFEX d.o.o., Izlake

Izdajatelj / Published by
Onkološki inštitut Ljubljana / Insitute of Oncology Ljubljana, Slovenia
Epidemiologija in register raka / Epidemiology and Cancer Registry
Register raka Republike Slovenije / Slovenian Cancer Registry

Naklada / Published in
600 izvodov / 600 copies

Nasvet za citiranje / Recommended reference
Rak v Sloveniji 2016. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2019.
Cancer in Slovenia 2016. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry, 2019.

Osebje Registra raka Republike Slovenije / Staff of the Slovenian Cancer Registry
Vesna Zadnik, vodja / head
Maruška Ferjančič, Andrej Kirn, Andrej Krašovec, Katarina Lokar, Darja Strle,
Fani Škrlec, Polona Škulj, Nataša Šturm, Urška Tomšič in Tina Žagar

Naslov / Correspondence to
Register raka Republike Slovenije / Slovenian Cancer Registry
Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana
Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija
Telefon / Phone: + 386 1 5879 450
E-pošta / E-mail: register@onko-i.si
Spletna stran / Web site:
http://www.onko-i.si/rrs/ http://www.slora.si/
http://www.onko-i.si/crs/ http://www.slora.si/en/

Vsebina

Contents

Uvod ... 7

Viri podatkov in metode registracije ... 9

Viri podatkov ... 9

Priprava podatkov za računalniško obdelavo ... 10

Kakovost podatkov RRRS in popolnost registracije ... 11

Statistične metode ... 12

Incidenca in umrljivost ... 12

Grobe in starostno specifične stopnje ... 12

Starostno standardizirane stopnje ... 12

Kumulativne stopnje in kumulativno tveganje ... 13

Prevalenca ... 13

Preživetje ... 14

Prebivalstvo Slovenije ... 15

Rak v Sloveniji 2016 ... 16

Zahvala ... 20

Introduction ... 21

Data sources and methods of registration ... 23

Data sources ... 23

Preparation of data for computer processing ... 24

Data quality and completeness of registration ... 25

Statistical methods ... 27

Incidence and mortality ... 27

Crude and age specific rates ... 27

Age standardised rates ... 27

Cumulative incidence rate and cumulative risk ... 28

Prevalence ... 28

Survival ... 28

Population of Slovenia ... 30

Cancer in Slovenia 2016 ... 31

Acknowledgment ... 35

Reference / References ... 36

Slike / Figures

Slika 1: Breme raka, Slovenija 2016. 38
Figure 1: Cancer burden, Slovenia 2016.

Slika 2: Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2016. 38
Figure 2: Percentage distribution of all cancer sites by age group and by sex, Slovenia 2016.

Slika 3: Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2016. 39
Figure 3: The leading cancer sites with percentage distribution by sex and for both sexes together, Slovenia 2016.

Slika 4: Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2016. 40
Figure 4: Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2016.

Slika 5: Groba letna incidenčna stopnja izbranih rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2016. 41
Figure 5: Crude annual incidence rates of selected primary cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2016.

Slika 6: Pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2007–2011 in 2012–2016 po spolu. 42
Figure 6: Five-year net survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2007–2011 and 2012–2016 by sex.

Slika 7a: Časovni trend grobe letne incidenčne stopnje raka materničnega vratu (C53) po stadijih s povrečno letno spremembo za tri obdobja: pred pričetkom presejalnega programa ZORA (1987–1996), v času pilotnega presejanja (1997–2002) in od pričetka presejalnega programa ZORA (2003–2016), Slovenija 1987–2016. 44
Figure 7a: Time trend of crude annual incidence rates for cervical cancer (C53) by stage with avarage annual change for three periods: before the start of screening program ZORA (1987–1996), during pilot screening (1997–2002) and since the start of screening programme ZORA (2003–2016), Slovenia 1987–2016.

Slika 7b: Delež žensk z rakom materničnega vratu (C53) glede na udeležbo v presejalnem programu ZORA in FIGO stadij, Slovenija 2012–2016. 44
Figure 7b: Proportion of women with cervical cancer (C53) according to attendance in organised screening programme ZORA and FIGO stage, Slovenia 2012–2016.

Slika 7c: Čisto preživetje bolnic z rakom materničnega vratu starih 20–64 let s 95 % intervalom zaupanja glede na udeležbo v presejalnem programu ZORA, Slovenija 2012–2016. 45
Figure 7c: Net survival of cervical cancer (women aged 20–64 years) with 95% confidence interval according to attendance in organised screening programme ZORA, Slovenia 2012–2016.

Slika 7d: Čisto preživetje bolnic z rakom materničnega vratu starih 20–64 let po FIGO stadiju glede na udeležbo v presejalnem programu ZORA, Slovenija 2012–2016. 45
Figure 7d: Net survival of cervical cancer (women aged 20–64 years) by FIGO stage according to attendance in organised screening programme ZORA, Slovenia 2012–2016.

Slika 8a: Časovni trend grobe letne incidenčne stopnje raka dojk pri ženskah (C50) po stadijih s povrečno letno spremembo za dve obdobji: pred pričetkom presejalnega programa DORA (1987–2010) in od pričetka presejalnega programa DORA (2011–2016), Slovenija 1987–2016. 46
Figure 8a: Time trend of crude annual incidence rates for breast cancer in women (C50) by stage with avarage annual change for two periods: before the start of screening program DORA (1987–2010) and since the start of screening programme DORA (2011–2016), Slovenia 1987–2016.

Slika 8b: Delež žensk z rakom dojke (C50) glede na udeležbo v presejalnem programu DORA in UICC stadij, Slovenija 2012–2016. 46
Figure 8b: Proportion of women with breast cancer (C50) according to attendance in organised screening programme DORA and UICC stage, Slovenia 2012–2016.

Slika 8c: Čisto preživetje bolnic z rakom dojk starih 50–69 let s 95 % intervalom zaupanja glede na udeležbo v presejalnem programu DORA, Slovenija 2012–2016. 47
Figure 8c: Net survival of breast cancer (women aged 50–69 years) with 95% confidence interval according to attendance in organised screening programme DORA, Slovenia 2012–2016.

Slika 8d: Čisto preživetje bolnic z rakom dojk starih 50–69 let po UICC stadiju glede na udeležbo v presejalnem programu DORA, Slovenija 2012–2016 47
Figure 8d: Net survival of breast cancer (women aged 50–69 years) by UICC stage according to attendance in organised screening programme DORA, Slovenia 2012–2016.

Slika 9a: Časovni trend grobe letne incidenčne stopnje raka debelega črevesa in danke (C18–C20) za oba spola skupaj po stadijih s povrečno letno spremembo za dve obdobji: pred pričetkom presejalnega programa Svit (1987–2009) in od pričetka presejalnega programa Svit (2010–2016), Slovenija 1987–2016. 48
Figure 9a: Time trend of crude annual incidence rates for colon and rectum cancers (C18–C20) for both sexes together by stage with avarage annual change for two periods: before the start of screening program Svit (1987–2009) and since the start of screening programme Svit (2010–2016), Slovenia 1987–2016.

Slika 9b: Delež bolnikov z rakom debelega črevesa in danke (C18–C20) glede na udeležbo v presejalnem programu Svit in UICC stadij, Slovenija 2012–2016. 48
Figure 9b: Proportion of patients with colon and rectum cancer (C18–C20) according to attendance in organised screening programme Svit and UICC stage, Slovenia 2012–2016.

Slika 9c: Čisto preživetje bolnikov z rakom debelega črevesa in danke starih 50–74 let s 95 % intervalom zaupanja glede na udeležbo v presejalnem programu Svit, Slovenija 2012–2016. 49
Figure 9c: Net survival of colorectal cancer (patients aged 50–74 years) with 95% confidence interval according to attendance in organised screening programme Svit, Slovenia 2012–2016.

Slika 9d: Čisto preživetje bolnikov z rakom debelega črevesa in danke starih 50–74 let po UICC stadiju glede na udeležbo v presejalnem programu Svit, Slovenija 2012–2016. 49
Figure 9d: Net survival of colorectal cancer (patients aged 50–74 years) by UICC stage according to attendance in organised screening programme Svit, Slovenia 2012–2016.

Podatki v tabelah / Data in tables

Tabela 1: Opazovana in ocenjena incidenca raka, Slovenija 2007–2016 in 2019. 50
Table 1: Opazovana in ocenjena incidenca raka, Slovenija 2007–2016 in 2019.

Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2016. 51
Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2016.

Tabela 3: Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2016. 52
Table 3: Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2016.

Tabela 4: Incidenca raka po lokaciji, spolu in starosti, Slovenija 2016. 56
Table 4: Cancer incidence by site, by sex and by age, Slovenia 2016.

Tabela 5: Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter komulativna stopnja (KS) po lokaciji in spolu, Slovenija 2016. 60
Table 5: Crude and age specific cancer incidence rate per 100,000 and comulative rate (CR) by site and by sex, Slovenia 2016.

Tabela 6a: Incidenca po statističnih regijah, spolu in izbrani primarni lokaciji raka, Slovenija 2016. 66
Table 6a: Incidence by statistical regions, by sex and by selected primary cancer site, Slovenia 2016.

Tabela 6b: Starostno standardizirana incidenčna stopnja po statističnih regijah, spolu in izbrani primarni lokaciji raka, Slovenija 2016. 67
Table 6b: Age standardised incidence rate by statistical regions, by sex and by selected primary cancer site, Slovenia 2016.

Tabela 7: Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2016. 68
Table 7: Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2016.

Tabela 8: Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2016. 77
Table 8: Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2016.

Tabela 9: Incidenca ne-Hodgkinovih limfomov po lokaciji, spolu in starosti, Slovenija 2016. 80
Table 9: Incidence of non-Hodgkin´s malignant lymphomas by site, by sex and by age, Slovenia 2016.

Tabela 10: Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, po spolu, Slovenija 2016. 81
Table 10: Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), by sex, Slovenia 2016.

Tabela 11a: Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2016, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemsko terapijo ali obsevani, po izbrani primarni lokaciji raka. ... 83
Table 11a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2016, that were treated by surgery, systemic therapy or radiotherapy during their first treatment by selected primary cancer site.

Tabela 11b: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2016, ki so bili v okviru prvega zdravljenja operirani, po izbrani primarni lokaciji raka in bolnici posega. 84
Table 11b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2016, that were treated by surgery during their first treatment by selected primary cancer site and treatment institution.

Tabela 11c: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2016, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje, po izbrani primarni lokaciji raka in bolnici zdravljenja. 85
Table 11c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2016, that were treated by systemic therapy during their first treatment by selected primary cancer site and treatment institution.

Tabela 12: Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2016. 86
Table 12: Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2016.

Tabela 13: Umrljivost za rakom po lokaciji, spolu in starosti, Slovenija 2016. 87
Table 13: Cancer mortality by site, by sex and by age, Slovenia 2016.

Tabela 14: Eno-, tro- in pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2012–2016 po spolu. 91
Table 14: One-, three- and five-year net survival (with 95% confidence interval) of patients diagnosed with selected cancers in period 2012–2016 by sex.

Izbor publikacij / Selected publications 92

Uvod

Register raka Republike Slovenije (RRRS) je eden najstarejših populacijskih registrov raka v Evropi. Leta 1950 ga je na Onkološkem inštitutu Ljubljana (OI) ustanovila in do leta 1975 vodila pokojna profesorica dr. Božena Ravnihar. Njeno delo je prevzela profesorica dr. Vera Pompe Kirn, ki je do upokojitve leta 2003 skrbela za nadaljnje uveljavljanje RRRS v domačem in mednarodnem merilu. Od leta 2003 je RRRS z Enoto za epidemiologijo posebna služba OI, ki se imenuje Epidemiologija in register raka; do leta 2018 jo je vodila dr. Maja Primic Žakelj. V njej delujejo še *bolnišnični register OI*, ki omogoča podrobnejši pregled nad bolniki, zdravljenimi na OI (ne glede na to, kje imajo stalno prebivališče), in RRRS oskrbuje z velikim delom podatkov, *državni register za vodenje in spremljanje organiziranega presejalnega programa za raka maternicnega vratu* (Register ZORA) in od leta 2007 *informacijski sistem za vabljenje žensk in epidemiološko spremljanje organiziranega presejalnega programa za raka dojk* (Register DORA).

Podatki o raku, incidenci, preživetju in prevalenci, ki se zbirajo v RRRS, so skupaj s podatki o umrljivosti, ki jih zbira in obdeluje Nacionalni inštitut za javno zdravje RS, osnova za ocenjevanje bremena rakavih bolezni v državi. Pomembni so za načrtovanje in ocenjevanje državnega programa obvladovanja raka (DPOR) na področju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za načrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska oprema, bolnišnične zmogljivosti); dragoceni so tudi za klinične in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje učinkovitosti presejalnih programov.

Redna letna poročila RRRS so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih z obdelanimi podatki RRRS. Ker nas omejuje tehnologija zbiranja podatkov, saj je njihovih virov več, je za dokončanje letne zbirke podatkov, njihovo analizo in objavo rezultatov potreben čas, ki je pri nas in v drugih državah podoben, običajno 2 do 3 leta. V poročilih pa zadnja leta objavimo tudi pričakovano incidenco raka v letu, ko je poročilo izdano (v tokratnem poročilu za leto 2019); izračunana je s posebno statistično metodo za napovedovanje incidence raka.

RRRS je prva letna poročila izdal v letih 1953–1957 za leta 1951–1955. Prva analiza podatkov za leto 1950 je bila objavljena v *Zdravstvenem vestniku leta 1951*. Podatki za leta 1957–1971 so bili objavljeni v periodičnih publikacijah Svetovne zdravstvene organizacije *Epidemiological and Vital Statistics* in v *World Health Statistics Report*. Od leta 1965 so bili podatki spet redno objavljani v posebnih letnih poročilih z naslovom *Rak v Sloveniji* (1965–1977 in 2007–2014), v vmesnem obdobju (1978–2006) pod imenom *Incidenca raka v Sloveniji*, in sicer v slovenskem in angleškem jeziku. Poleg letnih poročil so bile objavljene tudi 4 monografije: *Zemljevidi incidence raka v Sloveniji 1978–1987*, *Preživetje bolnikov z rakom v Sloveniji 1963–1990*, *Preživetje bolnikov z rakom v Sloveniji 1983–1997* in *Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji*. Seznam drugih pomembnejših del, objavljenih v zadnjih petih letih, je v dodatku na koncu poročila.

Podatki RRRS so vključeni v številne mednarodne podatkovne zbirke in projekte. Objavljeni so v vseh devetih zvezkih in v deseti elektronski verziji knjige *Rak na petih kontinentih (Cancer Incidence in Five Continents)*, ki jo izdaja Mednarodna

agencija za raziskovanje raka, in v podatkovnih zbirkah *ECO*, *GLOBOCAN* in *ACCIS*. Preživetje slovenskih bolnikov je obdelano v mednarodnih raziskavah *EUROCARE- 2*, *EUROCARE-3*, *EUROCARE-4*, *EUROCARE-5*, *EUROCARE-6*, *CONCORD-1*, *CONCORD-2*, *CONCORD-3*, *RARECARE* in *EUNICE*.

Leta 2010 smo v celoti prenovili računalniško bazo in posodobili obdelavo podatkov v RRRS. Od takrat deluje tudi *interaktivni spletni portal*, ki smo ga poimenovali *SLORA* po začetnih črkah besed »Slovenija in rak«. Dostopen je na elektronskem naslovu www.slora.si. Omogoča preprost in hiter dostop do večine podatkov o raku v Sloveniji, ki jih zbirata RRRS do zaključenega leta obdelave, trenutno 2016 (incidenca, prevalenca in preživetje), in Nacionalni inštitut za javno zdravje RS (umrljivost). S hitrim dostopom do tujih baz omogoča tudi primerjavo bremena raka v Sloveniji z drugimi državami v Evropi in v svetu. Dodane so tudi obširne strokovne razlage, ki pojasnjujejo podatke in seznanjajo uporabnike z nevarnostnimi dejavniki raka, možnostmi zgodnjega odkrivanja in uspešnostjo zdravljenja raka.

Viri podatkov

Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve RRRS (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92, št. 65/00, št. 47/15 in 31/18). Osnovni vir podatkov so *prijavnice rakave bolezni*. Registru jih pošiljajo iz vseh bolnišnic in diagnostičnih centrov v Sloveniji, iz ordinacij osnovnega zdravstvenega varstva pa le izjemoma, če bolnik ni napoten na nadaljnje preiskave in/ali zdravljenje. Dopolnilni vir podatkov so zdravniška poročila o vzroku smrti, ki nam jih pošilja Nacionalni inštitut za javno zdravje RS ter podatki o diagnosticiranih rakih, ki jih zabeležijo v treh državnih presejalnih programih: ZORA za odkrivanje predrakavih in zgodnjih rakavih sprememb na maternicnem vratu, DORA za odkrivanje raka dojk in Svit za odkrivanje predrakavih sprememb in raka na debelem črevesu in danki. S prijavnicami zbiramo osebne podatke, podatke o vrsti bolezni (anatomsko mesto raka, histološka oz. citološka diagnoza, stadij po TNM ali drugi klinični klasifikaciji) in o vrsti zdravljenja. Veliko časa porabimo za poizvedbe o bolnikih, za katere na prijavnicah niso zapisani popolni ali ustrezni podatki ter za tiste o katerih dobimo prvo informacijo šele iz enega od dopolnilnih virov.

Za izračun prevalence in preživetja bolnikov potrebujemo podatek, ki se imenuje *vitalno stanje* (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobimo iz Centralnega registra prebivalstva (CRP), in sicer za vse osebe iz RRRS. Od leta 2010 smo po prenovi računalniške baze s posebej varovano spletno tehnologijo neposredno povezani s CRP, zato ta podatek dobimo dnevno. Pri izgubljenih osebah upoštevamo kot datum izgube datum zadnje prijave oz. datum izgube, kot velja v CRP, odvisno od tega, kateri datum je kasnejši. Od leta 1985, odkar RRRS prejema od CRP enotno matično številko občana (EMŠO), je v RRRS delež izgubljenih manjši od 1 %; pri bolnikih, registriranih v zadnjem desetletju, je znašal le 0,1 %.

Podrobne analize prostorske razporeditve raka nam omogoča točno opredeljevanje naslovov bolnikov z rakom in redna povezava z Registrom prostorskih enot (RPE) Geodetske uprave RS. V Tabeli 6 tako prikazujemo breme raka na ravni 12 statističnih regij kot so bile v slovenskem prostoru v veljavi leta 2016.

Slovenske statistične regije



Priprava podatkov za računalniško obdelavo

Podatke, prispele v RRRS na prijavnicah, posebej usposobljene medicinske sestre najprej kodirajo v skladu z mednarodnimi in v RRRS dogovorjenimi pravili.

Za razvrščanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10), pred tem pa smo uporabljali osmo.

Pri uvrščanju med maligne bolezni je treba opozoriti še na klasifikacijo morfologije neoplazem, za katero uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo. Od leta 2012 uporabljamo njeno tretjo izdajo z dopolnitvami iz leta 2011. V tej izdaji je nekaj novosti, med drugimi navedba, katere histološke vrste sodijo med maligne, in nekaj novih histoloških vrst, ki do tedaj niso bile obravnavane posebej. Tako npr. gastrointestinalne stromalne tumorje (GIST) uvrščamo med posebne histološke vrste šele od leta 2001. V skladu z novimi pravili mejno malignih tumorjev jajčnikov ne uvrščamo več v kategorijo C56, pač pa v D39.1. Po tretji reviziji so med maligne uvrščene kronične mieloproliferativne bolezni in mielodisplastični sindromi (sedaj v topografski šifri C96.7) in policitemije, ki jih od 2001 uvrščamo v skupino C94.

Z razvojem molekularne in genske tehnologije je mogoče natančneje opredeliti vrsto celičnih sprememb, ki nastanejo pri malignomih krvotvornega in limfatičnega tkiva, in jih zato bolj usmerjeno zdraviti. S tem se veča tudi število različnih vrst bolezni, njihovo razvrščanje pa se vedno bolj izpopolnjuje. Svetovna zdravstvena organizacija je leta 2001 objavila posebno klasifikacijo, ki opredeljuje malignome krvotvornega in limfatičnega tkiva glede na imunofenotip, genetske spremembe in klinično sliko. Leta 2008 je bila ta klasifikacija posodobljena in v kliniki zamenjuje številne dodatne klasifikacije malignomov krvotvornega in limfatičnega tkiva. Povzema jo tudi Mednarodna klasifikacija bolezni za onkologijo (3. izdaja, dopolnitev 2011). V Tabeli 10 razvrščamo neoplazme limfatičnega tkiva tudi v skladu z verzijo 2008 klasifikacije Svetovne zdravstvene organizacije.

Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, označene s šifro 234.0 (carcinoma in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji MKB so vse intraepitelijske spremembe materničnega vratu uvrščene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03).

Za prikaz porazdelitve bolezni po stadiju ob diagnozi v letnih poročilih pri solidnih tumorjih uporabljamo poenostavljeno razvrščanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do obdukcije, če bolnik poprej ni bil zdravljen. Poenostavljena opredelitev stadijev praviloma sledi klasifikaciji TNM. V omejen stadij je tako praviloma uvrščen primer bolezni, pri katerem je tumor označen s T1 ali T2. Pri dojki, kožnem melanomu in ščitnici so v omejen stadij vključeni tudi tumorji T3; pri materničnem vratu, materničnem telesu in sarkomih, ter pri jajčniku, jajcevodu in trofoblastnih tumorjih

v omejen stadij sodijo le tumorji T1. Pri omejeni bolezni seveda niso prizadete področne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je primer, pri katerem je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi področne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvrščamo primere, pri katerih je zapisano, da so bili zasevki že v oddaljenih bezgavkah ali organih (M1). V bazi RRRS hranimo tudi podatek o stadiju bolezni po klasifikaciji TNM ali drugih klasifikacijah, če je bil tako opredeljen na prijavnici oz. je bilo na njej vsaj dovolj podatkov za njegovo naknadno opredelitev. Ginekološke tumorje tako opredeljujemo tudi po klasifikaciji FIGO, pri kožnem melanomu pa beležimo tudi velikost po Clarku in Breslowu. Maligni limfomi so opredeljeni po klasifikaciji Ann-Arbor.

Kakovost podatkov RRRS in popolnost registracije

Kakovost podatkov registrov raka opredeljujejo naslednji kazalniki: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških poročil o vzroku smrti. Vrednosti teh kazalcev so prikazane v *Tabeli 3*.

Popolnost registracije kaže delež vseh novih primerov raka na področju, ki ga pokriva register in ki so vključeni v podatkovno zbirko registra. Neposredno jo je mogoče meriti samo s posebnimi raziskavami, namenjenimi oceni popolnosti, npr. s ponovnim pregledom odpustnih diagnoz in popisov bolezni v bolnišnicah ali ambulantah na določenem območju. V Sloveniji takih raziskav zaenkrat še nismo delali, veliko pa nam k popolnosti zajema pomagajo kolegi kliniki, ki jih zanima, kakšno je preživetje bolnikov, zdravljenih pri njih; ko nam pošljejo podatke o svojih skupinah bolnikov, v njih velikokrat najdemo take, ki jih v podatkovni zbirki RRRS še ni.

Na splošno velja, da je popolnost podatkov večja tam, kjer ima register dostop do zdravniških poročil o vzroku smrti. Za tiste, ki so umrli za rakom, pa (še) niso zapisani v registru, RRRS tako išče dodatne podatke. Na ta način se izboljša popolnost registracije rakov s slabo napovedjo izida, ne pa manj usodnih. Domnevamo, da je v Sloveniji – in tudi v drugih evropskih populacijskih registrih raka – manj popolna registracija nemelanomskega kožnega raka in tistih malignomov, ki se zdravijo samo ambulantno.

Incidenca in umrljivost

Incidenca in *umrljivost* pomenita absolutno število vseh na novo ugotovljenih primerov kake bolezni oz. število vseh umrlih za to boleznijo v točno določeni populaciji v enem koledarskem letu. V incidenco raka ne štejemo novih primarnih rakov parnega organa iste lokacije, če je bila histološka vrsta obeh rakov, npr. leve in desne dojke, enaka. Prav tako v incidenco ne štejemo novega pojava raka iste histološke vrste na istem organu, npr. multiple lezije v debelem črevesu. V incidenco so vključeni primeri bolezni bolnikov s stalnim bivališčem na območju Republike Slovenije ne glede na to, kje so bili bolniki zdravljeni.

Za *oceno incidence* v letu 2019 (prikazano v *Tabeli 1*) je uporabljena metoda po Dybi in Hakulinenu, ki je primerna za napoved incidence v krajšem časovnem obdobju, saj upošteva samo obdobje diagnoze in starost; pri dolgoročnejših napovedih je treba upoštevati tudi vpliv rojstne kohorte.

Pri časovnih trendih smo ocenjevali delež letne spremembe z Joinpoint regresijsko analizo. Uporabili smo Joinpoint Regression Program (Verzija 4.1.1 – Avgust 2014), ki je narejen na podlagi metodologije, ki jo je razvil Kim s sodelavci.

Grobe in starostno specifične stopnje

Groba incidenčna stopnja je število novih primerov bolezni, preračunano na 100.000 oseb opazovane populacije, *groba umrljivostna stopnja* pa število umrlih na 100.000 oseb opazovane populacije. Natančneje sta stopnji definirani kot število novih primerov bolezni (oz. število umrlih) v določenem časovnem obdobju, praviloma enem letu (= incidenca oz. umrljivost), deljeno s številom oseb, ki so v istem obdobju izpostavljene tveganju, da zbolijo oz. umrejo zaradi določene bolezni; izražamo jo na 100.000 človek-let. *Starostno specifična stopnja* (incidenčna oz. umrljivostna stopnjo) se izračuna na enak način, vendar za posamezno starostno skupino.

Starostno standardizirane stopnje

Če analiziramo incidenco (ali umrljivost) v daljšem časovnem obdobju, v katerem se lahko starostna struktura prebivalstva v času spreminja, ali če primerjamo incidenco (ali umrljivost) med populacijami z različno starostno strukturo, je treba uporabiti eno od metod starostne standardizacije. Starostno standardizirana stopnja je teoretična incidenčna (oz. umrljivostna) stopnja, ki bi jo opazili, če bi bila starostna struktura opazovane populacije taka kot v standardni populaciji. V *Tabeli 2* poleg grobe incidenčne stopnje rakavih bolezni v Sloveniji prikazujemo še starostno standardizirane stopnje na svetovno, evropsko in slovensko standardno populacijo z metodo *neposredne standardizacije*. Starostno standardizirane umrljivostne stopnje so dostopne na spletišču SLORA. V *Tabeli 6b* je za primerjavo incidenčnih stopenj med slovenskimi statističnimi regijami uporabljen slovenski standard, starostna struktura prebivalcev Slovenije ob popisu leta 2002. Uporabljena standardna populacija je

vedno enaka za oba spola, kar v posameznih primerih lahko privede do nepričakovanih rezultatov, ko so standardizirane stopnje pri enem spolu (ponavadi pri moških, ki so v povprečju mlajši) večje od grobih stopenj, pri drugem spolu pa manjše.

Kumulativne stopnje in kumulativno tveganje

Kumulativna incidenčna (ali umrljivostna) stopnja (KS) (prikazana v zadnjem stolpiču *Tabele 5*) je petkratna vsota starostno specifičnih incidenčnih (ali umrljivostnih) stopenj po petletnih starostnih skupinah do 74. leta starosti, preračunana na 100 prebivalcev. Je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupinah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativno stopnjo smo uporabili za prikaz časovnega trenda incidence in umrljivosti v spodnjem delu *Slike 4*.

Kumulativno tveganje (KT) je verjetnost posameznika, da zboli za rakom v izbranem starostnem obdobju, npr. do 74. leta starosti, če ne umre prej zaradi drugih vzrokov. Kumulativno tveganje izražamo v odstotkih. Če je KS manjša kot 10/100, jo lahko uporabimo za približek kumulativnemu tveganju. Pri večjih kumulativnih stopnjah pa kumulativno tveganje izračunamo iz kumulativne stopnje po obrazcu: $KT = 100\ (1 - e^{-KS/100})$.

Kumulativno incidenčno stopnjo raka dojk pri ženskah 8,2/100 tako lahko uporabimo za oceno kumulativnega tveganja raka dojk, ki je v tem primeru 8,2-odstotno. To pomeni, da bo 8,2 % deklic (ali približno ena od 12), rojenih leta 2016, do 74. leta starosti verjetno zbolelo za rakom dojk.

Prevalenca

Prevalenca je število vseh bolnikov z rakom, ki so bili živi na izbrani datum, ne glede na to, kdaj so zboleli. Celotna prevalenca obsega vse bolnike, ne glede na to, kako dolgo pred datumom izračuna so zboleli, medtem ko delna prevalenca šteje samo bolnike, ki so zboleli v določenem obdobju, npr. 1, 5 ali 10 let pred datumom, na katerega to mero računamo. Pri raku so ta obdobja še zlasti pomembna, saj odsevajo število bolnikov v različnih fazah poteka bolezni, npr. enoletna vključuje bolnike v času prvega zdravljenja, triletna bolnike v obdobju rednih kontrolnih kliničnih pregledov, petletna in zlasti še desetletna pa vključuje bolnike, za katere vsaj pri večini rakavih bolezni menimo, da so ozdravljeni.

Nekateri bolniki zbolijo za več kot eno rakavo boleznijo, zato je vsota prevalenc bolnikov po posameznih vrstah raka večja kot skupna prevalenca, pri kateri štejemo samo bolnike ne glede na število posameznih rakavih diagnoz.

Preživetje

Pri skupinah bolnikov *preživetje* predstavlja delež bolnikov, ki so po izbranem časovnem obdobju od postavitve diagnoze še živi. Možnosti in metod za izračun preživetja je več. Osnovna in hkrati najpreprostejša mera preživetja je tako imenovano *opazovano preživetje*, kjer v izračun vključimo vse smrti, tudi tiste, ki jih ni povzročilo rakavo obolenje. Za oceno preživetij bolnikov z rakom, v kateri upoštevamo kot vzrok smrti le proučevanega raka, v populacijskih izračunih uporabljamo metode *relativnega* in *čistega preživetja*. Uradni vzroki smrti namreč niso dovolj točni, da bi bil izračun vzročno specifičnega opazovanega preživetja na populacijski ravni dovolj zanesljiv.

Relativno in čisto preživetje se izračunata s statističnim primerjanjem opazovanega preživetja proučevane skupine bolnikov in preživetjem, ki ga glede na spol in starost v določenem obdobju pričakujemo v celotni populaciji, iz katere prihajajo bolniki (t.i. pričakovano preživetje). Pričakovano preživetje se izračuna na podlagi podatkov o splošni umrljivosti, ki se v obliki tablic umrljivosti za posamezno državo rutinsko objavljajo v okviru demografske statistike; za naše izračune so uporabljene slovenske letne popolne momentne tablice umrljivosti. Od leta 2014 naprej v letnih poročilih prikazujemo čisto preživetje izračunano po metodi Pohar-Perme, do takrat pa smo prikazovali preživetje izračunano po metodi Ederer-II, ki je ena od metod relativnega preživetja.

Opozarjamo še, da metoda čistega preživetja, uporabljena za izračun preživetja, prikazanega v tem poročilu, ni enaka tisti, s katero je mogoče prikazati preživetje na spletnem portalu SLORA. Na spletnem portalu SLORA prikazujemo opazovano preživetje in pa relativno preživetje izračunano po Hakulinenovi metodi.

Prebivalstvo Slovenije

Podatki o številu prebivalcev in o starostni strukturi so pomembni pri izračunavanju in interpretiranju večine kazalnikov bremena raka. Za Slovenijo je točno število in starostna struktura prebivalcev na voljo za popisna leta že ves čas registracije raka. Nacionalni popis prebivalstva je bil napravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izračunu kazalnikov predpostavili, da je bila med dvema popisnima letoma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja Centralni register prebivalstva, je mogoče dobiti ažuren podatek o številu in starostni strukturi prebivalcev. V letnih poročilih uporabljamo podatek o prebivalcih na datum 1. julij posameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statističnega urada RS. Podatki o prebivalstvu po spolu in petletnih starostnih skupinah za celotno Slovenijo za leto 2016 so v spodnji tabeli.

Starostna skupina	Skupaj	Moški	Ženske
0–4	106.470	54.702	51.768
5–9	108.822	56.051	52.771
10–14	92.088	47.422	44.666
15–19	94.096	48.592	45.504
20–24	102.894	52.896	49.998
25–29	126.359	65.460	60.899
30–34	142.579	74.566	68.013
35–39	157.116	82.583	74.533
40–44	151.701	79.105	72.596
45–49	147.540	75.693	71.847
50–54	154.697	78.506	76.191
55–59	149.119	75.011	74.108
60–64	145.188	72.625	72.563
65–69	120.038	57.838	62.200
70–74	85.053	38.072	46.981
75–79	76.609	31.964	44.645
80+	103.872	32.786	71.086
Skupaj	**2.064.241**	**1.023.872**	**1.040.369**

Prebivalci Slovenije po starosti in spolu na dan 1. 7. 2016.

Pri razporeditvi prebivalcev v posamezne statistične regije (spodnja tabela) je uporabljen le podatek o stalnem naslovu oseb in ne tudi začasnem, kot je upoštevan v pripravi števila prebivalcev po klasični »statistični« definiciji.

Statistična regija	Skupaj	Moški	Ženske
Pomurska	115.818	56.939	58.879
Podravska	321.493	159.690	161.803
Koroška	71.010	35.623	35.387
Savinjska	254.824	127.598	127.226
Zasavska	57.466	28.324	29.142
Posavska	75.694	38.084	37.610
JV Slovenija	142.672	71.971	70.701
Osrednjeslovenska	537.893	263.149	274.744
Gorenjska	203.654	100.881	102.773
Primorsko-notranjska	52.593	26.624	25.969
Goriška	117.931	58.970	58.961
Obalno-Kraška	113.193	56.019	57.174
Slovenija	**2.064.241**	**1.023.872**	**1.040.369**

Prebivalci Slovenije po statističnih regijah in spolu na dan 1. 7. 2016.

Leta 2016 je v Sloveniji za rakom zbolelo 15.072 ljudi, 8.117 moških in 6.955 žensk. (*Slika 1*), umrlo pa 6.247 ljudi, 3.522 moških in 2.725 žensk. Od rojenih leta 2016 bosta do 75. leta starosti predvidoma za rakom zbolela eden od dveh moških in ena od treh žensk (*Tabela 5*).

Konec decembra 2016 je živelo 107.093 ljudi (48.641 moških in 58.452 žensk), ki so kadar koli od ustanovitve RRRS zboleli za rakom (*Slika 1*). Ocenjujemo, da je leta 2019 za rakom zbolelo skoraj 16.000 prebivalcev Slovenije, približno 8.700 moških in 7.100 žensk. Ocene incidence za posamezne lokacije raka so prikazane v *Tabeli 1* skupaj s povprečnimi petletnimi vrednostmi za zadnje 10-letno obdobje.

Ogroženost z rakom se zmerno veča in je največja v starejših letih; od vseh bolnikov z rakom je leta 2016 kar 63 % moških in 60 % žensk zbolelo po 65. letu starosti. Pri otrocih in mladostnikih (do 20. leta) obsegajo rakave bolezni manj kot 1 % vseh primerov raka (*Slika 2*). Ker se slovensko prebivalstvo stara, je samo zaradi vedno večjega deleža starejših pričakovati, da se bo število novih primerov raka še naprej večalo.

Ker na incidenco raka najbolj vpliva starostna struktura prebivalstva, so za verodostojnejšo primerjavo z drugimi državami z različno starostno strukturo v *Tabeli 2* poleg grobih stopenj izračunane tudi starostno standardizirane. Glede na to, da so v uporabi različni standardi, smo za namene različnih primerjav uporabili tri standardne populacije svetovno, evropsko in slovensko.

Pet najpogostejših vrst raka pri nas – nemelanomski kožni, rak prostate, debelega črevesa in danke, dojke in pljuč – obsega 60 % vseh novih primerov rakavih bolezni (*Slika 3*). Raki teh organov so povezani z nezdravim življenjskim slogom, čezmernim sončenjem, nepravilno prehrano, kajenjem in čezmernim pitjem alkoholnih pijač, zato je ogroženost z njimi treba zmanjšati z ukrepi primarne preventive. Pri moških je bil z 21 % vseh novih primerov na prvem mestu rak prostate. Pri ženskah predstavljata vsak po petino primerov vseh rakov nemelanomski kožni rak in rak dojk (*Slika 3*).

Od leta 1950 se je groba incidenčna stopnja raka v Sloveniji zvečala za 780 % pri moških in za 520 % pri ženskah; v zadnjih 10 letih se je pri moških večala povprečno za 2,3 % letno, pri ženskah pa za 1,9 %. Groba umrljivostna stopnja se je pri moških v zadnjih 10-ih letih večala povprečno za 0,8 % letno, pri ženskah pa za 0,9 % (*Slika 4*). Več kot polovica zvečanja incidence gre na račun staranja prebivalstva. Kumulativna incidenčna stopnja se je v zadnjih 10-ih letih pri moških večala v povprečju le za 0,2 % letno, pri ženskah pa za 0,9 %. Kumulativna umrljivostna stopnja se od leta 1985 pri obeh spolih manjša (*Slika 4*), v zadnjih 10-ih letih pri moških za 2,3 % letno, pri ženskah pa za 0,6 %. Manjšanje verjetnosti smrti za rakom ob večanju incidence kaže, da je zdravljenje uspešnejše in da vse več bolnikov ozdravi in/ali živi z rakom, medtem ko jih je prej več umrlo zaradi rakave bolezni. Vse povprečne letne spremembe, z izjemo kumulativne incidence pri moških, so statistično značilne pri stopnji tveganja 0,05.

Časovni trend pogostejših rakov pri moških kaže, da se je incidenčna stopnja pljučnega raka večala vse do začetka devetdesetih let prejšnjega stoletja, ko se je ustalila pri vrednosti okoli 90/100.000. Strmo pa pljučnega raka prehitevata rak prostate (povečanje za 3,0 % povprečno letno) in kožni nemelanomski rak (povečanje za 5,4 % povprečno letno). Izjemno povečanje incidence raka prostate v zadnjem

desetletju ni posledica kakega novega nevarnostnega dejavnika, pač pa predvsem vse širše rabe testa za določanje za prostato specifičnega antigena (PSA) pri zdravih moških in odkrivanja velikega števila primerov, ki bi drugače ostali vse življenje prikriti. Podatki za zadnja leta kažejo, da smo vrh incidence raka prostate vseeno najverjetneje že dosegli. Tudi časovne spremembe v pojavljanju raka debelega črevesa in danke je potrebno ocenjevati z upoštevanjem sprememb v diagnostiki – leta 2009 smo namreč v Sloveniji uvedli Državni program presejanja in zgodnjega odkrivanja predrakavih sprememb in raka na debelem črevesu in danki (Svit). Incidenca raka debelega črevesa in danke se je pri moških med leti 2007 in 2010 povečevala za 7,5 % letno, od leta 2010 do 2016 pa pada za 3,8 % letno. Pri ženskah se večajo incidenčne stopnje raka dojk (za 1,7 % povprečno letno), kože, razen melanoma (za 4,0 % povprečno letno), pljučnega raka (za 4,9 % povprečno letno) in raka materničnega telesa (za 2,7 % povprečno letno). Incidenčna stopnja raka materničnega vratu se od uvedbe Državnega presejalnega programa za odkrivanje predrakavih in zgodnjih rakavih sprememb na materničnem vratu (ZORA) strmo manjša (za 2,5 % povprečno letno v zadnjih desetih letih). Podobno kot pri moških se tudi pri ženskah zaradi uvedbe presejalnega programa Svit spreminja časovni trend pojavljanja raka debelega črevesa in danke – med leti 2007 in 2010 se je incidenca povečevala za 1,7 % letno, od leta 2010 do 2016 pa pada za 2,9 % letno. Povprečne letne odstotne spremembe so prikazane ob krivuljah na *Sliki 5*.

Slika 6 prikazuje petletno čisto preživetje bolnikov z vsemi (razen kožnega) in izbranimi raki, zbolelih v letih 2012–2016 po spolu. Za primerjavo je prikazano tudi relativno preživetje bolnikov, zbolelih v predhodnem petletnem obdobju (2007–2011). Pri moških se je skupno preživetje povečalo za 3 odstotne točke, predvsem zaradi večjega odkrivanja in boljšega prijavljanja raka prostate nižjih stadijev, ki so povezani z boljšo prognozo, saj je preživetje bolnikov, zbolelih v zadnjem obdobju, večje skoraj za 4 odstotne točke. Med pogostejšimi raki se je v zadnjem obdobju značilno povečalo tudi preživetje zbolelih za pljučnim rakom. Ker se 95 % intervala zaupanja ne prekrivata, lahko zaključimo, da je razlika statistično značilna. Petletno čisto preživetje bolnic, zbolelih v letih 2012–2016 prvič presega 60 %. Pri ženskah se je med pogostejšimi raki statistično značilno povečalo preživetje bolnic s pljučnim rakom (prvič presega 20 %), za 3 % pa je v zadnjem obdobju višje tudi preživetje zbolelih za rakom dojke.

Posebno pozornost v letošnjem poročilu posvečamo dosežkom treh državnih presejalnih programov ZORA, DORA in Svit kot jih lahko spremljamo s podatki RRRS. Na *Sliki 7a* (ZORA), *Sliki 8a* (DORA) in *Sliki 9a* (Svit) so za vsak presejalni rak posebej predstavljeni časovni trendi grobih incidenčnih stopenj med leti 1987 in 2016. Prikazane so spremembe v incidenci, ki so nastale z uvedbo programov. Tako se je incidenca raka materničnega vratu začela zmanjševati že z uvedbo pilota ZORA leta 1997; od uvedbe nacionalnega programa ZORA leta 2003 do leta 2016 pa se je več kot prepolovila. Podobno ugotavljamo pri programu Svit: Incidenca raka debelega črevesa in danke se je do uvedbe presejalnega programa povečevala, od takrat pa pri obeh spolih strmo pada. V trendu incidence raka dojk po uvedbi programa DORA ni opaziti sprememb, saj je DORA edini izmed treh presejalnih programov, ki ne odkriva predrakavih sprememb in z njim tako incidence ne zmanjšujemo.

Na *Sliki 7b* (ZORA), *Sliki 8b* (DORA) in *Sliki 9b* (Svit) prikazujemo razliko v stadiju ob diagnozi med raki, ki so bili odkriti v presejalnih programih in tistimi, ki so bili diagnosticirani izven presejanega programa. Pri vseh treh presejalnih programih se jasno vidi odlično izpolnjevanje enega od osnovnih ciljev programov – zgodnje odkrivaje bolezni, saj so raki odkriti v presejalnem programu statistično značilno nižjih stadijev. Pri interpretaciji teh rezultatov pa se je potrebno zavedati, da so intervalni raki (raki, ki jih odkrijemo po negativnem izvidu presejalnega testa) v analizi podatkov RRRS razporejeni v skupino diagnosticirani izven presejanega programa.

Sliki 7c in d (ZORA), *Sliki 8c in d* (DORA) in *Sliki 9c in d* (Svit) prikazujemo razliko v preživetju med bolniki, ki jim je bil rak odkrit v presejalnem programu in tistimi, ki so bili diagnosticirani izven presejanega programa. V vseh treh primerih imajo boljše preživetje bolniki, pri katerih je bil rak ugotovljen v presejalnem programu. Razlike ostajajo tudi, če primerjamo preživetje ločeno glede na stadij ob diagnozi. Ta rezultat vsekakor zahteva dodatne analize, saj iz v RRRS dostopnih podatkov ni možno zaključiti ali je obravnava bolnikov odkritih v presejalnem programu ustreznejša, koliko k rezultatu prispeva razvrstitev intervalnih rakov ipd.

Pri večini bolnikov je diagnoza bolezni potrjena mikroskopsko. Iz *Tabele 3* je razvidno, da je bila leta 2016 pri 95,1 % od 15.072 na novo registriranih primerov raka diagnoza potrjena mikroskopsko (histološko ali citološko), pri 4,7 % pa z drugimi preiskavami. Spodbudno je, da je že več let le 0,2 % primerov v RRRS vpisanih samo na osnovi zdravniškega poročila o vzroku smrti; RRRS verjetno niso bili prijavljeni ker niso bili zdravljeni v bolnišnici zaradi starosti ali napredovale bolezni. Iz *Tabele 3* je poleg načina postavitve diagnoze razvidno tudi število vseh novih primerov po posameznih mestih raka, v *Tabeli 4* je prikazano razporejanje teh primerov po 5-letnih starostnih skupinah, v *Tabeli 5* pa so te vrednosti preračunane v starostno specifične stopnje na 100.000 prebivalcev.

V *Tabeli 6a* je število novih primerov vseh in izbranih rakov prikazano po statističnih regijah. Ta števila so pomembna za načrtovanje zdravstvenih zmogljivosti. Starostno standardizirane vrednosti v *Tabeli 6b* pa kažejo razlike v ogroženosti z rakom v posameznih regijah, saj te niso posledica razlik v številu in starostni strukturi prebivalcev. V letu 2015 so se spremenile meje štirih statističnih regij (savinjske, posavske, osrednjeslovenske in zasavske), zato je potrebna pozornost pri primerjavi in interpretaciji podatkov iz prejšnjih let.

Kakšna je bila morfološka slika malignomov pri 14.337 primerih, pri katerih je bila diagnoza potrjena mikroskopsko, kaže *Tabela 7*. V njej so posebej prikazani primeri, ki so potrjeni histološko (96 %), in tisti, ki so bili potrjeni samo citološko (4 %).

Tabela 8 prikazuje porazdelitev bolnikov po stadiju, v katerem je bila bolezen odkrita. Uporabljena je poenostavljena opredelitev stadijev, ki upošteva vse preiskovalne metode, vključno z operacijo in tudi obdukcijo, če bolnik ni bil poprej zdravljen.

Tabela 9 kaže starostno porazdelitev ekstranodalnih in nodalnih lokacij ne-Hodgkinovih malignih limfomov. Ker je število ekstranodalnih lokacij majhno, so prikazane le absolutne številke.

V *Tabeli 10* je prikazana porazdelitev neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, ki jo uporabljajo kliniki in patologi.

Tabela 11 prikazuje osnovne podatke o zdravljenju bolnikov; objavljamo le podatke o prvem kurativnem zdravljenju. Ker je veliko bolnikov zdravljenih na več načinov, je vsota bolnikov po vrsti zdravljenja večja od števila novih primerov. Iz *Tabele 11a* je razvidno, kako so bili bolniki zdravljeni, v *Tabelah 11b* in *11c* pa, v katerih zdravstvenih ustanovah so bili bolniki v okviru prvega zdravljenja operirani in/ali zdravljeni s sistemskimi zdravili; z obsevanjem so bili z redkimi izjemami (tujina) zdravljeni samo na Onkološkem inštitutu Ljubljana.

Tabela 12 prikazuje prevalenco vseh in pogostejših rakov na dan 31. 12. 2016. Poleg celotne prikazujemo tudi delno, to je 1-, 3-, 5- in 10-letno prevalenco.

Uradne podatke o umrljivosti za rakom v letu 2016 prikazujemo v *Tabeli 13*; zbira jih Nacionalni inštitut za javno zdravje RS. Grobe in starostno standardizirane stopnje so na voljo na spletišču Slora.

V *Tabeli 14* so prikazana 1-, 3- in 5- letna čista preživetja bolnikov zbolelih med leti 2012 in 2016.

Zahvala

Zdravniki, medicinske sestre in administrativno osebje iz slovenskih bolnišnic in drugih zdravstvenih ustanov so RRRS dokaj vestno pošiljali prijavnice s podatki o novih primerih raka, o poteku bolezni in usodi bolnikov. Dopolnili so nam tudi morebitne pomanjkljive prijave. Podatke, ki so za RRRS nujni, a jih ni bilo mogoče najti v bolnišnicah, so nam z zavzetim delom priskrbeli družinski in splošni zdravniki.

Za bolnike, ki so bili obravnavani na Onkološkem inštitutu Ljubljana, sta podatke prispevali sodelavki Bolnišničnega registra Onkološkega inštituta Ljubljana, Maruška Ferjančič in Polona Škulj, podatke za vse kožne tumorje pa Agata Čampa, sodelavka Kliničnega registra kožnega melanoma.

Poročila bi skorajda ne mogli napraviti, njegovi podatki pa bi bili bistveno manj verodostojni, ko bi ne imeli naklonjenega sodelovanja Centralnega registra prebivalstva RS, Nacionalnega inštituta za javno zdravje RS in Statističnega urada RS.

Odgovore na vsa strokovna vprašanja nam priskrbijo zdravniki specialisti z Onkološkega inštituta Ljubljana. V prav posebno pomoč pa so vsi strokovni nasveti s področja patologije, ki nam jih nudi dr. Gorana Gašljević, dr. med., specialistka patologije.

Vsem imenovanim in tudi drugim, ki so kakorkoli prispevali k temu poročilu, se najlepše zahvaljujemo.

Uredniški odbor

Introduction

Slovenian Cancer Registry (SCR) is one of the oldest population based cancer registries in Europe. It was founded at the Institute of Oncology Ljubljana (IO) in 1950 by the late Professor Božena Ravnihar, who headed it till 1975. She was succeeded by Professor Vera Pompe-Kirn, who contributed a lot to the further development of the SCR as well as its recognition at the national and international level all until her retirement in 2003. Since 2003, the SCR has been merged with the Unit of Epidemiology into a single Epidemiology and Cancer Registry service. It was led by dr. Maja Primic Žakelj until 2018. Besides the SCR, the new service also comprises the *hospital-based Cancer Registry* of the IO, which contributes a considerable part of information to the SCR and facilitates a more detailed overview of patients treated at the IO, irrespective of their permanent residence. In 2003 a new *national registry in charge of coordinating and monitoring the organised cervical cancer screening programme* (Registry ZORA) has been established, while an *information system to support organized breast screening program* has been established in 2007 (Registry DORA).

The data on cancer collected by the SCR, incidence, survival and prevalence, serve together with mortality data collected by the National Institute of Public Health of RS as the basis for assessing the cancer burden in the country. They are important for planning and evaluation of the National Cancer Control Plan (NCCP), in the field of primary and secondary prevention, diagnostics, treatment and rehabilitation, for planning facilities and funding needed for cancer control (personnel, equipment and hospital capacities) as well as for clinical and epidemiological research in Slovenia and in international multicentric studies and for evaluation of effectiveness of cancer screening programs.

The Annual Reports of the SCR are one of the regular ways of disseminating information on cancer among professionals and other interested groups. As we are limited by the technology of data collection from a variety of sources, data collection, their linking and publication is rather time consuming (here and elsewhere) and usually takes two to three years. Over the last few years the estimated numbers and rates for the expected incidence in the year the Annual Report is published (in this report for the year 2019) are presented; they are calculated by a special statistical method.

The first annual reports of the SCR for the period 1951–1955 were issued during the years 1953–1957. The first data analysis for the year 1950 was published in *Zdravstveni vestnik* in 1951. The data for the period 1957–1971 were appearing in the periodicals *Epidemiological and Vital Statistics Report* and *World Health Statistics Report*, both edited by the World Health Organization. From 1965 onwards, the data have been appearing regularly in special bi-lingual (Slovene-English) annual reports, entitled *Cancer in Slovenia* in years 1965–1977 and 2007–2014, and *Cancer Incidence in Slovenia* in the period 1978–2006. Besides Annual Reports, four special publications have been published: *Atlas of Cancer Incidence in Slovenia 1978–1987*, *Cancer Patients' Survival in Slovenia 1963–1990*, *Cancer Patients' Survival in Slovenia 1983–1997* and *Survival of Cancer Patients, diagnosed in 1991–2005 in Slovenia*. The list of other relevant publications in last five years is at the end of this report.

Data of the SCR are included in several international databases and projects. They have been published in all nine volumes and the tenth electronic version of the

Cancer Incidence in Five Continents issued by the International Agency for Research on Cancer. The data are included in international databases *ECO*, *GLOBOCAN* and *ACCIS*. The survival of Slovenian cancer patients is analysed in the international studies *EUROCARE-2*, *EUROCARE-3*, *EUROCARE-4*, *EUROCARE-5*, *EUROCARE-6*, *CONCORD-1*, *CONCORD-2*, *CONCORD-3*, *RARECARE* and *EUNICE*.

In 2010, the SCR's database has been upgraded and data processing modernized. At the same time an *interactive web portal* named *SLORA* was launched as well. The name comes from the first letters of the sentence in Slovenian language: "SLOvenia and RAk/cancer". It is available at www.slora.si/en/. It enables a simple access to data on cancer in Slovenia collected by the SCR (incidence, prevalence and survival; currently till 2016) and the National Institute of Public Health of Republic of Slovenia (RS) (mortality) as well as the comparisons with other countries in the European Union and in the world. It describes the data and offers its users professional explanations of cancer risk factors, screening and early detection and treatment outcomes.

Data sources

Notification of cancer has been compulsory in Slovenia since the foundation of the SCR and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92, 65/00, 47/15 and 31/18). The main sources of data are *notifications of cancer*, gathered from all hospitals and diagnostic centres in Slovenia, exceptionally also from primary health care centres in case the patient has not been referred for further diagnostic investigations and/or treatment. Complementary sources of information are death certificates that we get from National Institute of Public Health of Republic of Slovenia and data on diagnosed cancers that are recorded in three national screening programs: ZORA for the detection of pre-cancerous and early cancerous lesions of cervix uteri, DORA for early detection of breast cancer and Svit for the detection of pre- cancerous lesions and cancer of colon and rectum. The data gathered with notifications are identification data, data on the cancer disease (anatomic cancer site, histological or cytological diagnosis and stage by TNM or other clinical classification) and basic data on treatment. Where patients' data reported on notifications are not complete or adequate and where the only information about their disease is acquired from the death certificate, time consuming queries about patients must be performed by the SCR's staff.

Calculation of patient prevalence and survival requires the patient's *vital status* (a person may be alive, dead or lost to follow-up). This data is obtained from the Central Population Registry for all persons registered in the SCR data base as alive. Since 2010, together with the upgrade of SCR's database, an on-line connection with the Central Population Registry has been established using a specially secured web technology. This enables an on-line connection and up-to-date vital status of all registered patients. In persons lost to follow-up the date of last notification or the date of loss obtained from the Central Population Registry, whichever first, is considered as the date of loss to follow-up. From 1985, since the uniform personal ID number has been used in Slovenia, the proportion of the lost to follow-up in SCR is below 1%, furthermore, in patients registered in the last decade being only 0.1%.

Detailed analyses of the spatial distribution of cancer are enabled by accurately defined addresses of patients with cancer and regular connection to the Registry of Spatial Units of the Surveying and Mapping Authority. Table 6 shows cancer burden at the level of 12 statistical regions as in effect in Slovenia in 2016.

Statistical regions of Slovenia

Preparation of data for computer processing

In SCR specially trained nurses code the data retrieved from notifications of cancer in accordance with the international and internal SCR guidelines.

Since 1997, cancer sites are coded according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10); before, the 8th revision was used (ICD-8).

When classifying tumours as malignant, the behaviour digit of the morphology code of the third edition of International Classification of Diseases for Oncology has been used since the report for 2001. In this edition some changes were introduced in terms of morphology and behaviour code and some new morphology codes were added for tumours that till 2001 have not been coded separately. For example, gastrointestinal stromal tumours (GIST) are a distinct entity since 2001. According to the new rules, ovarian tumours of borderline malignancy are currently coded as D39.1 (and not C56). According to the third edition, chronic myeloproliferative disorders and myelodisplastic syndromes as well as policytaemia are classified as malignant, the former two being assigned to C96.7 and the policytaemia is classified under the topography code C94 from year 2001 on. From year 2012 on, the third edition with 2011 updates is used.

Development of molecular and genetic technologies enabled more detailed classification of the type of cellular changes, found in neoplasms of the lymphoid and haematopoietic tissues. Better and more detailed identification enables targeted treatment. All this correspond to greater number of disease types and its classification is constantly updating. In 2001, the World Health Organization published special classification of the lymphoid and haematopoietic tissue based on imunophenotype, genetic changes and clinical picture. The classification was updated in 2008 and replaced several other classifications of the lymphoid and haematopoietic tissue in clinical use. Furthermore, the International Classification of Diseases for Oncology

(third revision, 2011 update) follows this classification. Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue are systemized in Table 10 according to 2008 version of the classification of the World Health Organization.

In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Till then, only carcinoma in situ (code 234.0) was registered. Thus, the comparison with the data for the period 1961–1992 is not possible. According to ICD-10, all cervical intraepithelial neoplasms (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast (D05) and since 1995, all reported intraepithelial carcinomas of the bladder (D09.0) and all malignant melanomas Clark I (D03) have been registered as well.

For stage description, a simplified definition of stages at diagnosis is used for solid tumors, classifying them into localized, regional and distant stage of disease. The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is considered as well. The simplified stage definition generally follows the TNM classification. Localized stage includes all cancers where the tumor has been classified as T1 and T2. In breast cancer, skin melanoma and thyroid cancer T3 tumor is also included in localized stage. In uterine cervix, corpus and sarcomas, ovarian cancer, tube and trophoblastic tumors only T1 tumor is included in localized stage. In all of these cases neither regional lymph node involvement nor distant metastases are found (N0, M0). The regional stage includes tumors classified as T3 and T4 (with aforementioned exceptions) and/or regional lymph node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). The disease with metastases in distant lymph nodes or organs is classified as the distant stage (M1). Stage according to TNM or any other appropriate classification is also stored in the SCR database, if available. Gynecological tumors are thus defined also according to the FIGO classification and in skin melanoma size according to Clark's level and Breslow's thickness is registered. Malignant lymphomas are classified according to Ann-Arbor System.

Data quality and completeness of registration

The quality of information can be assessed by the following parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters are presented in *Table 3*.

The completeness of registration shows the proportion of all new cancer cases in the region covered by the registry that are included in the registry's data base. It can be measured directly only by means of special surveys for the evaluation of completeness, e.g. by reviewing patients' records in the hospitals or outpatient clinics in a particular region. In Slovenia, no such surveys have been carried out so far. However, a considerable contribution towards the completeness of registration is made by our colleagues – clinicians, who send us the data on their groups of patients

in order to provide us with information about their vital status and among them we often find cases that have not been entered into the SCR database yet.

In general, the registration is more complete where the registries have access to death certificates. This enables the registry to send out additional inquiries where disease for the deceased has not been entered into the database yet. This improves the completeness of registration of cancers with poor prognosis, but not also of less fatal ones. It is presumed that in Slovenia – as well as in other European population based cancer registries – registration is less complete in non-melanoma skin cancer and in malignomas that are treated on the out-patient basis only.

Incidence and mortality

Incidence and *mortality* are absolute numbers of all newly diagnosed cases of any disease or number of deceased from this disease in a defined population in one calendar year. New primary cancers of the same histology in paired organs, e. g. in the left and right breast, are not comprised in the incidence figures, neither are any new cancers of the same histology appearing in the same organ, e.g. multiple lesions of the colon. The incidence registered by SCR includes only the data on patients with permanent residence in Slovenia, regardless of the country where they have been treated.

The method by Dyba and Hakulinen was used for estimation of incidence in 2019 (presented in *Table 1*). This method is suitable for predictions in shorter time period, taking into account the period of diagnosis and age structure of population. For long-term predictions the cohort effect should be included also.

For assessing time trends, the average annual change was calculated with joinpoint regression analysis by Joinpoint Regression Program (Version 4.1.1 - August 2014), which follows the models developed by Kim et all.

Crude and age specific rates

Crude incidence rate is the number of new cases per 100,000 inhabitants, while *crude mortality rate* is the number of deaths per 100,000 population. More precisely it is defined as number of new cases (or number of deaths) in a specified time interval, usually one calendar year (= incidence or mortality), divided by the number of persons at risk of disease (or death) in the same period; it is expressed per 100,000 person-years. The *age specific rate* (incidence or mortality rate) is calculated in the same way, but for each age group.

Age standardized rates

When analysing the incidence (or mortality) rate within longer time period (if the age structure of population changes) or comparing the incidence (or mortality) between populations with different age structure, age standardization is needed to adjust the rate for the effect of age. The age-standardized rate is a theoretical incidence (or mortality) rate assuming that the age structure in the observed population is the same as in the standard population. In *Table 2*, besides crude cancer incidence rates, age standardized rates by *direct method* are presented, using World, European and Slovenian standard population. Age standardized mortality rates are also available at SLORA web-portal. In *Table 6b* the incidence rates in different statistical regions in Slovenia are compared using the Slovenian standard, which is the age structure of Slovenian 2002 census population. Because the standard population is always the same for both sexes, there are some situations where standardized rate is bigger than crude rate in one sex, usually in males who are on average younger, and smaller in the other.

Cumulative incidence rate and cumulative risk

The cumulative incidence (or mortality) rate (CR), (cumulative incidence rate is presented in the last column of *Table 5*) is five times the sum of the age-specific incidence (or mortality) rates over five-year age groups up to the age of 74 years, calculated per 100 inhabitants. The cumulative rate can be interpreted as a form of direct age standardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. The cumulative incidence rate was also used to present the incidence time trend in the lower part of the *Figure 4*.

The cumulative risk is the risk an individual would have of developing the disease in question during a certain age period, e.g. up to the age of 74, if no other causes of death were in operation. The cumulative risk is expressed as a percentage. If cumulative rate is lower than 10/100, its value is practically equal to that of the cumulative risk. When cumulative rate is greater than 10/100, it should be calculated as cumulative risk according to the following formula: $CRisk = 100\ (1 - e^{-KS/100})$.

Cumulative incidence rate of breast cancer in females 8.2/100 can be used to estimate cumulative risk of breast cancer that is in this case 8.2%. This means that 8.2% of women born in 2016 (approximately one out of 12) are expected to develop breast cancer by their age of 74 in the absence of any other cause of death.

Prevalence

Prevalence is the number of all cancer patients that are alive on a given date, regardless of when they were diagnosed with cancer. Lifetime cancer prevalence is defined as all persons ever diagnosed with cancer and being alive at specific time date, while partial prevalence counts only those patients, diagnosed with cancer within a defined period of time e. g. 1, 5 or 10 years before the date on which prevalence is calculated. In cancer these periods are important, as they reflect the number of cancer cases in different course of disease, e. g. the one-year prevalence includes patients during their primary treatment, 1–4 years prevalence those requiring regular follow-up, while 5–9 and especially 10 and more years prevalence includes predominantly those considered cured from cancer.

Some patients have more than one cancer, hence the sum of prevalence of cancer patients by individual cancer site is bigger than the prevalence of all cancer patients, as patients are counted only once regardless of the number of cancer diagnoses.

Survival

In groups of patients, the *survival* represents the proportion of patients still alive after a selected period of time from diagnosis. There are several options and methods for survival calculation. The basic and at the same time the simplest measure of survival is the so-called *observed survival*, where all deaths, also those

not caused by cancer, are included in the calculation. In order to evaluate the survival of cancer patients, which takes into account the cancer-specific deaths only, the methods of *relative* and *net survival* are used in population studies. The data on official causes of death are often insufficiently accurate for the calculation of the causal specific observed survival at the population level.

Relative and net survival are calculated by statistical comparison of the observed survival in the group of patients under study and survival with respect to gender and age over a certain period of time in the population the patients come from (i.e. the expected survival). The expected survival is calculated from general mortality data and is published routinely in the form of country specific life tables within the framework of its vital statistics; for our calculations, the Slovenian complete yearly life tables are used. Since 2014 net survival is presented in the annual reports. It is calculated using the Pohar-Perme method. In previous years we calculated survival with the Ederer-II approach, which is one of the methods of relative survival.

It should be noted that the method used for survival calculation in this report is different from the one used to present survival at web-portal SLORA. The SLORA web portal shows the observed survival and the relative survival computed by the Hakulinen method.

Population of Slovenia

Population data, especially the number and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration. Census has been performed nearly every 10 years, but till 1985 no data were available for intermediate years, so for this time period it was assumed that the population structure between two censuses was the same. Since the middle of the eighties, the population data are available for any particular date from the Central Population Registry. In SCR Annual Reports the population data on July 1 of a particular year are used, which are obtained from Statistical Office of Republic of Slovenia. In the following table, numbers of inhabitants of Slovenia in 2016 by age and by sex are presented.

Population of Slovenia by age and by sex, July 1, 2016.

Age	Total	Males	Females
0–4	106,470	54,702	51,768
5–9	108,822	56,051	52,771
10–14	92,088	47,422	44,666
15–19	94,096	48,592	45,504
20–24	102,894	52,896	49,998
25–29	126,359	65,460	60,899
30–34	142,579	74,566	68,013
35–39	157,116	82,583	74,533
40–44	151,701	79,105	72,596
45–49	147,540	75,693	71,847
50–54	154,697	78,506	76,191
55–59	149,119	75,011	74,108
60–64	145,188	72,625	72,563
65–69	120,038	57,838	62,200
70–74	85,053	38,072	46,981
75–79	76,609	31,964	44,645
80+	103,872	32,786	71,086
Total	**2,064,241**	**1,023,872**	**1,040,369**

In the number of inhabitants by statistical regions (following table) the permanent, but not the temporary residence of the Slovenian citizens is used, contrary to the standard "statistical" definition.

Population by Slovenian statistical regions and by sex, July 1, 2016.

Statistical region	Total	Males	Females
Pomurska	115,818	56,939	58,879
Podravska	321,493	159,690	161,803
Koroška	71,010	35,623	35,387
Savinjska	254,824	127,598	127,226
Zasavska	57,466	28,324	29,142
Posavska	75,694	38,084	37,610
JV Slovenija	142,672	71,971	70,701
Osrednjeslovenska	537,893	263,149	274,744
Gorenjska	203,654	100,881	102,773
Primorsko-notranjska	52,593	26,624	25,969
Goriška	117,931	58,970	58,961
Obalno-Kraška	113,193	56,019	57,174
Slovenia	**2,064,241**	**1,023,872**	**1,040,369**

In 2016, 15,072 patients were diagnosed with cancer, 8,117 males and 6,955 females, and 6,247 patients died from cancer, 3,522 males and 2,725 females (*Figure 1*). From those born in 2016, one in two males and one in three females are expected to develop cancer by their age of 74 (*Table 5*).

At the end of December 2016, there were 107,093 people (48,641 males and 58,452 females) alive who were diagnosed with cancer at any time since the foundation of the SCR (*Figure 1*). It is estimated that in 2019 there were almost 16,000 Slovenian inhabitants newly diagnosed with cancer, approximately 8,700 males and 7,100 females. The estimated incidence of different cancer sites together with 5-year average values in the last 10-year period are presented in *Table 1*.

The risk of cancer is slowly increasing and is the highest in older age groups; from all cancer patients, diagnosed in 2016, 63% males and 60% females were aged 65 or more at diagnosis. Cancer among children and young adults (till the age of 20) accounts for less than 1% (*Figure 2*). As Slovenian population is ageing, it is expected that the cancer burden will continue to increase because of longer life expectancy.

As cancer incidence depends on the age structure of a population, *Table 2* presents crude as well as age standardized rates. For the purposes of different comparisons with other countries and as different standard populations are used worldwide, three standard populations, World, European and Slovenian, were applied.

First five most frequent cancers (non-melanoma skin, prostate, colorectal, lung and breast) comprise 60% of all new cancer cases (*Figure 3*). Cancer of these sites is associated with unhealthy lifestyle, such as excessive sunbathing, unhealthy diet, smoking and excessive alcohol consumption; the aim of primary prevention is to lower the risk associated with these factors. In males, the most frequent cancer site in 2016 was prostate (21% of all new cases). In females, breast cancer and non-melanoma skin cancer were the most frequent cancer sites with one fifth of all new cases each (*Figure 3*).

Since 1950, the crude cancer incidence rate in Slovenia increased by 780% in males and by 520% in females. In the last 10 years, the average annual increase in males was 2.3% and 1.9% in females. The increase in crude mortality rate in the last 10 years was on average 0.8% per year in males and 0.9% per years in females (*Figure 4*). More than half of the crude incidence rate increase is a consequence of ageing of the population. In the last 10 years, the average annual increase in cumulative incidence rate in males was 0.2%, but 0.9% in females. Cumulative mortality rate is decreasing since 1985 in both sexes (*Figure 4*), in the last 10 years, in males on average by 2.3% and in females on average by 0.6% annually. The decreasing mortality despite increasing incidence indicates improvement in treatment of cancer patients. It is a proof that more and more are cured of or living with and not dying from cancer. All average annual changes with the exception of cumulative incidence in males are statistically significant at a risk level of 0.05.

The time trends of common cancers in males show that lung cancer incidence was increasing till the beginning of the nineties, while it became stable onwards (around 90/100.000). Lung cancer was finally overcome by prostate cancer (average increase

by 3.0% per year) and by non-melanoma skin cancer (average increase by 5.4% per year). The huge increase in prostate cancer incidence rate in the last years is not due to some new risk factor, but more frequent use of prostate specific antigen (PSA) test as an opportunistic screening method, resulting in detection of many cancers that would have never progressed or would even not have been detected during lifetime without screening. The data for the last few years show that the incidence peak of prostate cancer has been reached. Similarly, the changes in the colorectal cancer incidence should be interpreted taking into consideration the changes in the diagnostic practice – in Slovenia the National colorectal cancer screening programme (Svit) has been introduced in 2009. The average annual increase in colorectal cancers in males in the period 2007–2010 was 7.5%, but there was an average annual decrease of 3.8% in the following years 2010–2016. In females, the incidence rate of breast (by 1.7% per year on average), lung (by 4.9% per year on average), non-melanoma skin (by 4.0% per year on average), and uterine cancer (by 2.7% per year on average) is increasing, while the incidence of cervical cancer is rapidly decreasing since the introduction of the National cervical cancer screening programme (ZORA); the average annual decrease in last ten years was 2.5%. Like in males also in females the colorectal cancer incidence time trends have been changed because the national screening programme Svit has been introduced: in the period 2007–2010 the incidence raised for 1.7% annually, but in the years 2010–2016 it decreased by 2.9% annually. The average annual percentage changes of incidence rates are presented in *Figure 5*.

In *Figure 6*, five-year net survival of all cancer patients (without patients with non-melanoma skin cancer) and patients with cancer of selected sites diagnosed in 2012–2016 is presented and compared to those diagnosed in 2007–2011. In males, the overall five-year net survival increased for 3 percentage points, especially because of better detection and reporting of earlier stage prostate cancer with better prognosis, as for these patients with the most common male cancer the survival increased by almost 4 percentage points. As 95% confidence intervals are not overlapping, it can be concluded that the difference is statistically significant. In females, the overall five-year net survival for the first time exceeds 60%. Among the common cancers, survival statistically significant increased in lung cancer patients (exceeding 20% for the first time), and in breast cancer survivors where it increased for 3% in recent years.

In this year's report, special attention is given to the achievements of the three Slovenian national cancer screening programmes ZORA, DORA and Svit, as can be monitored by the SCR data. *Figure 7a* (ZORA), *Figure 8a* (DORA) and *Figure 9*a (Svit) show, for each screening cancer location, time trends of crude incidence rates between 1987 and 2016. The changes in incidence trends resulting from the introduction of the programmes are highlighted. Thus, the incidence of cervical cancer began to decline already after the introduction of the ZORA pilot in 1997. Further, the incidence has more than halved since the launch of the ZORA in 2003. Similarly, for the Svit: colorectal cancer incidence has been increasing until the introduction of the screening programme, and has declined steadily since then. There is no change in the trend of breast cancer incidence since the introduction of the DORA programme, as DORA is the only one of the three screening programmes that does not detect precancerous lesions and thus does not reduce the incidence.

Figure 7b (ZORA), *Figure 8b* (DORA) and *Figure 9b* (Svit) show the difference in the stage at diagnosis between cancers detected in screening programme and those diagnosed outside the screening programme. All three screening programmes clearly show excellent fulfilment of one of the basic goals of each programme - early detection of diseases: cancers diagnosed in the screening programme are in significantly lower stages. Interpreting these results, however, it should be borne in mind that interval cancers (cancers that are detected after a negative screening test) are allocated to a group diagnosed outside the screening program in the analysis of SCR data.

Figures 7c and d (ZORA), *Figures 8c and d* (DORA) and *Figures 9c and d* (Svit) show the difference in survival between patients diagnosed with cancer in the screening programme and those diagnosed outside the screening programme. In all three cases, patients with cancer identified in the screening programme are better off. Differences also remain when comparing survival separately by stage at diagnosis. This result certainly requires additional analysis, since from the data available in the SCR it is not possible to estimate whether the treatment of patients detected in the screening programme is more advantageous or how much the classification of interval cancers contributes to such result.

In the majority of new cases, the diagnosis was confirmed microscopically. *Table 3* shows that in 2016, in 95.1% from 15,072 newly diagnosed cancer cases, the diagnosis was confirmed by histology or by cytology, in 4.7% with other investigations. It is encouraging that for several years only 0.2% of cases in the SCR were registered from death certificates only. They were probably not reported to SCR because they represent the patients not treated in the hospital due to age or advanced disease. *Table 3* presents the number of new cases by cancer site by basis of diagnosis, while in *Table 4* their distribution by 5-year age group is presented. In *Table 5*, there are age specific incidence rates for all and specific cancer sites.

In *Table 6a*, the number of new cases of all and selected cancer sites by different statistical regions is presented. While these data are important for planning health care facilities, the age standardised rates in *Table 6b* indicate the differences in the risk of cancer, as these differences are not due to different number and age structure of population in these regions. In 2015 the borders of four statistical regions changed (Savinjska, Posavska, Osrednjeslovenska and Zasavska) so the comparision and interpretation of data from previous years needs to be done carefully.

The morphology of tumours in 14,337 microscopically diagnosed cases is presented in *Table 7*. In this table, cases confirmed by histology (96%) and by cytology only (4%) are presented separately.

Table 8 shows the distribution of cancer patients by stage at diagnosis. A simplified definition of stages at diagnosis is used, which takes into account all investigation methods, including surgery or autopsy in case the patient has not been treated before death.

Age distribution of extra nodal and nodal sites of non-Hodgkin's malignant lymphomas is presented in *Table 9*. Owing to a small number of extra nodal sites, only the absolute numbers are given.

Table 10 shows the distribution of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues, published by World Health Organization.

Table 11 presents basic data on cancer patients' primary curative treatment. As in many cases combined treatment is applied, the sum of patients treated by different modalities is bigger than the number of new cases. *Table 11a* presents the mode of treatment of all cancer patients. *Tables 11b* and *11c* show the hospital where patients had surgery and/or systemic treatment as primary treatment; radiotherapy is performed at the Institute of Oncology Ljubljana only (with few exceptions, irradiated abroad).

In *Table 12*, prevalence of all cancer patients and patients with selected cancer diseases on December 31, 2016 is presented. Along with lifetime prevalence, there is also partial prevalence (1-, 3-, 5- and 10-years).

In *Table 13*, there are official data on cancer mortality in 2016. The data for this table have been prepared at the National Institute of Public Health of the RS. Crude and age standardised mortality rates are available on the internet portal Slora (http://www.slora.si/en/).

Table 14 shows 1-, 3-, 5-, and 10-years net survival of patients diagnosed between 2012 and 2016.

Acknowledgement

Physicians, nurses, and the administrative staff from the Slovenian hospitals and other healthcare institutions have been conscientiously providing data on new cancer cases, on the course of each individual disease as well as of its eventual outcome. If data on new cases had been incomplete, they effectively sought and completed the missing information. If data necessary for the Registry had not been available in hospitals, they were kindly provided by the family and general physicians.

The data of the patients diagnosed and treated at the Institute of Oncology Ljubljana were processed by Mrs. Maruška Ferjančič and Mrs. Polona Škulj from the Institute of Oncology's Hospital Registry. Data for melanoma and non-melanoma skin cancers were provided by Mrs. Agata Čampa from the Slovenian Melanoma Clinical Registry.

The Report could not be published – at least with the currently assured high credibility of data – without the traditional good cooperation of the Republic of Slovenia Population Registry, National Institute of Public Health of RS, and Statistical Office of RS.

Answers to all expert questions are provided by clinical specialists from the Institute of Oncology Ljubljana. Expert advice in the field of pathology is especially helpful, and has been offered to us by dr. Gorana Gašljević, MD.

The Registry is grateful to the above mentioned as well as to all others who have contributed to the current Report.

Editors

- Ravnihar B, Gruden I. Statističen pregled in kratka analiza prijavljenih rakovnih obolenj iz področja LRS za leto 1950. Zdrav Vestn 1951; 20: 264–77.
- Epidemiological and vital statistics report. Geneva: World Health Organization, 1961–1966.
- World health statistics report. Geneva: World Health Organization, 1970–1974.
- Rak v Sloveniji (1965–77). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1967–1980.
- Incidenca raka v Sloveniji (1978–2001). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1981–2004.
- Doll R, Payne P, Waterhouse J, eds. Cancer incidence in five continents. Vol 1. Berlin: Springer, 1966.
- Doll R, Muir C, Waterhouse J, eds. Cancer incidence in five continents. Vol 2. Lyon: International Agency for Research on Cancer, 1970.
- Waterhouse J, Muir C, Correa C, Powell J, eds. Cancer incidence in five continents. Vol 3. Lyon: International Agency for Research on Cancer, 1976 (IARC Sci Publ 15).
- Waterhouse J, Muir C, Shanmugaratnam K, Powell J, eds. Cancer incidence in five continents. Vol 4. Lyon: International Agency for Research on Cancer, 1982 (IARC Sci Publ 42).
- Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. Cancer incidence in five continents. Vol 5. Lyon: International Agency for Research on Cancer, 1987 (IARC Sci Publ 88).
- Parkin DM, Muir C, Whelan S, Gao Y, Ferlay J, Powell J, eds. Cancer incidence in five continents Lyon. Vol 6. International Agency for Research on Cancer, 1992 (IARC Sci Publ 120).
- Parkin DM, Whelan S, Ferlay J, Raymond L, Young J, eds. Cancer incidence in five continents. Vol 7. Lyon: International Agency for Research on Cancer, 1997 (IARC Sci Publ 143).
- Parkin DM, Whelan S, Ferlay J, Teppo L, Thomas DB, eds. Cancer incidence in five continents. Vol 8. Lyon: International Agency for Research on Cancer, 2002 (IARC Sci Publ 155).
- Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, eds. Cancer incidence in five continents. Vol 9. Lyon: International Agency for Research on Cancer, 2007 (IARC Sci Publ 160).
- Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J eds. Cancer Incidence in Five Continents, Vol. X (electronic version) Lyon, IARC, 2013. URL: http://ci5.iarc.fr.
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F.GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. URL: http://globocan.iarc.fr.
- Steliarova-Foucher E, O'Callaghan M, Ferlay J, Masuyer E, Forman D, Comber H, Bray F: European Cancer Observatory: Cancer Incidence, Mortality, Prevalence and Survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer. URL: http://eco.iarc.fr.
- Berrino F, Capocaccia R, Esteve J et al, eds. Survival of cancer patients in Europe: the EUROCARE-2 study. Lyon: International Agency for Research on Cancer, 1999.
- Berrino F, Capocaccia R, Gatta G et al, eds. Survival of cancer patients in Europe: the EUROCARE-3 study. Ann Oncol 2003: 14 (Suppl 5).
- Berrino F, DeAngelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–1999: Results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773–83.
- De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2013; 15: 23–34
- Gatta G, Botta L, Rossi S et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15: 35-47.
- Coleman, MP, Quaresma, M, Berrino, F..., and the CONCORD Working Group. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008; 9: 730–756
- Allemani C, Weir HK, Carreira H … and the CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015; 385: 977-1010.

- Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M and CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023-75.
- Gatta G, van der Zwan JM, Casali PG et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011: 47; 2493–511.
- Pompe-Kirn V, Primic Žakelj M, Ferligoj A, Škrk J. Zemljevidi incidence raka v Sloveniji 1978–1987 (Atlas of cancer incidence in Slovenia 1978–1987). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1992.
- Pompe-Kirn V, Zakotnik B, Benulič T, Volk N, Škrk J. Preživetje bolnikov z rakom v Sloveniji 1963–1990 (Cancer patients' survival in Slovenia 1963–1990). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1995.
- Pompe-Kirn V, Zakotnik B, Zadnik V. Preživetje bolnikov z rakom v Sloveniji 1983–1997 (Cancer patients' survival in Slovenia 1983–1997). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2003.
- Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji (Survival of cancer patients, diagnosed in 1991–2005 in Slovenia). Ljubljana: Onkološki inštitut, 2009.
- Uredba o standardni klasifikaciji teritorialnih enot – SKTE. Ur. l. RS št. 28/2000.
- Uredba komisije (EU) št. 1319/2013 o spremembi prilog k Uredbi (ES) št. 1059/2003 Evropskega parlamenta in Sveta o oblikovanju skupne klasifikacije statističnih teritorialnih enot (NUTS)
- Savezni zavod za zdravstvenu zaštitu. Međunarodna klasifikacija bolesti, povreda i uzroka smrti. 8. revizija. Novi sad: Savezni zavod za zdravstvenu zaštitu, 1970.
- Inštitut za varovanje zdravja RS. Mednarodna klasifikacija bolezni in sorodnih zdravstvenih problemov za statistične namene. 10. revizija (International statistical classification of diseaseses and related health problems). Ljubljana: Inštitut za varovanje zdravja, 1995.
- World Health Organisation. International statistical classification of diseases and related health problems. Tenth revision, edition 2010 (4th edition). Geneva: WHO Press, 2011.
- World Health Organisation. International classification of diseases for Oncology. 3rd Edition. Geneva: World Health Organisation, 2000.
- World Health Organisation. International Classification of Diseases for Oncology, Third Edition, First Revision. Geneva: World Health Organization, 2013.
- Swerdlow SH., Campo E, Harris NL et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO/IARC Classification of Tumours, 4th Edition, Volume 2. Geneva: World Health Organization, 2008.
- Jensen OM, Parkin M et al, eds. Cancer registration: principles and methods. Lyon: International Agency for Research on Cancer, 1991. (IARC Sci Publ 95).
- Dos Santos Silva I. Cancer epidemiology: principles and methods. Lyon: International Agency for Research on Cancer, 1999.
- Moller B, Fekjaer H, Hakulinen T et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med 2003; 15: 2751–66.
- SI-STAT podatkovni portal. Ljubljana, Statistični urad Republike Slovenije, 2014. URL: http://pxweb.stat.si/.
- Dyba T, Hakulinen T, Päivärinta L. A simple non-linear model in incidence prediction. Statistics in Medicine 16: 2297–309, 1997.
- Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Statistics in medicine 2000; 19(3): 335–51.
- Pohar M, Stare J. Relative survival analysis in R. Computer Methods and Programs in Biomedicine 2006; 81: 272–8.
- Perme MP, Stare J, Estève J. On estimation in relative survival. Biometrics. 2012;68(1):113-20.
- Žagar T. Lifetables for Slovenia 1982–2007. Rostock: Max Planck, 2008. URL: http://www.lifetable.de/cgi-bin/Country.plx?Country=Slovenia.
- Del Turco MR, Ponti A, Bick U, Biganzoli L, Cserni G, Cutuli B et al. Quality indicators in breast cancer care. Eur J Cancer 2010; 46: 2344-56.
- Projekt TRANSCAN/HIGHCARE: www.transcanfp7.eu/index.php/abstract/highcare.html.

Slika 1: Breme raka, Slovenija 2016.
Figure 1: Cancer burden, Slovenia 2016.



Slika 2: Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2016.
Figure 2: Percentage distribution of all cancer sites by age group and by sex, Slovenia 2016.



Slika 3: Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2016.
Figure 3: The leading cancer sites with percentage distribution by sex and for both sexes together, Slovenia 2016.





* Pojasnilo / Explanation:

Glava in vrat / Head and neck (C00–C14, C30–C32)
Debelo črevo in danka / Colorectum (C18–C20)
Sapnik, sapnici in pljuča / Trachea, bronchus and lung (C33–C34)
Ledvica z ledvičnim mehom / Kidney with renal pelvis (C64–C65)

Slika 4: Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2016.

Figure 4: Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2016.





* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05

* Average annual change is statistically significant at 0.05 significance level

Slika 5: Groba letna incidenčna stopnja izbranih rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2016.

Figure 5: Crude annual incidence rates of selected primary cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2016.



* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05

* Average annual change is statistically significant at 0.05 significance level

Slika 6: Pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2007–2011 in 2012–2016 po spolu.

Figure 6: Five-year net survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2007–2011 and 2012–2016 by sex.



Slika 6: Nadaljevanje.
Figure 6: Continued.



Slika 7a: Časovni trend grobe letne incidenčne stopnje raka materničnega vratu (C53) po stadijih s povrečno letno spremembo za tri obdobja: pred pričetkom presejalnega programa ZORA (1987–1996), v času pilotnega presejanja (1997–2002) in od pričetka presejalnega programa ZORA (2003–2016), Slovenija 1987–2016.

Figure 7a: Time trend of crude annual incidence rates for cervical cancer (C53) by stage with avarage annual change for three periods: before the start of screening program ZORA (1987–1996), during pilot screening (1997–2002) and since the start of screening programme ZORA (2003–2016), Slovenia 1987–2016.



Slika 7b: Delež žensk z rakom materničnega vratu (C53) glede na udeležbo v presejalnem programu ZORA in FIGO stadij, Slovenija 2012–2016.

Figure 7b: Proportion of women with cervical cancer (C53) according to attendance in organised screening programme ZORA and FIGO stage, Slovenia 2012–2016.



Slika 7c: Čisto preživetje bolnic z rakom maternične vratu starih 20–64 let s 95 % intervalom zaupanja glede na udeležbo v presejalnem programu ZORA, Slovenija 2012–2016.

Figure 7c: Net survival of cervical cancer (women aged 20–64 years) with 95% confidence interval according to attendance in organised screening programme ZORA, Slovenia 2012–2016.



Slika 7d: Čisto preživetje bolnic z rakom maternične vratu starih 20–64 let po FIGO stadiju glede na udeležbo v presejalnem programu ZORA, Slovenija 2012–2016.

Figure 7d: Net survival of cervical cancer (women aged 20–64 years) by FIGO stage according to attendance in organised screening programme ZORA, Slovenia 2012–2016.



Slika 8a: Časovni trend grobe letne incidenčne stopnje raka dojk pri ženskah (C50) po stadijih s povrečno letno spremembo za dve obdobji: pred pričetkom presejalnega programa DORA (1987–2010) in od pričetka presejalnega programa DORA (2011–2016), Slovenija 1987–2016.

Figure 8a: Time trend of crude annual incidence rates for breast cancer in women (C50) by stage with avarage annual change for two periods: before the start of screening program DORA (1987–2010) and since the start of screening programme DORA (2011–2016), Slovenia 1987–2016.



*Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05
*Average annual change is statistically significant at 0.05 significance level

Slika 8b: Delež žensk z rakom dojke (C50) glede na udeležbo v presejalnem programu DORA in UICC stadij, Slovenija 2012–2016.

Figure 8b: Proportion of women with breast cancer (C50) according to attendance in organised screening programme DORA and UICC stage, Slovenia 2012–2016.



Slika 8c: Čisto preživetje bolnic z rakom dojk starih 50–69 let s 95 % intervalom zaupanja glede na udeležbo v presejalnem programu DORA, Slovenija 2012–2016.

Figure 8c: Net survival of breast cancer (women aged 50–69 years) with 95% confidence interval according to attendance in organised screening programme DORA, Slovenia 2012–2016.



Slika 8d: Čisto preživetje bolnic z rakom dojk starih 50–69 let po UICC stadiju glede na udeležbo v presejalnem programu DORA, Slovenija 2012–2016.

Figure 8d: Net survival of breast cancer (women aged 50–69 years) by UICC stage according to attendance in organised screening programme DORA, Slovenia 2012–2016.



Slika 9a: Časovni trend grobe letne incidenčne stopnje raka debelega črevesa in danke (C18–C20) za oba spola skupaj po stadijih s povrečno letno spremembo za dve obdobji: pred pričetkom presejalnega programa Svit (1987–2009) in od pričetka presejalnega programa Svit (2010–2016), Slovenija 1987–2016.

Figure 9a: Time trend of crude annual incidence rates for colon and rectum cancers (C18–C20) for both sexes together by stage with avarage annual change for two periods: before the start of screening program Svit (1987–2009) and since the start of screening programme Svit (2010–2016), Slovenia 1987–2016.



*Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05
*Average annual change is statistically significant at 0.05 significance level

Slika 9b: Delež bolnikov z rakom debelega črevesa in danke (C18–C20) glede na udeležbo v presejalnem programu Svit in UICC stadij, Slovenija 2012–2016.

Figure 9b: Proportion of patients with colon and rectum cancer (C18–C20) according to attendance in organised screening programme Svit and UICC stage, Slovenia 2012–2016.



Slika 9c: Čisto preživetje bolnikov z rakom debelega črevesa in danke starih 50–74 let s 95 % intervalom zaupanja glede na udeležbo v presejalnem programu Svit, Slovenija 2012–2016.

Figure 9c: Net survival of colorectal cancer (patients aged 50–74 years) with 95% confidence interval according to attendance in organised screening programme Svit, Slovenia 2012–2016.



Slika 9d: Čisto preživetje bolnikov z rakom debelega črevesa in danke starih 50–74 let po UICC stadiju glede na udeležbo v presejalnem programu Svit, Slovenija 2012–2016.

Figure 9d: Net survival of colorectal cancer (patients aged 50–74 years) by UICC stage according to attendance in organised screening programme Svit, Slovenia 2012–2016.



Tabela 1: Opazovana in ocenjena incidenca raka, Slovenija 2007–2016 in 2019.

Table 1: Observed and estimated cancer incidence, Slovenia 2007–2016 and 2019.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Povprečne letne opazovane vrednosti 2007–2011		Povprečne letne opazovane vrednosti 2012–2016		Ocena za 2019			
			Število	Incidenčna stopnja na 100.000	Število	Incidenčna stopnja na 100.000	Število (95 % napovedni interval)		Incidenčna stopnja na 100.000 (95 % napovedni interval)	
			Povprečne letne opazovane vrednosti 2007–2011		Average annual observed values 2012–2016		Estimation for 2019			
			Number	Incidence rate per 100,000	Number	Incidence rate per 100,000	Number (95% prediction interval)		Incidence rate per 100,000 (95% prediction interval)	
C00–C96	Vse lokacije All sites	M+Ž	12795	627,9	14252	691,5	15844	15496–16192	761	745–778
		M	6916	686,6	7753	759,3	8726	8456–8996	840	814–866
		Ž	5879	570,5	6499	625,0	7118	6898–7337	683	662–704
C00–C14	Usta in žrelo	M	272	27,1	274	26,9	271	228–314	26	22–30
	Mouth and pharynx	Ž	70	6,8	77	7,4	80	62–99	8	6–9
C15	Požiralnik	M	69	6,9	72	7,0	66	45–87	6	4–8
	Oesophagus	Ž	17	1,6	15	1,5	16	5–26	2	1–3
C16	Želodec	M	292	29,0	292	28,6	287	178–395	28	17–38
	Stomach	Ž	188	18,3	171	16,4	159	127–192	15	12–18
C18	Debelo črevo	M	510	50,6	489	47,9	502	436–569	48	42–55
	Colon	Ž	394	38,2	373	35,9	382	330–434	37	32–42
C19–C20	Rektum in rektosigmoidna zveza	M	409	40,6	365	35,8	341	294–388	33	28–37
	Rectum and rectosigmoid junction	Ž	255	24,7	209	20,1	173	140–206	17	13–20
C22	Jetra in intrahepatični vodi	M	118	11,7	155	15,2	175	139–211	17	13–20
	Liver and intrahepatic bile ducts	Ž	46	4,5	55	5,3	65	43–87	6	4–8
C23–C24	Žolčnik in žolčevodi	M	65	6,5	84	8,2	105	76–133	10	7–13
	Gallbladder and billiary tract	Ž	101	9,8	106	10,2	103	77–130	10	7–12
C25	Trebušna slinavka	M	164	16,3	195	19,1	220	180–260	21	17–25
	Pancreas	Ž	176	17,1	183	17,6	197	160–235	19	15–23
C32	Grlo	M	99	9,9	86	8,4	81	57–106	8	6–10
	Larynx	Ž	11	1,0	13	1,3	14	4–24	1	0–2
C33–C34	Sapnik, sapnici in pljuča	M	870	86,4	923	90,4	954	870–1038	92	84–100
	Trachea, bronchus and lung	Ž	361	35,0	457	44,0	572	511–632	55	49–61
C43	Maligni melanom kože	M	227	22,5	286	28,0	350	302–399	34	29–38
	Malignant melanoma of skin	Ž	245	23,8	256	24,7	266	223–309	26	21–30
C44	Druge maligne neoplazme kože	M	1014	100,7	1342	131,4	1701	1593–1809	164	153–174
	Skin, other malignomas	Ž	1067	103,5	1312	126,1	1548	1447–1650	149	139–158
C48–C49	Vezivno in mehko tkivo	M	27	2,7	32	3,1	33	19–47	3	2–5
	Connective and soft tissue	Ž	37	3,6	44	4,2	48	29–67	5	3–6
C50	Dojka	M	10	1,0	13	1,3	15	5–26	1	0–3
	Breast	Ž	1189	115,4	1322	127,1	1422	1323–1521	136	127–146
C53	Maternični vrat	M	–	–	–	–	–	–	–	–
	Cervix uteri	Ž	140	13,5	120	11,5	106	82–130	10	8–13
C54	Maternično telo	M	–	–	–	–	–	–	–	–
	Corpus uteri	Ž	296	28,8	344	33,1	389	337–440	37	32–42
C56	Jajčnik	M	–	–	–	–	–	–	–	–
	Ovary	Ž	169	16,4	156	15,0	135	106–165	13	10–16
C61	Prostata	M	1393	138,2	1567	153,5	1834	1718–1950	177	165–188
	Prostate	Ž	–	–	–	–	–	–	–	–
C62	Modo	M	100	10,0	113	11,0	125	94–156	12	9–15
	Testis	Ž	–	–	–	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehom	M	229	22,7	247	24,2	268	225–312	26	22–30
	Kidney with renal pelvis	Ž	117	11,4	135	12,9	153	119–186	15	11–18
C67	Sečni mehur	M	214	21,2	248	24,3	278	233–323	27	22–31
	Bladder	Ž	79	7,6	93	8,9	107	79–135	10	8–13
C70–C72	Centralni in avtonomni živčni sistem	M	83	8,2	93	9,1	110	83–137	11	8–13
	Central and autonomic nervous system	Ž	65	6,3	69	6,7	75	52–98	7	5–9
C73	Ščitnica	M	36	3,6	44	4,3	52	32–72	5	3–7
	Thyroid gland	Ž	118	11,5	138	13,2	159	127–191	15	12–18
C81	Hodgkinova bolezen	M	26	2,6	24	2,4	25	12–38	2	1–4
	Hodgkin's disease	Ž	25	2,4	24	2,3	28	14–41	3	1–4
C82–C85	Ne-Hodgkinovi limfomi	M	150	14,9	210	20,6	282	239–325	27	23–31
	Non-Hodgkin's lymphoma	Ž	148	14,4	200	19,3	243	202–283	23	19–27
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov	M	65	6,5	70	6,9	72	50–94	7	5–9
	Multiple myeloma and malignant plasma cell neoplasms	Ž	59	5,7	63	6,0	62	42–82	6	4–8
C91–C95	Levkemije	M	158	15,7	171	16,8	180	143–216	17	14–21
	Leukaemias	Ž	121	11,8	131	12,6	144	113–176	14	11–17

Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2016.

Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2016.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število Number	Groba incidenčna stopnja na 100.000 Crude incidence rate per 100,000	SSS* – svetovni standard ASR** – World standard	SSS* – evropski standard ASR** – European standard	SSS* – slovenski standard ASR** – Slovenian standard
C00–C96	Vse lokacije All sites	M+Ž	15072	730,1	350,4	497,4	590,4
		M	8117	792,8	403,8	588,3	712,4
		Ž	6955	668,5	311,9	432,9	504,0
C00–C14	Usta in žrelo	M	255	24,9	14,1	19,3	21,6
	Mouth and pharynx	Ž	98	9,4	5,1	6,8	7,7
C15	Požiralnik	M	50	4,9	2,7	3,8	4,3
	Oesophagus	Ž	14	1,3	0,6	0,9	1,0
C16	Želodec	M	272	26,6	12,6	19,2	23,6
	Stomach	Ž	171	16,4	6,1	9,1	10,9
C18	Debelo črevo	M	514	50,2	24,2	36,6	45,8
	Colon	Ž	393	37,8	15,1	22,2	27,0
C19–C20	Rektum in rektosigmoidna zveza	M	357	34,9	17,7	26,0	31,2
	Rectum and rectosigmoid junction	Ž	204	19,6	8,0	11,7	14,2
C22	Jetra in intrahepatični vodi	M	140	13,7	6,5	9,9	12,2
	Liver and intrahepatic bile ducts	Ž	61	5,9	2,1	3,3	4,0
C23–C24	Žolčnik in žolčevodi	M	100	9,8	4,4	6,9	8,6
	Gallbladder and billiary tract	Ž	97	9,3	3,1	4,8	6,0
C25	Trebušna slinavka	M	194	18,9	9,2	13,8	17,1
	Pancreas	Ž	195	18,7	6,9	10,3	12,7
C32	Grlo	M	92	9,0	4,7	6,7	7,7
	Larynx	Ž	17	1,6	0,8	1,1	1,3
C33–C34	Sapnik, sapnici in pljuča	M	966	94,3	47,1	69,2	82,6
	Trachea, bronchus and lung	Ž	555	53,3	23,9	34,2	39,5
C43	Maligni melanom kože	M	304	29,7	16,7	23,1	27,2
	Malignant melanoma of skin	Ž	276	26,5	15,0	19,6	22,0
C44	Druge maligne neoplazme kože	M	1491	145,6	69,3	105,7	131,5
	Skin, other malignomas	Ž	1459	140,2	56,1	81,5	97,7
C48–C49	Vezivno in mehko tkivo	M	30	2,9	2,4	2,6	2,7
	Connective and soft tissue	Ž	46	4,4	3,4	3,6	3,7
C50	Dojka	M	14	1,4	0,6	0,9	1,1
	Breast	Ž	1386	133,2	72,2	97,5	110,6
C53	Maternični vrat	M	–	–	–	–	–
	Cervix uteri	Ž	123	11,8	7,8	9,8	10,8
C54	Maternično telo	M	–	–	–	–	–
	Corpus uteri	Ž	361	34,7	16,1	22,9	26,4
C56	Jajčnik	M	–	–	–	–	–
	Ovary	Ž	129	12,4	6,0	8,5	9,8
C61	Prostata	M	1690	165,1	81,0	119,8	147,9
	Prostate	Ž	–	–	–	–	–
C62	Modo	M	107	10,5	9,5	10,3	11,0
	Testis	Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehom	M	250	24,4	12,5	18,3	21,7
	Kidney with renal pelvis	Ž	142	13,6	5,4	8,0	9,9
C67	Sečni mehur	M	252	24,6	11,6	17,7	22,0
	Bladder	Ž	115	11,1	3,9	5,9	7,2
C70–C72	Centralni in avtonomni živčni sistem	M	102	10,0	7,1	8,5	9,3
	Central and autonomic nervous system	Ž	60	5,8	3,9	4,5	4,9
C73	Ščitnica	M	36	3,5	2,3	2,9	3,3
	Thyroid gland	Ž	166	16,0	11,5	13,6	14,9
C81	Hodgkinova bolezen	M	30	2,9	2,6	2,8	2,9
	Hodgkin's disease	Ž	29	2,8	3,0	3,0	3,1
C82–C85	Ne-Hodgkinovi limfomi	M	242	23,6	13,1	18,2	21,6
	Non-Hodgkin's lymphoma	Ž	205	19,7	9,3	12,9	15,1
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov	M	82	8,0	3,9	5,9	7,2
	Multiple myeloma and malignant plasma cell neoplasms	Ž	47	4,5	1,8	2,7	3,3
C91–C95	Levkemije	M	169	16,5	9,1	12,6	15,1
	Leukaemias	Ž	137	13,2	6,9	8,5	9,5

* SSS – starostno standardizirana incidenčna stopnja na 100.000

** ASR – age-standardised incidence rate per 100,000

Tabela 3: Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2016.
Table 3: Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2016.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri Microscopically confirmed cases		Ugotovljeni z drugimi preiskavami Confirmed by other investigations		Registrirani samo iz zdravniških poročil o vzroku smrti Registered from death certificates only	
				Število Number	%* %*	Število Number	%* %*	Število Number	%* %*
C00–C96	Vse lokacije All sites	M+Ž	15072	14337	95,1	703	4,7	32	0,2
		M	8117	7715	95,0	388	4,8	14	0,2
		Ž	6955	6622	95,2	315	4,5	18	0,3
C00	Ustnica Lip	M	15	15	100	0	0	0	0
		Ž	10	10	–	0	–	0	–
C01	Baza jezika Base of tongue	M	22	22	100	0	0	0	0
		Ž	7	7	–	0	–	0	–
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	13	13	–	0	–	0	–
		Ž	17	17	100	0	0	0	0
C03	Dlesen Gum	M	6	6	–	0	–	0	–
		Ž	10	10	–	0	–	0	–
C04	Ustno dno Floor of mouth	M	24	24	100	0	0	0	0
		Ž	8	8	–	0	–	0	–
C05	Nebo Palate	M	10	10	–	0	–	0	–
		Ž	7	7	–	0	–	0	–
C06	Usta, drugi deli Mouth, other & unspecified parts	M	13	13	–	0	–	0	–
		Ž	7	7	–	0	–	0	–
C07	Parotidna žleza Parotid gland	M	11	11	–	0	–	0	–
		Ž	8	8	–	0	–	0	–
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0	0	–	0	–	0	–
		Ž	2	2	–	0	–	0	–
C09	Tonzila Tonsil	M	41	41	100	0	0	0	0
		Ž	13	13	–	0	–	0	–
C10	Orofarinks Oropharynx	M	40	40	100	0	0	0	0
		Ž	4	4	–	0	–	0	–
C11	Nazofarinks Nasopharynx	M	8	8	–	0	–	0	–
		Ž	1	1	–	0	–	0	–
C12	Piriformni sinus Pyriform sinus	M	32	32	100	0	0	0	0
		Ž	1	1	–	0	–	0	–
C13	Hipofarinks Hypopharynx	M	20	20	100	0	0	0	0
		Ž	3	3	–	0	–	0	–
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–
C15	Požiralnik Oesophagus	M	50	48	96,0	2	4,0	0	0
		Ž	14	13	–	1	–	0	–
C16	Želodec Stomach	M	272	270	99,3	2	0,7	0	0
		Ž	171	160	93,6	10	5,8	1	0,6
C17	Tanko črevo Small intestine	M	25	25	100	0	0	0	0
		Ž	19	19	100	0	0	0	0
C18	Debelo črevo Colon	M	514	497	96,7	17	3,3	0	0
		Ž	393	370	94,1	20	5,1	3	0,8
C19	Rektosigmoidna zveza Rectosigmoid junction	M	64	64	100	0	0	0	0
		Ž	40	39	97,5	1	2,5	0	0
C20	Rektum Rectum	M	293	288	98,3	5	1,7	0	0
		Ž	164	160	97,6	4	2,4	0	0
C21	Anus in analni kanal Anus and anal canal	M	10	10	–	0	–	0	–
		Ž	11	11	–	0	–	0	–
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	140	81	57,9	58	41,4	1	0,7
		Ž	61	37	60,7	23	37,7	1	1,6
C23	Žolčnik Gallbladder	M	18	11	61,1	7	38,9	0	0
		Ž	37	26	70,3	10	27,0	1	2,7
C24	Drugi in neopredeljeni deli biliarnega trakta Billiary tract, other and unspecified parts	M	82	55	67,1	27	32,9	0	0
		Ž	60	31	51,7	28	46,7	1	1,7

Nadaljevanje —>
Continued —>

Tabela 3: Nadaljevanje.
Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri Microscopically confirmed cases		Ugotovljeni z drugimi preiskavami Confirmed by other investigations		Registrirani samo iz zdravniških poročil o vzroku smrti Registered from death certificates only	
				Število Number	%* %*	Število Number	%* %*	Število Number	%* %*
C25	Trebušna slinavka	M	194	134	69,1	59	30,4	1	0,5
	Pancreas	Ž	195	121	62,1	73	37,4	1	0,5
C26	Druga in slabo opredeljena mesta v prebavnih organih	M	1	0	–	1	–	0	–
	Other and ill-defined digestive organs	Ž	3	2	–	1	–	0	–
C30	Nosna votlina in srednje uho	M	2	2	–	0	–	0	–
	Nasal cavity and middle ear	Ž	5	5	–	0	–	0	–
C31	Obnosni sinusi	M	2	2	–	0	–	0	–
	Accessory sinuses	Ž	2	2	–	0	–	0	–
C32	Grlo	M	92	92	100	0	0	0	0
	Larynx	Ž	17	17	100	0	0	0	0
C33	Sapnik	M	0	0	–	0	–	0	–
	Trachea	Ž	0	0	–	0	–	0	–
C34	Sapnica in pljuča	M	966	881	91,2	81	8,4	4	0,4
	Bronchus and lung	Ž	555	505	91,0	50	9,0	0	0
C37	Timus	M	5	5	–	0	–	0	–
	Thymus	Ž	7	7	–	0	–	0	–
C38	Srce, mediastinum, plevra	M	4	4	–	0	–	0	–
	Heart, mediastinum, pleura	Ž	3	2	–	1	–	0	–
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih	M	0	0	–	0	–	0	–
	Other and ill-defined sites in the respiratory system and intrathoracic organs	Ž	0	0	–	0	–	0	–
C40	Kosti, sklepni hrustanec udov	M	5	5	–	0	–	0	–
	Bone and articular cartilage of limbs	Ž	5	5	–	0	–	0	–
C41	Kosti, sklepni hrustanec, drugje	M	5	5	–	0	–	0	–
	Bone and articular cartilage of other and unspecified parts	Ž	4	4	–	0	–	0	–
C43	Maligni melanom kože	M	304	304	100	0	0	0	0
	Malignant melanoma of skin	Ž	276	276	100	0	0	0	0
C44	Druge maligne neoplazme kože	M	1491	1487	99,7	4	0,3	0	0
	Skin, other malignomas	Ž	1459	1459	100	0	0	0	0
C45	Mezoteliom	M	29	29	100	0	0	0	0
	Mesothelioma	Ž	14	14	–	0	–	0	–
C46	Kaposijev sarkom	M	1	1	–	0	–	0	–
	Kaposi's sarcoma	Ž	1	1	–	0	–	0	–
C47	Periferni živci in avtonomno živčevje	M	2	2	–	0	–	0	–
	Peripheral nerves and autonomic nervous system	Ž	2	2	–	0	–	0	–
C48	Peritonej in retroperitonej	M	6	6	–	0	–	0	–
	Peritoneum and retroperitoneum	Ž	14	13	–	1	–	0	–
C49	Drugo vezivno in mehko tkivo	M	24	24	100	0	0	0	0
	Other connective and soft tissue	Ž	32	31	96,9	1	3,1	0	0
C50	Dojka	M	14	13	–	1	–	0	–
	Breast	Ž	1386	1380	99,6	2	0,1	4	0,3
C51	Žensko zunanje spolovilo	M	–	–	–	–	–	–	–
	Vulva	Ž	57	57	100	0	0	0	0
C52	Nožnica	M	–	–	–	–	–	–	–
	Vagina	Ž	14	14	–	0	–	0	–
C53	Maternični vrat	M	–	–	–	–	–	–	–
	Cervix uteri	Ž	123	123	100	0	0	0	0
C54	Maternično telo	M	–	–	–	–	–	–	–
	Corpus uteri	Ž	361	360	99,7	1	0,3	0	0
C55	Maternica, neopredeljeno	M	–	–	–	–	–	–	–
	Uterus, unspecified	Ž	18	15	83,3	2	11,1	1	5,6
C56	Jajčnik	M	–	–	–	–	–	–	–
	Ovary	Ž	129	125	96,9	4	3,1	0	0

Nadaljevanje —>
Continued —>

Tabela 3: Nadaljevanje.
Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri Microscopically confirmed cases		Ugotovljeni z drugimi preiskavami Confirmed by other investigations		Registrirani samo iz zdravniških poročil o vzroku smrti Registered from death certificates only	
				Število Number	%* %*	Število Number	%* %*	Število Number	%* %*
C57	Drugi in neopredeljeni ženski spolni organi	M	–	–	–	–	–	–	–
	Other and unspecified parts of female genital organs	Ž	19	18	94,7	1	5,3	0	0
C58	Posteljica	M	–	–	–	–	–	–	–
	Placenta	Ž	0	0	–	0	–	0	–
C60	Penis	M	17	17	100	0	0	0	0
	Penis	Ž	–	–	–	–	–	–	–
C61	Prostata	M	1690	1642	97,2	44	2,6	4	0,2
	Prostate	Ž	–	–	–	–	–	–	–
C62	Modo	M	107	107	100	0	0	0	0
	Testis	Ž	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi	M	3	3	–	0	–	0	–
	Other and unspecified male genital organs	Ž	–	–	–	–	–	–	–
C64	Ledvica razen meha	M	228	210	92,1	18	7,9	0	0
	Kidney, except renal pelvis	Ž	131	115	87,8	16	12,2	0	0
C65	Ledvični meh	M	22	21	95,5	1	4,5	0	0
	Renal pelvis	Ž	11	9	–	2	–	0	–
C66	Sečevod	M	15	13	86,7	2	13,3	0	0
	Ureter	Ž	5	4	–	1	–	0	–
C67	Sečni mehur	M	252	244	96,8	7	2,8	1	0,4
	Bladder	Ž	115	112	97,4	2	1,7	1	0,9
C68	Drugi in neopredeljeni sečni organi	M	2	2	–	0	–	0	–
	Other and unspecified urinary organs	Ž	1	1	–	0	–	0	–
C69	Oko in očesni adneksi	M	10	10	–	0	–	0	–
	Eye and adnexa	Ž	11	10	–	1	–	0	–
C70	Meninge	M	2	2	–	0	–	0	–
	Meninges	Ž	0	0	–	0	–	0	–
C71	Možgani	M	97	82	84,5	15	15,5	0	0
	Brain	Ž	55	45	81,8	9	16,4	1	1,8
C72	Hrbtni mozeg, možganski živci in drugi deli CŽS	M	3	2	–	1	–	0	–
	Spinal cord, cranial nerves and other parts of CNS	Ž	5	4	–	1	–	0	–
C73	Ščitnica	M	36	36	100	0	0	0	0
	Thyroid gland	Ž	166	166	100	0	0	0	0
C74	Nadledvična žleza	M	4	4	–	0	–	0	–
	Adrenal gland	Ž	6	6	–	0	–	0	–
C75	Druge endokrine žleze in sorodne strukture	M	1	1	–	0	–	0	–
	Other endocrine glands and related structures	Ž	0	0	–	0	–	0	–
C76	Druga in slabo opredeljena mesta	M	3	2	–	1	–	0	–
	Other and ill-defined sites	Ž	18	7	38,9	11	61,1	0	0
C77	Metastaza in neopredeljena maligna neoplazma bezgavk	M	20	19	95,0	1	5,0	0	0
	Metastasis and unspecified malignant neoplasm of lymph nodes	Ž	17	15	88,2	2	11,8	0	0
C78	Metastaze dihal in prebavil	M	37	21	56,8	15	40,5	1	2,7
	Metastases of respiratory and digestive organs	Ž	41	26	63,4	15	36,6	0	0
C79	Metastaze, drugje	M	15	9	60,0	6	40,0	0	0
	Metastases of other sites	Ž	13	10	–	3	–	0	–
C80	Maligna neoplazma brez opredeljenega mesta	M	69	57	82,6	12	17,4	0	0
	Malignant neoplasm without specification of site	Ž	66	46	69,7	18	27,3	2	3,0
C81	Hodgkinova bolezen	M	30	30	100	0	0	0	0
	Hodgkin's disease	Ž	29	29	100	0	0	0	0
C82	Folikularni ne-Hodgkinov limfom	M	60	60	100	0	0	0	0
	Follicular non-Hodgkin's lymphoma	Ž	57	57	100	0	0	0	0
C83	Difuzni ne-Hodgkinov limfom	M	159	159	100	0	0	0	0
	Diffuse non-Hodgkin's lymphoma	Ž	122	122	100	0	0	0	0

Nadaljevanje —>
Continued —>

Tabela 3: Nadaljevanje.
Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri Microscopically confirmed cases		Ugotovljeni z drugimi preiskavami Confirmed by other investigations		Registrirani samo iz zdravniških poročil o vzroku smrti Registered from death certificates only	
				Število Number	%* %*	Število Number	%* %*	Število Number	%* %*
C84	Limfomi celic T in kožni limfom celic T	M	19	19	100	0	0	0	0
	Peripheral and cutaneous T-cell lymphomas	Ž	16	16	100	0	0	0	0
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma	M	4	4	–	0	–	0	–
	Other and unspecified types of non-Hodgkin's lymphoma	Ž	10	10	–	0	–	0	–
C88	Maligne imunoproliferativne bolezni	M	5	5	–	0	–	0	–
	Malignant immunoproliferative diseases	Ž	3	3	–	0	–	0	–
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov	M	82	82	100	0	0	0	0
	Multiple myeloma and malignant plasma cell neoplasms	Ž	47	47	100	0	0	0	0
C91.0	Limfatična levkemija, akutna	M	7	7	–	0	–	0	–
	Lymphoblastic leukaemia, acute	Ž	11	11	–	0	–	0	–
C91.1–C91.9	Limfatična levkemija, druga	M	76	74	97,4	0	0	2	2,6
	Lymphoid leukaemia, other	Ž	56	55	98,2	0	0	1	1,8
C92	Mieloična levkemija	M	65	65	100	0	0	0	0
	Myeloid leukaemia	Ž	52	52	100	0	0	0	0
C93	Monocitna levkemija	M	4	4	–	0	–	0	–
	Monocytic leukaemia	Ž	2	2	–	0	–	0	–
C94	Druge opredeljene levkemije	M	17	16	94,1	1	5,9	0	0
	Other leukaemias of specified cells	Ž	15	15	100	0	0	0	0
C95	Levkemija z neopredeljenim celičnim tipom	M	0	0	–	0	–	0	–
	Leukaemia, unspecified cell type	Ž	1	1	–	0	–	0	–
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva	M	86	86	100	0	0	0	0
	Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	Ž	104	104	100	0	0	0	0

Zgoraj neupoštevani
Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri Microscopically confirmed cases		Ugotovljeni z drugimi preiskavami Confirmed by other investigations		Registrirani samo iz zdravniških poročil o vzroku smrti Registered from death certificates only	
				Število Number	%* %*	Število Number	%* %*	Število Number	%* %*
D03	Melanom, in situ	M	139	139	100	0	0	0	0
	Melanoma, in situ	Ž	140	140	100	0	0	0	0
D05	Dojka, in situ	M	1	1	–	0	–	0	–
	Breast, in situ	Ž	136	136	100	0	0	0	0
D06	Maternični vrat, in situ (CIN III)	M	–	–	–	–	–	–	–
	Cervix uteri, in situ (CIN III)	Ž	1094	1094	100	0	0	0	0
D09.0	Sečni mehur, in situ	M	176	176	100	0	0	0	0
	Bladder, in situ	Ž	60	60	100	0	0	0	0
D32.0, D42.0	Meninge, benigna neoplazma in neoplazma negotovega značaja	M	34	25	73,5	9	26,5	0	0
	Benign neoplasm and neoplasm of uncertain behaviour of meninges	Ž	95	65	68,4	30	31,6	0	0
D33.0–D33.2	Možgani, benigna neoplazma	M	2	1	–	1	–	0	–
	Benign neoplasm of brain	Ž	1	1	–	0	–	0	–
D39.1	Jajčnik, neoplazma negotovega značaja	M	–	–	–	–	–	–	–
	Ovary, neoplasm of uncertain behavior	Ž	52	52	100	0	0	0	0
D43.0–D43.2	Možgani, neopredeljeno	M	14	5	–	9	–	0	–
	CNS, uncertain or unknown	Ž	7	2	–	5	–	0	–

* Odstotki niso računani, če je število novih primerov manjše od 15
* Percentages are not calculated when number of new cases is less than 15

Tabela 4: Incidenca raka po lokaciji, spolu in starosti, Slovenija 2016.

Table 4: Cancer incidence by site, by sex and by age, Slovenia 2016.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C00–C96	Vse lokacije All sites	M+Ž	15072	24	16	10	33	29	93	144	215	361	541	956	1329	2053	2318	2059	2013	2878
		M	8117	12	7	4	18	16	42	66	78	128	220	491	693	1214	1394	1269	1167	1298
		Ž	6955	12	9	6	15	13	51	78	137	233	321	465	636	839	924	790	846	1580
C00	Ustnica Lip	M	15	0	0	0	0	0	0	0	1	2	2	0	2	1	0	0	1	6
		Ž	10	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2	7
C01	Baza jezika Base of tongue	M	22	0	0	0	0	0	0	0	0	0	1	2	4	7	6	2	0	0
		Ž	7	0	0	0	0	0	0	0	0	1	0	0	1	3	1	0	0	1
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	13	0	0	0	0	0	0	0	0	1	1	2	2	3	3	0	1	0
		Ž	17	0	0	0	0	0	1	0	0	1	2	0	0	3	4	3	2	1
C03	Dlesen Gum	M	6	0	0	0	0	0	0	0	0	0	0	2	0	0	2	1	1	0
		Ž	10	0	0	0	0	0	0	0	0	0	0	0	1	2	4	1	1	1
C04	Ustno dno Floor of mouth	M	24	0	0	0	0	0	0	0	0	3	2	3	2	10	2	0	1	1
		Ž	8	0	0	0	0	0	0	0	0	0	0	2	0	2	2	1	0	1
C05	Nebo Palate	M	10	0	0	0	0	0	0	0	0	0	0	2	1	2	4	0	1	0
		Ž	7	0	0	0	0	0	1	0	1	1	0	1	0	3	0	0	0	0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	13	0	0	0	0	0	0	0	0	0	1	3	1	4	4	0	0	0
		Ž	7	0	0	0	0	0	0	0	0	1	0	1	0	2	1	1	0	1
C07	Parotidna žleza Parotid gland	M	11	0	0	0	0	0	0	0	0	1	3	0	2	1	0	2	2	0
		Ž	8	0	0	0	0	0	0	0	1	0	1	2	2	0	1	1	0	0
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
C09	Tonzila Tonsil	M	41	0	0	0	0	0	0	0	1	3	4	4	4	10	5	5	5	0
		Ž	13	0	0	0	0	0	0	1	0	1	1	3	3	0	1	0	2	1
C10	Orofarinks Oropharynx	M	40	0	0	0	0	0	0	0	0	1	2	5	10	8	10	2	1	1
		Ž	4	0	0	0	0	0	0	0	0	0	1	1	0	0	2	0	0	0
C11	Nazofarinks Nasopharynx	M	8	0	0	0	0	0	0	0	0	0	0	1	1	2	2	0	1	1
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
C12	Piriformni sinus Pyriform sinus	M	32	0	0	0	0	0	0	0	0	0	3	5	7	5	4	1	5	2
		Ž	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
C13	Hipofarinks Hypopharynx	M	20	0	0	0	0	0	0	0	0	0	2	1	5	5	5	1	1	0
		Ž	3	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	M	50	0	0	0	0	0	0	0	1	1	4	5	7	13	7	6	2	4
		Ž	14	0	0	0	0	0	0	0	0	0	1	1	3	1	0	3	1	4
C16	Želodec Stomach	M	272	0	0	0	0	0	0	2	1	2	7	20	16	39	47	33	48	57
		Ž	171	0	0	0	0	0	1	0	0	3	4	9	17	16	15	20	22	64
C17	Tanko črevo Small intestine	M	25	0	0	0	0	1	0	0	0	0	0	6	2	2	1	5	4	4
		Ž	19	0	0	0	0	0	0	0	1	3	1	0	0	3	4	1	4	2
C18	Debelo črevo Colon	M	514	0	0	0	0	0	0	0	4	11	11	25	32	70	73	110	78	100
		Ž	393	0	0	1	1	1	0	4	0	4	8	22	27	39	44	74	60	108
C19	Rektosigmoidna zveza Rectosigmoid junction	M	64	0	0	0	0	0	0	0	1	0	4	5	5	11	6	10	11	11
		Ž	40	0	0	0	0	0	0	0	1	1	1	3	3	5	4	6	3	13
C20	Rektum Rectum	M	293	0	0	0	0	0	1	2	2	5	10	19	41	44	46	47	40	36
		Ž	164	0	0	0	0	0	0	0	1	3	5	8	13	15	25	32	20	42
C21	Anus in analni kanal Anus and anal canal	M	10	0	0	0	0	0	0	0	0	0	0	0	3	2	2	1	1	1
		Ž	11	0	0	0	0	0	0	0	0	1	0	0	1	1	3	3	2	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	140	0	0	0	0	0	0	0	0	1	1	9	11	16	33	22	22	25
		Ž	61	0	0	0	0	0	0	0	0	0	0	3	4	7	10	9	11	17
C23	Žolčnik Gallbladder	M	18	0	0	0	0	0	0	0	0	0	0	0	3	2	1	3	2	7
		Ž	37	0	0	0	0	0	0	0	0	0	0	2	1	3	8	2	8	13
C24	Drugi in neopredeljeni deli biliarnega trakta Billiary tract, other and unspecified parts	M	82	0	0	0	0	0	0	0	0	0	1	2	7	10	15	12	18	17
		Ž	60	0	0	0	0	0	0	1	1	0	1	3	4	3	2	9	9	27
C25	Trebušna slinavka Pancreas	M	194	0	0	0	0	0	0	2	0	1	5	11	11	28	36	35	33	32
		Ž	195	0	0	0	0	0	0	0	0	1	7	5	12	20	25	32	28	65
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1

Nadaljevanje —>
Continued —>

Tabela 4: Nadaljevanje.
Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C30	Nosna votlina in srednje uho	M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0
	Nasal cavity and middle ear	Ž	5	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	2
C31	Obnosni sinusi	M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0
	Accessory sinuses	Ž	2	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
C32	Grlo	M	92	0	0	0	0	0	0	0	1	0	2	8	16	19	18	10	8	10
	Larynx	Ž	17	0	0	0	0	0	0	0	0	0	0	1	3	3	5	3	2	0
C33	Sapnik	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Trachea	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C34	Sapnica in pljuča	M	966	0	0	0	1	0	0	1	2	7	13	62	113	181	194	138	123	131
	Bronchus and lung	Ž	555	0	0	0	0	0	1	1	1	1	11	30	76	105	108	66	64	91
C37	Timus	M	5	0	0	0	0	0	0	0	0	0	1	0	1	0	2	1	0	0
	Thymus	Ž	7	0	0	0	0	0	0	1	0	0	1	0	1	0	3	1	0	0
C38	Srce, mediastinum, plevra	M	4	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0
	Heart, mediastinum, pleura	Ž	3	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Other and ill-defined sites in the respiratory system and intrathoracic organs	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C40	Kosti, sklepni hrustanec udov	M	5	0	1	0	3	0	0	0	0	1	0	0	0	0	0	0	0	0
	Bone and articular cartilage of limbs	Ž	5	0	0	0	0	0	0	0	0	1	1	1	1	1	0	0	0	0
C41	Kosti, sklepni hrustanec, drugje	M	5	1	0	0	0	0	1	0	2	0	1	0	0	0	0	0	0	0
	Bone and articular cartilage of other and unspecified parts	Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	1
C43	Maligni melanom kože	M	304	0	0	0	1	1	6	15	9	9	19	29	23	42	38	37	36	39
	Malignant melanoma of skin	Ž	276	0	0	1	0	1	9	12	8	23	16	31	29	25	33	19	21	48
C44	Druge maligne neoplazme kože	M	1491	0	0	0	1	0	6	6	23	26	43	84	93	163	208	228	254	356
	Skin, other malignomas	Ž	1459	0	1	0	0	1	8	7	26	47	54	70	98	143	165	151	210	478
C45	Mezoteliom	M	29	0	0	0	0	1	0	0	0	1	0	1	1	4	6	6	8	1
	Mesothelioma	Ž	14	0	0	0	0	0	0	0	0	0	1	0	2	3	3	2	3	0
C46	Kaposijev sarkom	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
	Kaposi's sarcoma	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
C47	Periferni živci in avtonomno živčevje	M	2	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	Peripheral nerves and autonomic nervous system	Ž	2	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0
C48	Peritonej in retroperitonej	M	6	1	0	0	0	0	0	0	0	1	0	0	0	2	1	0	0	1
	Peritoneum and retroperitoneum	Ž	14	2	0	0	0	0	0	0	0	0	0	0	1	1	4	2	2	2
C49	Drugo vezivno in mehko tkivo	M	24	2	2	0	0	0	0	2	0	1	1	1	1	3	2	5	3	1
	Other connective and soft tissue	Ž	32	3	0	0	1	0	2	1	1	1	3	2	3	3	4	1	2	5
C50	Dojka	M	14	0	0	0	0	0	0	0	0	0	0	0	1	2	4	0	3	4
	Breast	Ž	1386	0	0	0	0	1	8	14	50	75	116	161	146	210	191	129	131	154
C51	Žensko zunanje spolovilo	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Vulva	Ž	57	0	0	0	0	0	0	1	1	0	1	2	7	4	1	6	11	23
C52	Nožnica	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Vagina	Ž	14	0	0	0	0	0	1	0	0	0	1	2	1	2	1	2	2	2
C53	Maternični vrat	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Cervix uteri	Ž	123	0	0	0	0	0	3	8	13	17	14	9	14	12	10	7	5	11
C54	Maternično telo	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Corpus uteri	Ž	361	0	0	0	0	0	0	2	4	7	20	19	53	52	61	34	52	57
C55	Maternica, neopredeljeno	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Uterus, unspecified	Ž	18	0	0	0	0	0	0	0	1	2	0	2	0	1	5	1	1	5
C56	Jajčnik	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Ovary	Ž	129	0	0	0	0	0	1	0	1	5	7	16	15	15	18	15	16	20
C57	Drugi in neopredeljeni ženski spolni organi	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Other and unspecified parts of female genital organs	Ž	19	0	0	0	0	0	0	0	1	0	0	1	2	1	4	1	3	6
C58	Posteljica	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Placenta	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C60	Penis	M	17	0	0	0	0	0	0	0	1	0	1	1	2	1	2	1	7	1
	Penis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C61	Prostata	M	1690	0	0	0	0	0	0	0	0	0	14	60	127	314	394	344	253	184
	Prostate	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 4: Nadaljevanje.
Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C62	Modo Testis	M Ž	107 –	0 –	0 –	0 –	2 –	8 –	16 –	22 –	7 –	20 –	12 –	12 –	5 –	2 –	0 –	1 –	0 –	0 –
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M Ž	3 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	1 –	1 –	1 –
C64	Ledvica razen meha Kidney, except renal pelvis	M Ž	228 131	0 0	0 0	0 0	0 0	0 0	0 0	1 0	3 2	5 1	4 3	21 9	32 8	35 14	35 16	37 27	27 20	28 31
C65	Ledvični meh Renal pelvis	M Ž	22 11	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	2 0	0 0	0 1	4 0	6 0	2 3	4 1	4 6
C66	Sečevod Ureter	M Ž	15 5	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	2 0	0 0	4 2	3 2	1 0	5 1
C67	Sečni mehur Bladder	M Ž	252 115	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	2 0	8 3	13 2	16 8	37 13	37 18	41 13	39 17	59 41
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M Ž	2 1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	1 0	0 1
C69	Oko in očesni adneksi Eye and adnexa	M Ž	10 11	1 1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	1 0	2 1	2 1	0 0	0 1	0 1	2 3	1 3
C70	Meninge Meninges	M Ž	2 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	1 0	0 0	0 0
C71	Možgani Brain	M Ž	97 55	3 1	2 2	2 0	3 0	0 2	1 0	2 2	2 2	3 2	6 2	9 3	7 6	13 5	11 5	12 8	9 8	12 7
C72	Hrbtni mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS	M Ž	3 5	1 0	0 1	0 0	0 1	1 0	0 0	0 1	1 0	0 1	0 0	0 0	0 1	0 0	0 0	0 0	0 0	0 0
C73	Ščitnica Thyroid gland	M Ž	36 166	0 0	0 0	0 3	0 5	0 2	2 7	1 10	4 11	5 16	3 8	3 10	5 15	3 27	5 20	2 15	2 9	1 8
C74	Nadledvična žleza Adrenal gland	M Ž	4 6	1 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 1	0 1	1 1	0 1	0 0	1 1	0 1	0 0	0 0
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M Ž	1 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	0 0	0 0	0 0
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M Ž	3 18	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 1	1 1	0 2	0 1	0 2	1 1	1 9
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M Ž	20 17	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	1 0	3 1	5 2	6 3	1 0	0 1	4 9
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M Ž	37 41	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 1	0 0	1 1	2 0	3 2	9 6	11 4	11 26
C79	Metastaze, drugje Metastases of other sites	M Ž	15 13	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	1 0	1 1	2 0	3 2	1 3	0 1	0 0	7 5
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M Ž	69 66	0 0	0 0	0 0	0 0	0 0	0 2	1 0	1 0	0 0	1 2	5 2	7 6	16 5	10 5	11 4	6 10	11 30
C81	Hodgkinova bolezen Hodgkin's disease	M Ž	30 29	0 0	0 1	1 1	4 3	0 3	1 3	2 6	4 3	2 1	3 0	2 1	2 0	6 2	1 1	1 1	1 1	0 2
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M Ž	60 57	0 0	0 0	0 0	1 1	0 0	1 0	2 1	0 1	4 2	0 2	6 3	6 7	6 10	11 13	8 5	11 6	4 6
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M Ž	159 122	0 0	1 0	0 0	0 1	1 1	5 0	1 3	5 2	2 2	7 3	8 4	17 11	16 11	30 20	21 22	18 15	27 27
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M Ž	19 16	0 0	1 0	0 0	0 0	0 0	0 0	0 0	1 0	1 0	1 3	2 1	3 2	1 3	3 2	1 0	4 1	1 4
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M Ž	4 10	0 0	0 0	0 0	0 0	1 0	0 0	0 0	0 0	1 1	0 0	0 0	0 1	0 1	1 0	0 3	1 2	0 2

Nadaljevanje —>
Continued —>

Tabela 4: Nadaljevanje.
Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M Ž	5 3	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	1 0	0 1	1 1	0 0	2 1
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M Ž	82 47	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	1 0	2 1	6 5	7 4	10 3	13 5	13 11	11 7	18 11
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M Ž	7 11	1 3	0 4	1 0	1 0	1 0	0 0	1 0	0 0	0 0	0 0	1 0	0 1	1 1	0 0	0 0	0 1	0 1
C91.1–C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M Ž	76 56	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	4 2	8 2	5 4	9 8	14 11	9 8	12 4	15 17
C92	Mieloična levkemija Myeloid leukaemia	M Ž	65 52	1 1	0 0	0 0	1 1	1 0	0 2	2 1	0 0	1 0	2 1	4 3	4 3	7 9	6 5	6 4	12 6	18 16
C93	Monocitna levkemija Monocytic leukaemia	M Ž	4 2	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 2	3 0
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M Ž	17 15	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	1 1	3 1	1 0	1 1	3 0	1 1	4 2	1 5	1 4
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M Ž	0 1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 0
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M Ž	86 104	0 0	0 0	0 0	0 0	0 1	1 1	0 1	0 2	0 4	0 4	6 2	6 4	6 8	8 14	13 9	16 18	30 36

Zgoraj neupoštevani
Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
D03	Melanom, in situ Melanoma, in situ	M Ž	139 140	0 0	0 0	0 0	0 2	1 0	1 2	6 5	4 5	5 8	8 17	8 7	10 7	21 15	17 22	22 20	16 19	20 11
D05	Dojka, in situ Breast, in situ	M Ž	1 136	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 3	0 5	0 18	0 23	0 25	0 29	1 23	0 6	0 2	0 2
D06	Maternični vrat, in situ (CIN III) Cervix uteri, in situ (CIN III)	M Ž	– 1094	– 0	– 0	– 0	– 0	– 100	– 222	– 223	– 205	– 122	– 73	– 51	– 37	– 32	– 15	– 10	– 4	– 0
D09.0	Sečni mehur, in situ Bladder, in situ	M Ž	176 60	0 0	0 0	0 0	0 0	0 0	1 0	1 0	1 1	1 0	4 3	7 3	21 6	37 3	24 7	24 14	29 7	26 16
D32.0, D42.0	Meninge, benigna neoplazma in neoplazma negotovega značaja Benign neoplasm and neoplasm of uncertain behaviour of meninges	M Ž	34 95	0 0	0 0	0 0	0 0	1 0	0 0	1 0	2 5	1 3	2 5	0 14	3 9	3 8	5 13	4 11	8 10	4 17
D33.0–D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M Ž	2 1	0 1	0 0	1 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	0 0	0 0
D39.1	Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior	M Ž	– 52	– 0	– 0	– 0	– 0	– 0	– 2	– 5	– 5	– 5	– 6	– 2	– 9	– 5	– 1	– 3	– 3	– 6
D43.0–D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M Ž	14 7	0 0	1 1	0 0	2 0	0 0	1 0	0 1	1 0	0 0	0 0	1 0	0 0	1 1	0 0	2 0	3 0	2 4

Tabela 5: Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter kumulativna stopnja (KS) po lokaciji in spolu, Slovenija 2016.

Table 5: Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex, Slovenia 2016.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74
C00–C96	Vse lokacije All sites	M+Ž	730,1	22,5	14,7	10,9	35,1	28,2	73,6	101,0	136,8	238,0	366,7	618,0	891,2	1414,0	1931,1	2420,8	2627,6	2770,7	41,5
		M	792,8	21,9	12,5	8,4	37,0	30,2	64,2	88,5	94,5	161,8	290,6	625,4	923,9	1671,6	2410,2	3333,2	3651,0	3959,0	48,9
		Ž	668,5	23,2	17,1	13,4	33,0	26,0	83,7	114,7	183,8	321,0	446,8	610,3	858,2	1156,2	1485,5	1681,5	1894,9	2222,7	35,3
C00	Ustnica	M	1,5	0	0	0	0	0	0	0	1,2	2,5	2,6	0	2,7	1,4	0	0	3,1	18,3	0,1
	Lip	Ž	1,0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	4,5	9,8	0,0
C01	Baza jezika	M	2,1	0	0	0	0	0	0	0	0	0	1,3	2,5	5,3	9,6	10,4	5,3	0	0	0,2
	Base of tongue	Ž	0,7	0	0	0	0	0	0	0	0	1,4	0	0	1,3	4,1	1,6	0	0	1,4	0,0
C02	Jezik, drugi deli	M	1,3	0	0	0	0	0	0	0	0	1,3	1,3	2,5	2,7	4,1	5,2	0	3,1	0	0,1
	Tongue, other & unspecified parts	Ž	1,6	0	0	0	0	0	1,6	0	0	1,4	2,8	0	0	4,1	6,4	6,4	4,5	1,4	0,1
C03	Dlesen	M	0,6	0	0	0	0	0	0	0	0	0	0	2,5	0	0	3,5	2,6	3,1	0	0,0
	Gum	Ž	1,0	0	0	0	0	0	0	0	0	0	0	0	1,3	2,8	6,4	2,1	2,2	1,4	0,1
C04	Ustno dno	M	2,3	0	0	0	0	0	0	0	0	3,8	2,6	3,8	2,7	13,8	3,5	0	3,1	3,1	0,2
	Floor of mouth	Ž	0,8	0	0	0	0	0	0	0	0	0	0	2,6	0	2,8	3,2	2,1	0	1,4	0,1
C05	Nebo	M	1,0	0	0	0	0	0	0	0	0	0	0	2,5	1,3	2,8	6,9	0	3,1	0	0,1
	Palate	Ž	0,7	0	0	0	0	0	1,6	0	1,3	1,4	0	1,3	0	4,1	0	0	0	0	0,0
C06	Usta, drugi deli	M	1,3	0	0	0	0	0	0	0	0	0	1,3	3,8	1,3	5,5	6,9	0	0	0	0,1
	Mouth, other & unspecified parts	Ž	0,7	0	0	0	0	0	0	0	0	1,4	0	1,3	0	2,8	1,6	2,1	0	1,4	0,0
C07	Parotidna žleza	M	1,1	0	0	0	0	0	0	0	0	1,3	4,0	0	2,7	1,4	0	5,3	6,3	0	0,1
	Parotid gland	Ž	0,8	0	0	0	0	0	0	0	1,3	0	1,4	2,6	2,7	0	1,6	2,1	0	0	0,1
C08	Druge in neopredeljene velike žleze slinavke	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Other & unspecified major salivary glands	Ž	0,2	0	0	0	0	0	0	0	0	0	1,4	0	0	0	0	0	0	1,4	0,0
C09	Tonzila	M	4,0	0	0	0	0	0	0	0	1,2	3,8	5,3	5,1	5,3	13,8	8,6	13,1	15,6	0	0,3
	Tonsil	Ž	1,2	0	0	0	0	0	0	1,5	0	1,4	1,4	3,9	4,0	0	1,6	0	4,5	1,4	0,1
C10	Orofarinks	M	3,9	0	0	0	0	0	0	0	0	1,3	2,6	6,4	13,3	11,0	17,3	5,3	3,1	3,1	0,3
	Oropharynx	Ž	0,4	0	0	0	0	0	0	0	0	0	1,4	1,3	0	0	3,2	0	0	0	0,0
C11	Nazofarinks	M	0,8	0	0	0	0	0	0	0	0	0	0	1,3	1,3	2,8	3,5	0	3,1	3,1	0,0
	Nasopharynx	Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	1,6	0	0	0	0,0
C12	Piriformni sinus	M	3,1	0	0	0	0	0	0	0	0	0	4,0	6,4	9,3	6,9	6,9	2,6	15,6	6,1	0,2
	Pyriform sinus	Ž	0,1	0	0	0	0	0	0	0	0	0	1,4	0	0	0	0	0	0	0	0,0
C13	Hipofarinks	M	2,0	0	0	0	0	0	0	0	0	0	2,6	1,3	6,7	6,9	8,6	2,6	3,1	0	0,1
	Hypopharynx	Ž	0,3	0	0	0	0	0	0	0	0	0	1,4	0	1,3	0	0	2,1	0	0	0,0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Other and ill-defined sites in the lip, oral cavity and pharynx	Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C15	Požiralnik	M	4,9	0	0	0	0	0	0	0	1,2	1,3	5,3	6,4	9,3	17,9	12,1	15,8	6,3	12,2	0,3
	Oesophagus	Ž	1,3	0	0	0	0	0	0	0	0	0	1,4	1,3	4,0	1,4	0	6,4	2,2	5,6	0,1
C16	Želodec	M	26,6	0	0	0	0	0	0	2,7	1,2	2,5	9,2	25,5	21,3	53,7	81,3	86,7	150,2	173,9	1,4
	Stomach	Ž	16,4	0	0	0	0	0	1,6	0	0	4,1	5,6	11,8	22,9	22,0	24,1	42,6	49,3	90,0	0,7
C17	Tanko črevo	M	2,4	0	0	0	0	1,9	0	0	0	0	0	7,6	2,7	2,8	1,7	13,1	12,5	12,2	0,1
	Small intestine	Ž	1,8	0	0	0	0	0	0	0	1,3	4,1	1,4	0	0	4,1	6,4	2,1	9,0	2,8	0,1
C18	Debelo črevo	M	50,2	0	0	0	0	0	0	0	4,8	13,9	14,5	31,8	42,7	96,4	126,2	288,9	244,0	305,0	3,1
	Colon	Ž	37,8	0	0	2,2	2,2	2,0	0	5,9	0	5,5	11,1	28,9	36,4	53,7	70,7	157,5	134,4	151,9	1,9

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.
Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74
C19	Rektosigmoidna zveza	M	6,3	0	0	0	0	0	0	0	1,2	0	5,3	6,4	6,7	15,1	10,4	26,3	34,4	33,6	0,4
	Rectosigmoid junction	Ž	3,8	0	0	0	0	0	0	0	1,3	1,4	1,4	3,9	4,0	6,9	6,4	12,8	6,7	18,3	0,2
C20	Rektum	M	28,6	0	0	0	0	0	1,5	2,7	2,4	6,3	13,2	24,2	54,7	60,6	79,5	123,5	125,1	109,8	1,8
	Rectum	Ž	15,8	0	0	0	0	0	0	0	1,3	4,1	7,0	10,5	17,5	20,7	40,2	68,1	44,8	59,1	0,8
C21	Anus in analni kanal	M	1,0	0	0	0	0	0	0	0	0	0	0	0	4,0	2,8	3,5	2,6	3,1	3,1	0,1
	Anus and anal canal	Ž	1,1	0	0	0	0	0	0	0	0	1,4	0	0	1,3	1,4	4,8	6,4	4,5	0	0,1
C22	Jetra in intrahepatični vodi	M	13,7	0	0	0	0	0	0	0	0	1,3	1,3	11,5	14,7	22,0	57,1	57,8	68,8	76,3	0,8
	Liver and intrahepatic bile ducts	Ž	5,9	0	0	0	0	0	0	0	0	0	0	3,9	5,4	9,6	16,1	19,2	24,6	23,9	0,3
C23	Žolčnik	M	1,8	0	0	0	0	0	0	0	0	0	0	0	4,0	2,8	1,7	7,9	6,3	21,4	0,1
	Gallbladder	Ž	3,6	0	0	0	0	0	0	0	0	0	0	2,6	1,3	4,1	12,9	4,3	17,9	18,3	0,1
C24	Drugi in neopredeljeni deli biliarnega trakta	M	8,0	0	0	0	0	0	0	0	0	0	1,3	2,5	9,3	13,8	25,9	31,5	56,3	51,9	0,4
	Billiary tract, other and unspecified parts	Ž	5,8	0	0	0	0	0	0	1,5	1,3	0	1,4	3,9	5,4	4,1	3,2	19,2	20,2	38,0	0,2
C25	Trebušna slinavka	M	18,9	0	0	0	0	0	0	2,7	0	1,3	6,6	14,0	14,7	38,6	62,2	91,9	103,2	97,6	1,2
	Pancreas	Ž	18,7	0	0	0	0	0	0	0	0	1,4	9,7	6,6	16,2	27,6	40,2	68,1	62,7	91,4	0,8
C26	Druga in slabo opredeljena mesta v prebavnih organih	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,1	0,0
	Other and ill-defined digestive organs	Ž	0,3	0	0	0	0	0	0	0	0	0	0	0	0	2,8	0	0	0	1,4	0,0
C30	Nosna votlina in srednje uho	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	1,4	0	2,6	0	0	0,0
	Nasal cavity and middle ear	Ž	0,5	0	0	0	0	0	0	0	0	0	0	0	1,3	0	1,6	0	2,2	2,8	0,0
C31	Obnosni sinusi	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	1,4	1,7	0	0	0	0,0
	Accessory sinuses	Ž	0,2	0	0	0	2,2	0	0	0	0	0	0	0	0	0	0	0	0	1,4	0,0
C32	Grlo	M	9,0	0	0	0	0	0	0	0	1,2	0	2,6	10,2	21,3	26,2	31,1	26,3	25,0	30,5	0,6
	Larynx	Ž	1,6	0	0	0	0	0	0	0	0	0	0	1,3	4,0	4,1	8,0	6,4	4,5	0	0,1
C33	Sapnik	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Trachea	Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C34	Sapnica in pljuča	M	94,3	0	0	0	2,1	0	0	1,3	2,4	8,8	17,2	79,0	150,6	249,2	335,4	362,5	384,8	399,6	6,0
	Bronchus and lung	Ž	53,3	0	0	0	0	0	1,6	1,5	1,3	1,4	15,3	39,4	102,6	144,7	173,6	140,5	143,4	128,0	3,1
C37	Timus	M	0,5	0	0	0	0	0	0	0	0	0	1,3	0	1,3	0	3,5	2,6	0	0	0,0
	Thymus	Ž	0,7	0	0	0	0	0	0	1,5	0	0	1,4	0	1,3	0	4,8	2,1	0	0	0,1
C38	Srce, mediastinum, plevra	M	0,4	0	0	0	0	0	0	1,3	0	0	0	0	0	0	1,7	2,6	3,1	0	0,0
	Heart, mediastinum, pleura	Ž	0,3	1,9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4,5	0	0,0
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Other and ill-defined sites in the respiratory system and intrathoracic organs	Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C40	Kosti, sklepni hrustanec udov	M	0,5	0	1,8	0	6,2	0	0	0	0	1,3	0	0	0	0	0	0	0	0	0,0
	Bone and articular cartilage of limbs	Ž	0,5	0	0	0	0	0	0	0	0	1,4	1,4	1,3	1,3	1,4	0	0	0	0	0,0

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.
Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74
C41	Kosti, sklepni hrustanec, drugje	M	0,5	1,8	0	0	0	0	1,5	0	2,4	0	1,3	0	0	0	0	0	0	0	0,0
	Bone and articular cartilage of other and unspecified parts	Ž	0,4	0	0	0	0	0	0	0	0	0	0	0	0	2,8	0	2,1	0	1,4	0,0
C43	Maligni melanom kože	M	29,7	0	0	0	2,1	1,9	9,2	20,1	10,9	11,4	25,1	36,9	30,7	57,8	65,7	97,2	112,6	119,0	1,8
	Malignant melanoma of skin	Ž	26,5	0	0	2,2	0	2,0	14,8	17,6	10,7	31,7	22,3	40,7	39,1	34,5	53,1	40,4	47,0	67,5	1,5
C44	Druge maligne neoplazme kože	M	145,6	0	0	0	2,1	0	9,2	8,0	27,9	32,9	56,8	107,0	124,0	224,4	359,6	598,9	794,6	1085,8	7,8
	Skin, other malignomas	Ž	140,2	0	1,9	0	0	2,0	13,1	10,3	34,9	64,7	75,2	91,9	132,2	197,1	265,3	321,4	470,4	672,4	6,0
C45	Mezoteliom	M	2,8	0	0	0	0	1,9	0	0	0	1,3	0	1,3	1,3	5,5	10,4	15,8	25,0	3,1	0,2
	Mesothelioma	Ž	1,3	0	0	0	0	0	0	0	0	0	1,4	0	2,7	4,1	4,8	4,3	6,7	0	0,1
C46	Kaposijev sarkom	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,1	0	0,0
	Kaposi's sarcoma	Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,2	0	0,0
C47	Periferni živci in avtonomno živčevje	M	0,2	0	0	0	0	0	0	0	0	0	1,3	1,3	0	0	0	0	0	0	0,0
	Peripheral nerves and autonomic nervous system	Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	2,7	0	0	0	0	0	0,0
C48	Peritonej in retroperitonej	M	0,6	1,8	0	0	0	0	0	0	0	1,3	0	0	0	2,8	1,7	0	0	3,1	0,0
	Peritoneum and retroperitoneum	Ž	1,3	3,9	0	0	0	0	0	0	0	0	0	0	1,3	1,4	6,4	4,3	4,5	2,8	0,1
C49	Drugo vezivno in mehko tkivo	M	2,3	3,7	3,6	0	0	0	0	2,7	0	1,3	1,3	1,3	1,3	4,1	3,5	13,1	9,4	3,1	0,2
	Other connective and soft tissue	Ž	3,1	5,8	0	0	2,2	0	3,3	1,5	1,3	1,4	4,2	2,6	4,0	4,1	6,4	2,1	4,5	7,0	0,2
C50	Dojka	M	1,4	0	0	0	0	0	0	0	0	0	0	0	1,3	2,8	6,9	0	9,4	12,2	0,1
	Breast	Ž	133,2	0	0	0	0	2,0	13,1	20,6	67,1	103,3	161,5	211,3	197,0	289,4	307,1	274,6	293,4	216,6	8,2
C51	Žensko zunanje spolovilo	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Vulva	Ž	5,5	0	0	0	0	0	0	1,5	1,3	0	1,4	2,6	9,4	5,5	1,6	12,8	24,6	32,4	0,2
C52	Nožnica	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Vagina	Ž	1,3	0	0	0	0	0	1,6	0	0	0	1,4	2,6	1,3	2,8	1,6	4,3	4,5	2,8	0,1
C53	Maternični vrat	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Cervix uteri	Ž	11,8	0	0	0	0	0	4,9	11,8	17,4	23,4	19,5	11,8	18,9	16,5	16,1	14,9	11,2	15,5	0,8
C54	Maternično telo	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Corpus uteri	Ž	34,7	0	0	0	0	0	0	2,9	5,4	9,6	27,8	24,9	71,5	71,7	98,1	72,4	116,5	80,2	1,9
C55	Maternica, neopredeljeno	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Uterus, unspecified	Ž	1,7	0	0	0	0	0	0	0	1,3	2,8	0	2,6	0	1,4	8,0	2,1	2,2	7,0	0,1
C56	Jajčnik	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Ovary	Ž	12,4	0	0	0	0	0	1,6	0	1,3	6,9	9,7	21,0	20,2	20,7	28,9	31,9	35,8	28,1	0,7
C57	Drugi in neopredeljeni ženski spolni organi	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Other and unspecified parts of female genital organs	Ž	1,8	0	0	0	0	0	0	0	1,3	0	0	1,3	2,7	1,4	6,4	2,1	6,7	8,4	0,1
C58	Posteljica	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Placenta	Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C60	Penis	M	1,7	0	0	0	0	0	0	0	1,2	0	1,3	1,3	2,7	1,4	3,5	2,6	21,9	3,1	0,1
	Penis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.
Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74
C61	Prostata	M	165,1	0	0	0	0	0	0	0	0	0	18,5	76,4	169,3	432,4	681,2	903,6	791,5	561,2	11,4
	Prostate	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C62	Modo	M	10,5	0	0	0	4,1	15,1	24,4	29,5	8,5	25,3	15,9	15,3	6,7	2,8	0	2,6	0	0	0,8
	Testis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi	M	0,3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,6	3,1	3,1	0,0
	Other and unspecified male genital organs	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha	M	22,3	0	0	0	0	0	0	1,3	3,6	6,3	5,3	26,7	42,7	48,2	60,5	97,2	84,5	85,4	1,5
	Kidney, except renal pelvis	Ž	12,6	0	0	0	0	0	0	0	2,7	1,4	4,2	11,8	10,8	19,3	25,7	57,5	44,8	43,6	0,7
C65	Ledvični meh	M	2,1	0	0	0	0	0	0	0	0	0	2,6	0	0	5,5	10,4	5,3	12,5	12,2	0,1
	Renal pelvis	Ž	1,1	0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	6,4	2,2	8,4	0,0
C66	Sečevod	M	1,5	0	0	0	0	0	0	0	0	0	0	0	2,7	0	6,9	7,9	3,1	15,3	0,1
	Ureter	Ž	0,5	0	0	0	0	0	0	0	0	0	0	0	0	0	3,2	4,3	0	1,4	0,0
C67	Sečni mehur	M	24,6	0	0	0	0	0	0	0	0	2,5	10,6	16,6	21,3	50,9	64,0	107,7	122,0	180,0	1,4
	Bladder	Ž	11,1	0	0	0	0	0	0	0	0	0	4,2	2,6	10,8	17,9	28,9	27,7	38,1	57,7	0,5
C68	Drugi in neopredeljeni sečni organi	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	1,7	0	3,1	0	0,0
	Other and unspecified urinary organs	Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,4	0,0
C69	Oko in očesni adneksi	M	1,0	1,8	0	0	0	0	0	0	0	1,3	1,3	2,5	2,7	0	0	0	6,3	3,1	0,0
	Eye and adnexa	Ž	1,1	1,9	0	0	0	0	0	0	0	0	0	1,3	1,3	0	1,6	2,1	6,7	4,2	0,0
C70	Meninge	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	1,7	2,6	0	0	0,0
	Meninges	Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C71	Možgani	M	9,5	5,5	3,6	4,2	6,2	0	1,5	2,7	2,4	3,8	7,9	11,5	9,3	17,9	19,0	31,5	28,2	36,6	0,6
	Brain	Ž	5,3	1,9	3,8	0	0	4,0	0	2,9	2,7	2,8	2,8	3,9	8,1	6,9	8,0	17,0	17,9	9,8	0,3
C72	Hrbtni mozeg, možganski živci in drugi deli CŽS	M	0,3	1,8	0	0	0	1,9	0	0	1,2	0	0	0	0	0	0	0	0	0	0,0
	Spinal cord, cranial nerves and other parts of CNS	Ž	0,5	0	1,9	0	2,2	0	0	1,5	0	1,4	0	0	1,3	0	0	0	0	0	0,0
C73	Ščitnica	M	3,5	0	0	0	0	0	3,1	1,3	4,8	6,3	4,0	3,8	6,7	4,1	8,6	5,3	6,3	3,1	0,2
	Thyroid gland	Ž	16,0	0	0	6,7	11,0	4,0	11,5	14,7	14,8	22,0	11,1	13,1	20,2	37,2	32,2	31,9	20,2	11,3	1,2
C74	Nadledvična žleza	M	0,4	1,8	0	0	0	0	0	0	0	1,3	0	1,3	0	0	1,7	0	0	0	0,0
	Adrenal gland	Ž	0,6	0	0	0	0	0	0	0	0	1,4	1,4	1,3	1,3	0	1,6	2,1	0	0	0,0
C75	Druge endokrine žleze in sorodne strukture	M	0,1	0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0,0
	Other endocrine glands and related structures	Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C76	Druga in slabo opredeljena mesta	M	0,3	0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	3,1	3,1	0,0
	Other and ill-defined sites	Ž	1,7	0	0	0	0	0	0	0	0	0	1,4	1,3	1,3	2,8	1,6	4,3	2,2	12,7	0,1
C77	Metastaza in neopredeljena maligna neoplazma bezgavk	M	2,0	0	0	0	0	0	0	0	0	0	0	1,3	4,0	6,9	10,4	2,6	0	12,2	0,1
	Metastasis and unspecified malignant neoplasm of lymph nodes	Ž	1,6	0	0	0	0	0	0	0	0	0	1,4	0	1,3	2,8	4,8	0	2,2	12,7	0,1

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.
Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74
C78	Metastaze dihal in prebavil	M	3,6	0	0	0	0	0	0	0	0	0	0	0	1,3	2,8	5,2	23,6	34,4	33,6	0,2
	Metastases of respiratory and digestive organs	Ž	3,9	0	0	0	0	0	0	0	1,3	0	1,4	0	1,3	0	3,2	12,8	9,0	36,6	0,1
C79	Metastaze, drugje	M	1,5	0	0	0	0	0	0	0	0	0	1,3	1,3	2,7	4,1	1,7	0	0	21,4	0,1
	Metastases of other sites	Ž	1,2	0	0	0	0	0	0	0	0	1,4	0	1,3	0	2,8	4,8	2,1	0	7,0	0,1
C80	Maligna neoplazma brez opredeljenega mesta	M	6,7	0	0	0	0	0	0	1,3	1,2	0	1,3	6,4	9,3	22,0	17,3	28,9	18,8	33,6	0,4
	Malignant neoplasm without specification of site	Ž	6,3	0	0	0	0	0	3,3	0	0	0	2,8	2,6	8,1	6,9	8,0	8,5	22,4	42,2	0,2
C81	Hodgkinova bolezen	M	2,9	0	0	2,1	8,2	0	1,5	2,7	4,8	2,5	4,0	2,5	2,7	8,3	1,7	2,6	3,1	0	0,2
	Hodgkin's disease	Ž	2,8	0	1,9	2,2	6,6	6,0	4,9	8,8	4,0	1,4	0	1,3	0	2,8	1,6	2,1	2,2	2,8	0,2
C82	Folikularni ne-Hodgkinov limfom	M	5,9	0	0	0	2,1	0	1,5	2,7	0	5,1	0	7,6	8,0	8,3	19,0	21,0	34,4	12,2	0,4
	Follicular non-Hodgkin's lymphoma	Ž	5,5	0	0	0	2,2	0	0	1,5	1,3	2,8	2,8	3,9	9,4	13,8	20,9	10,6	13,4	8,4	0,3
C83	Difuzni ne-Hodgkinov limfom	M	15,5	0	1,8	0	0	1,9	7,6	1,3	6,1	2,5	9,2	10,2	22,7	22,0	51,9	55,2	56,3	82,4	1,0
	Diffuse non-Hodgkin's lymphoma	Ž	11,7	0	0	0	2,2	2,0	0	4,4	2,7	2,8	4,2	5,2	14,8	15,2	32,2	46,8	33,6	38,0	0,7
C84	Limfomi celic T in kožni limfom celic T	M	1,9	0	1,8	0	0	0	0	0	1,2	1,3	1,3	2,5	4,0	1,4	5,2	2,6	12,5	3,1	0,1
	Peripheral and cutaneous T-cell lymphomas	Ž	1,5	0	0	0	0	0	0	0	0	0	4,2	1,3	2,7	4,1	3,2	0	2,2	5,6	0,1
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma	M	0,4	0	0	0	0	1,9	0	0	0	1,3	0	0	0	0	1,7	0	3,1	0	0,0
	Other and unspecified types of non-Hodgkin's lymphoma	Ž	1,0	0	0	0	0	0	0	0	0	1,4	0	0	1,3	1,4	0	6,4	4,5	2,8	0,1
C88	Maligne imunoproliferativne bolezni	M	0,5	0	0	0	0	0	0	0	0	0	0	0	1,3	1,4	0	2,6	0	6,1	0,0
	Malignant immunoproliferative diseases	Ž	0,3	0	0	0	0	0	0	0	0	0	0	0	0	0	1,6	2,1	0	1,4	0,0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov	M	8,0	0	0	0	0	0	1,5	0	0	1,3	2,6	7,6	9,3	13,8	22,5	34,1	34,4	54,9	0,5
	Multiple myeloma and malignant plasma cell neoplasms	Ž	4,5	0	0	0	0	0	0	0	0	0	1,4	6,6	5,4	4,1	8,0	23,4	15,7	15,5	0,2
C91.0	Limfatična levkemija, akutna	M	0,7	1,8	0	2,1	2,1	1,9	0	1,3	0	0	0	1,3	0	1,4	0	0	0	0	0,1
	Lymphoblastic leukaemia, acute	Ž	1,1	5,8	7,6	0	0	0	0	0	0	0	0	0	1,3	1,4	0	0	2,2	1,4	0,1
C91.1 – C91.9	Limfatična levkemija, druga	M	7,4	0	0	0	0	0	0	0	0	0	5,3	10,2	6,7	12,4	24,2	23,6	37,5	45,8	0,4
	Lymphoid leukaemia, other	Ž	5,4	0	0	0	0	0	0	0	0	0	2,8	2,6	5,4	11,0	17,7	17,0	9,0	23,9	0,3
C92	Mieloična levkemija	M	6,3	1,8	0	0	2,1	1,9	0	2,7	0	1,3	2,6	5,1	5,3	9,6	10,4	15,8	37,5	54,9	0,3
	Myeloid leukaemia	Ž	5,0	1,9	0	0	2,2	0	3,3	1,5	0	0	1,4	3,9	4,0	12,4	8,0	8,5	13,4	22,5	0,2
C93	Monocitna levkemija	M	0,4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,6	0	9,2	0,0
	Monocytic leukaemia	Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4,5	0	0,0

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.
Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74
C94	Druge opredeljene levkemije	M	1,7	0	0	0	0	0	0	0	1,2	1,3	4,0	1,3	1,3	4,1	1,7	10,5	3,1	3,1	0,1
	Other leukaemias of specified cells	Ž	1,4	0	0	0	0	0	0	0	0	1,4	1,4	0	1,3	0	1,6	4,3	11,2	5,6	0,0
C95	Levkemija z neopredeljenim celičnim tipom	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Leukaemia, unspecified cell type	Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,1	0	0	0,0
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva	M	8,4	0	0	0	0	0	1,5	0	0	0	0	7,6	8,0	8,3	13,8	34,1	50,1	91,5	0,4
	Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	Ž	10,0	0	0	0	0	2,0	1,6	1,5	2,7	5,5	5,6	2,6	5,4	11,0	22,5	19,2	40,3	50,6	0,4

Zgoraj neupoštevani
Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74
D03	Melanom, in situ	M	13,6	0	0	0	0	1,9	1,5	8,0	4,8	6,3	10,6	10,2	13,3	28,9	29,4	57,8	50,1	61,0	0,9
	Melanoma, in situ	Ž	13,5	0	0	0	4,4	0	3,3	7,4	6,7	11,0	23,7	9,2	9,4	20,7	35,4	42,6	42,6	15,5	0,9
D05	Dojka, in situ	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	1,7	0	0	0	0,0
	Breast, in situ	Ž	13,1	0	0	0	0	0	0	0	4,0	6,9	25,1	30,2	33,7	40,0	37,0	12,8	4,5	2,8	0,9
D06	Maternični vrat, in situ (CIN III)	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Cervix uteri, in situ (CIN III)	Ž	105,2	0	0	0	0	200,0	364,5	327,9	275,0	168,1	101,6	66,9	49,9	44,1	24,1	21,3	9,0	0	8,2
D09.0	Sečni mehur, in situ	M	17,2	0	0	0	0	0	1,5	1,3	1,2	1,3	5,3	8,9	28,0	50,9	41,5	63,0	90,7	79,3	1,0
	Bladder, in situ	Ž	5,8	0	0	0	0	0	0	0	1,3	0	4,2	3,9	8,1	4,1	11,3	29,8	15,7	22,5	0,3
D32.0, D42.0	Meninge, benigna neoplazma in neoplazma negotovega značaja	M	3,3	0	0	0	0	1,9	0	1,3	2,4	1,3	2,6	0	4,0	4,1	8,6	10,5	25,0	12,2	0,2
	Benign neoplasm and neoplasm of uncertain behaviour of meninges	Ž	9,1	0	0	0	0	0	0	0	6,7	4,1	7,0	18,4	12,1	11,0	20,9	23,4	22,4	23,9	0,5
D33.0 – D33.2	Možgani, benigna neoplazma	M	0,2	0	0	2,1	0	0	0	0	0	0	0	0	0	1,4	0	0	0	0	0,0
	Benign neoplasm of brain	Ž	0,1	1,9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
D39.1	Jajčnik, neopl. negotovega značaja	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Ovary, neopl. of uncertain behavior	Ž	5,0	0	0	0	0	0	3,3	7,4	6,7	6,9	8,4	2,6	12,1	6,9	1,6	6,4	6,7	8,4	0,3
D43.0 – D43.2	Možgani, neopredeljeno	M	1,4	0	1,8	0	4,1	0	1,5	0	1,2	0	0	1,3	0	1,4	0	5,3	9,4	6,1	0,1
	CNS, uncertain or unknown	Ž	0,7	0	1,9	0	0	0	0	1,5	0	0	0	0	0	1,4	0	0	0	5,6	0,0

Tabela 6a: Incidenca po statističnih regijah, spolu in izbrani primarni lokaciji raka, Slovenija 2016.
Table 6a: Incidence by statistical regions, by sex and by selected primary cancer site, Slovenia 2016.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Slovenija, skupaj Slovenia, total	Statistična regija / Statistical region											
				Pomurska	Podravska	Koroška	Savinjska	Zasavska	Posavska	Jugovzhodna Slovenija	Osrednjeslovenska	Gorenjska	Primorsko-notranjska	Goriška	Obalno-kraška
C00–C96	Vse lokacije All sites	M+Ž	15072	1014	2601	541	1640	307	453	928	4108	1511	340	935	694
		M	8117	558	1405	291	864	162	253	516	2206	787	194	504	377
		Ž	6955	456	1196	250	776	145	200	412	1902	724	146	431	317
C00–C14	Usta in žrelo Mouth and pharynx	M	255	24	49	8	36	4	15	16	45	29	4	12	13
		Ž	98	5	20	6	8	5	3	2	28	8	0	6	7
C15	Požiralnik Oesophagus	M	50	3	12	4	6	2	3	4	8	5	2	1	0
		Ž	14	1	1	0	1	2	0	0	4	1	0	3	1
C16	Želodec Stomach	M	272	20	63	13	30	7	8	20	58	26	4	15	8
		Ž	171	10	34	5	19	4	11	13	39	20	0	9	7
C18	Debelo črevo Colon	M	514	24	84	16	65	17	18	43	130	39	15	36	27
		Ž	393	23	58	14	47	14	9	22	108	47	8	28	15
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	357	40	49	17	39	9	14	21	86	31	10	22	19
		Ž	204	21	37	11	26	7	3	14	44	13	3	10	15
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	140	9	21	2	22	5	8	14	33	12	1	4	9
		Ž	61	1	6	4	9	0	5	3	20	6	0	4	3
C23–C24	Žolčnik in žolčevodi Gallbladder and billiary tract	M	100	5	18	2	13	1	2	5	28	6	4	7	9
		Ž	97	3	14	6	12	0	2	5	23	8	5	9	10
C25	Trebušna slinavka Pancreas	M	194	12	19	6	21	8	7	14	47	28	6	15	11
		Ž	195	10	37	4	18	7	1	10	59	23	6	13	7
C32	Grlo Larynx	M	92	5	22	3	9	3	5	10	18	3	2	3	9
		Ž	17	1	3	0	3	0	1	2	4	2	0	1	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	966	59	149	43	99	18	37	67	255	99	31	56	53
		Ž	555	34	79	20	53	12	14	30	168	59	15	37	34
C43	Maligni melanom kože Malignant melanoma of skin	M	304	18	47	14	34	8	8	18	98	32	5	12	10
		Ž	276	19	45	9	26	5	8	14	93	27	6	13	11
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1491	101	299	54	168	18	36	104	420	153	18	101	19
		Ž	1459	132	284	67	190	15	36	94	383	138	16	86	18
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	30	2	6	0	4	0	1	4	8	2	0	0	3
		Ž	46	2	7	1	7	2	1	1	12	8	0	2	3
C50	Dojka Breast	M	14	0	1	0	4	0	2	1	2	3	1	0	0
		Ž	1386	71	253	39	147	35	49	72	371	147	38	86	78
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	123	7	23	12	16	0	1	6	27	11	6	5	9
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	361	30	57	7	38	7	11	25	95	42	6	24	19
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	129	4	24	3	16	3	5	8	34	17	2	4	9
C61	Prostata Prostate	M	1690	122	295	64	149	26	45	88	484	158	49	114	96
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–
C62	Modo Testis	M	107	10	13	1	11	3	3	8	36	8	7	5	2
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	M	250	25	45	10	24	4	2	26	58	19	4	20	13
		Ž	142	15	18	6	19	2	6	17	37	12	2	4	4
C67	Sečni mehur Bladder	M	252	18	37	4	14	6	8	9	93	30	7	8	18
		Ž	115	7	15	3	10	5	2	8	35	20	3	4	3
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	102	5	11	4	10	3	8	3	27	9	5	8	9
		Ž	60	3	13	6	4	1	3	3	10	5	5	4	3
C73	Ščitnica Thyroid gland	M	36	1	10	1	3	1	0	0	11	4	1	2	2
		Ž	166	9	13	3	31	6	5	13	41	21	1	15	8
C81	Hodgkinova bolezen Hodgkin's disease	M	30	0	10	0	5	0	1	1	5	2	0	4	2
		Ž	29	1	4	0	3	2	0	1	8	0	3	5	2
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	242	18	39	7	32	4	10	17	65	26	2	10	12
		Ž	205	10	33	6	17	1	10	8	61	29	3	10	17
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	82	7	12	0	8	2	2	1	24	11	2	7	6
		Ž	47	2	8	3	4	1	1	1	16	4	1	2	4
C91–C95	Levkemije Leukaemias	M	169	7	33	5	11	4	2	10	57	12	5	14	9
		Ž	137	7	29	1	11	1	3	6	45	11	3	12	8

Tabela 6b: Starostno standardizirana* incidenčna stopnja po statističnih regijah, spolu in izbrani primarni lokaciji raka, Slovenija 2016.

Table 6b: Age standardised* incidence rate by statistical regions, by sex and by selected primary cancer site, Slovenia 2016.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Slovenija, skupaj Slovenia, total	Statistična regija / Statistical region											
				Pomurska	Podravska	Koroška	Savinjska	Zasavska	Posavska	Jugovzhodna Slovenija	Osrednjeslovenska	Gorenjska	Primorsko-notranjska	Goriška	Obalno-kraška
C00–C96	Vse lokacije All sites	M+Ž	590,4	660,1	631,5	589,7	532,9	421,4	469,1	545,5	652,5	604,4	521,7	596,0	474,6
		M	712,4	826,1	766,2	684,7	624,3	506,0	574,5	676,2	800,0	694,9	638,6	719,8	567,1
		Ž	504,0	532,5	535,9	524,7	473,7	361,5	388,6	445,7	549,6	543,4	439,9	507,7	408,7
C00–C14	Usta in žrelo Mouth and pharynx	M	21,6	34,4	26,5	16,5	25,5	13,2	30,6	19,7	16,0	25,2	13,1	15,4	17,4
		Ž	7,7	7,1	10,3	14,3	6,2	15,2	6,1	1,5	8,1	5,9	0,0	7,1	10,2
C15	Požiralnik Oesophagus	M	4,3	3,5	6,8	9,0	4,1	6,1	7,2	5,3	2,9	3,9	5,2	1,4	0,0
		Ž	1,0	1,2	0,7	0,0	0,6	5,4	0,0	0,0	0,7	0,7	0,0	4,0	1,8
C16	Želodec Stomach	M	23,6	30,1	33,7	32,8	21,6	21,0	17,3	25,7	20,7	21,4	12,1	20,4	13,4
		Ž	10,9	9,2	13,7	10,5	9,6	10,6	17,5	13,0	10,1	13,4	0,0	7,9	9,4
C18	Debelo črevo Colon	M	45,8	35,9	45,4	40,6	46,9	49,7	41,8	59,4	48,4	33,7	46,3	55,3	41,9
		Ž	27,0	25,4	22,3	27,8	27,3	29,0	17,1	25,0	31,4	31,6	23,3	30,2	19,0
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	31,2	60,3	26,6	36,6	27,5	26,8	32,8	28,5	31,5	27,2	30,3	30,1	28,0
		Ž	14,2	21,6	15,6	18,4	14,4	16,0	7,4	12,9	13,0	10,8	9,4	12,4	17,4
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	12,2	12,6	11,5	4,8	15,7	15,7	19,7	18,6	11,9	10,8	4,7	5,7	12,1
		Ž	4,0	0,6	2,3	7,9	5,4	0,0	8,4	2,8	5,9	3,7	0,0	4,0	2,5
C23–C24	Žolčnik in žolčevodi Gallbladder and billiary tract	M	8,6	6,6	10,1	4,7	9,4	3,5	4,6	6,1	9,5	5,5	11,6	9,9	12,7
		Ž	6,0	2,9	5,7	9,9	8,1	0,0	3,4	4,2	5,7	4,4	11,7	6,4	9,7
C25	Trebušna slinavka Pancreas	M	17,1	17,8	10,7	12,3	15,2	27,3	15,9	19,7	17,2	24,5	18,6	21,8	17,1
		Ž	12,7	11,4	13,9	8,7	9,4	15,0	1,9	10,3	15,4	16,5	15,3	14,2	8,7
C32	Grlo Larynx	M	7,7	6,4	11,2	7,0	6,5	9,0	10,5	13,7	6,2	2,6	6,1	4,0	12,3
		Ž	1,3	1,2	1,4	0,0	2,0	0,0	2,1	2,3	1,3	1,4	0,0	1,8	0,0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	82,6	78,0	79,0	101,3	68,7	54,4	82,4	85,0	91,9	86,7	100,2	76,9	76,7
		Ž	39,5	41,0	36,1	39,4	30,1	31,1	25,1	32,9	47,6	45,5	40,2	38,0	44,2
C43	Maligni melanom kože Malignant melanoma of skin	M	27,2	26,0	25,9	33,4	25,1	24,0	20,0	21,3	36,0	29,5	18,6	18,3	15,2
		Ž	22,0	28,7	22,7	22,5	16,3	15,2	13,8	17,3	28,4	23,1	19,1	17,1	15,8
C44	Druge maligne neoplazme kože Skin, other malignomas	M	131,5	155,4	165,0	130,9	125,2	58,0	81,7	133,6	149,4	135,9	56,9	146,3	31,4
		Ž	97,7	143,8	117,9	135,2	105,5	38,9	64,5	91,7	103,0	96,2	33,7	94,0	22,7
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	2,7	2,9	3,4	0,0	2,7	0,0	2,2	5,8	2,9	1,7	0,0	0,0	5,3
		Ž	3,7	2,8	4,1	1,9	4,9	6,7	1,9	1,2	3,7	5,9	0,0	1,7	3,1
C50	Dojka Breast	M	1,1	0,0	0,5	0,0	2,9	0,0	4,4	1,3	0,7	2,4	2,8	0,0	0,0
		Ž	110,6	93,7	127,0	84,6	98,9	94,7	101,5	89,9	117,7	115,5	124,8	122,4	98,8
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	10,8	9,7	12,9	32,4	11,3	0,0	3,1	7,0	9,1	9,5	23,7	8,1	14,3
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	26,4	33,9	25,1	15,5	24,0	15,3	21,1	29,3	27,5	31,7	20,9	28,6	27,0
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	9,8	4,2	11,2	4,7	10,4	5,5	9,6	8,2	10,2	15,1	7,0	4,6	13,3
C61	Prostata Prostate	M	147,9	180,3	158,6	147,8	106,6	77,5	100,0	118,4	177,1	140,1	166,5	158,7	146,8
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–
C62	Modo Testis	M	11,0	18,6	8,7	2,9	8,6	11,7	8,4	10,8	14,4	8,3	27,2	9,1	3,4
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	M	21,7	37,5	24,5	24,4	17,0	12,0	4,5	33,7	20,6	16,6	14,7	30,0	18,4
		Ž	9,9	16,3	7,6	10,6	11,4	3,6	13,2	15,9	10,7	9,1	7,7	3,8	4,4
C67	Sečni mehur Bladder	M	22,0	26,0	20,3	10,4	10,3	18,3	16,5	11,4	33,2	26,9	23,8	11,1	25,5
		Ž	7,2	6,3	6,1	4,7	5,2	10,8	2,9	7,8	8,5	14,2	5,5	3,9	3,6
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	9,3	6,3	5,8	9,2	7,4	12,7	20,0	3,8	10,1	8,2	17,5	13,2	14,7
		Ž	4,9	5,8	5,9	13,9	2,7	3,6	7,1	3,7	3,3	4,3	23,2	4,7	4,6
C73	Ščitnica Thyroid gland	M	3,3	1,6	5,8	3,1	2,2	4,0	0,0	0,0	4,0	4,1	3,7	2,4	3,4
		Ž	14,9	14,9	7,6	9,6	23,9	17,5	13,6	16,9	13,7	18,7	4,3	21,8	12,4
C81	Hodgkinova bolezen Hodgkin's disease	M	2,9	0,0	5,3	0,0	3,8	0,0	2,4	1,4	2,0	2,2	0,0	8,4	2,8
		Ž	3,1	2,7	2,9	0,0	2,3	4,2	0,0	2,0	3,4	0,0	15,5	9,6	3,0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	21,6	27,8	21,5	17,3	22,8	12,7	21,1	20,8	24,9	22,6	5,4	14,3	19,3
		Ž	15,1	11,0	14,5	15,4	10,7	2,7	19,2	9,7	18,6	21,2	11,3	10,4	20,8
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	7,2	10,2	6,8	0,0	5,6	5,4	4,8	1,3	8,5	9,6	7,6	9,0	9,8
		Ž	3,3	2,8	3,3	6,7	2,4	1,2	2,5	0,5	4,7	2,4	1,3	3,5	6,5
C91–C95	Levkemije Leukaemias	M	15,1	12,0	18,9	11,0	8,0	13,7	4,9	12,8	20,5	11,0	15,7	20,1	13,0
		Ž	9,5	6,8	11,4	1,2	6,2	2,4	7,4	7,0	13,0	9,2	7,1	11,3	10,7

* Standard – prebivalstvo Slovenije po popisu 2002

* Standard – population of Slovenia according to census 2002

Tabela 7: Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2016.

Table 7: Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2016.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C00		C01		C02		C03		C04		C05		C06		C07		C08		C09	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	13699	638	19	6	28	1	30	0	16	0	32	0	17	0	20	0	19	0	2	0	54	0
Small cell carcinoma	192	59	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	71	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1459	68	19	6	27	0	29	0	14	0	32	0	12	0	18	0	0	0	0	0	54	0
Basal cell carcinoma	2446	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	383	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6724	274	0	0	0	0	0	0	0	0	0	0	4	0	2	0	9	0	2	0	0	0
Other specified carcinomas	135	4	0	0	1	0	1	0	0	0	0	0	1	0	0	0	5	0	0	0	0	0
Carcinoma, unspecified	76	115	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant thymoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	616	7	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	21	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	72	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	0	0	0	0	0
Malignat fibroepithelial tumors	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	40	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	130	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	426	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	58	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	126	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	115	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	151	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	123	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	94	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	5	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C10		C11		C12		C13		C14		C15		C16		C17		C18		C19	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	13699	638	44	0	8	1	33	0	23	0	0	0	59	2	427	3	44	0	864	3	103	0
Small cell carcinoma	192	59	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Non-small cell carcinoma	71	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1459	68	43	0	7	1	33	0	23	0	0	0	43	1	4	0	0	0	0	0	0	0
Basal cell carcinoma	2446	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	383	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6724	274	0	0	0	0	0	0	0	0	0	0	15	1	385	2	26	0	857	1	101	0
Other specified carcinomas	135	4	1	0	0	0	0	0	0	0	0	0	0	0	4	0	2	0	2	0	1	0
Carcinoma, unspecified	76	115	0	0	0	0	0	0	0	0	0	0	0	0	11	0	1	0	5	2	1	0
Malignant thymoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	616	7	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	6	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	21	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	72	1	0	0	0	0	0	0	0	0	0	0	0	0	22	1	15	0	0	0	0	0
Malignat fibroepithelial tumors	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	40	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	130	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	426	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	58	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	126	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	115	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	151	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	123	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	94	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	5	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C20		C21		C22		C23		C24		C25		C26		C30		C31		C32	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	13699	638	446	2	21	0	97	21	36	1	81	5	189	66	2	0	7	0	4	0	109	0
Small cell carcinoma	192	59	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	71	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1459	68	1	0	18	0	0	0	1	0	0	0	0	0	0	0	3	0	2	0	104	0
Basal cell carcinoma	2446	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	383	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6724	274	436	1	3	0	96	19	29	0	76	4	176	58	1	0	0	0	0	0	1	0
Other specified carcinomas	135	4	0	0	0	0	0	0	3	0	3	0	4	0	0	0	0	0	1	0	2	0
Carcinoma, unspecified	76	115	7	1	0	0	0	2	2	1	2	1	8	8	0	0	0	0	0	0	2	0
Malignant thymoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	616	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0	0	0	0	0
Fibrosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	13	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	12	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	21	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	72	1	1	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0
Malignat fibroepithelial tumors	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	40	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	130	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	426	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	58	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	126	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	115	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	151	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	123	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	94	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	5	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C33		C34		C37		C38		C39		C40		C41		C43		C44		C45	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	13699	638	0	0	1160	226	12	0	5	1	0	0	10	0	9	0	577	3	2885	61	40	3
Small cell carcinoma	192	59	0	0	180	56	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	71	24	0	0	68	23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1459	68	0	0	347	25	2	0	0	1	0	0	0	0	0	0	0	0	421	28	0	0
Basal cell carcinoma	2446	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2439	30	0	0
Transitional cell carcinoma	383	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6724	274	0	0	535	105	0	0	0	0	0	0	0	0	0	0	0	0	13	0	0	0
Other specified carcinomas	135	4	0	0	25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Carcinoma, unspecified	76	115	0	0	3	15	0	0	0	0	0	0	0	0	0	0	0	0	1	3	0	0
Malignant thymoma	10	0	0	0	0	0	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	616	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	577	3	0	0	0	0
Fibrosarcoma	8	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0	0	0
Liposarcoma	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
Rhabdomyosarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	6	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	1	0	0	0
Kaposi sarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	5	0	1	0	0	0	0	0	0	0
Chondrosarcoma	9	0	0	0	0	0	0	0	0	0	0	0	3	0	5	0	0	0	0	0	0	0
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	2	0	3	0	0	0	0	0	0	0
Other specified sarcomas	6	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	21	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
Malignant complex mixed and stromal tumors	72	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignat fibroepithelial tumors	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	40	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	40	3
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	73	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	130	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	426	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	58	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	126	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	115	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	151	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	123	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	94	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	5	6	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C46		C47		C48		C49		C50		C51		C52		C53		C54		C55	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	13699	638	2	0	4	0	19	0	54	1	1312	81	57	0	14	0	123	0	360	0	15	0
Small cell carcinoma	192	59	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	71	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1459	68	0	0	0	0	0	0	0	0	0	0	43	0	13	0	99	0	0	0	0	0
Basal cell carcinoma	2446	30	0	0	0	0	0	0	0	0	0	0	7	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	383	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6724	274	0	0	0	0	9	0	0	0	1294	34	3	0	1	0	16	0	301	0	0	0
Other specified carcinomas	135	4	0	0	0	0	0	0	0	0	12	0	0	0	0	0	5	0	43	0	1	0
Carcinoma, unspecified	76	115	0	0	0	0	0	0	0	0	6	47	2	0	0	0	0	0	0	0	0	0
Malignant thymoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	3	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	616	7	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0
Fibrosarcoma	8	0	0	0	0	0	0	0	5	0	0	0	0	0	0	0	0	0	0	0	1	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	17	0	0	0	0	0	6	0	10	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	13	0	0	0	0	0	0	0	5	0	0	0	0	0	0	0	0	0	0	0	4	0
Rhabdomyosarcoma	12	0	0	0	0	0	1	0	6	0	0	0	0	0	0	0	1	0	0	0	2	0
Synovial sarcoma	5	0	0	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	6	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	2	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	9	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	6	0	0	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	21	1	0	0	0	0	0	0	14	1	0	0	0	0	0	0	0	0	0	0	3	0
Malignant complex mixed and stromal tumors	72	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	2	0	16	0	4	0
Malignat fibroepithelial tumors	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	40	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	28	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	130	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	6	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	3	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	426	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	58	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	126	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	115	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	151	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	123	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	94	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	5	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C56		C57		C58		C60		C61		C62		C63		C64		C65		C66	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	13699	638	118	7	15	3	0	0	17	0	1640	2	107	0	3	0	314	11	27	3	17	0
Small cell carcinoma	192	59	1	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	1	0	0
Non-small cell carcinoma	71	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1459	68	1	0	0	0	0	0	17	0	0	0	0	0	1	0	0	0	0	0	0	0
Basal cell carcinoma	2446	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	383	7	0	0	0	0	0	0	0	0	5	0	0	0	0	0	0	0	27	1	17	0
Adenocarcinoma	6724	274	107	3	12	3	0	0	0	0	1627	2	0	0	1	0	310	9	0	0	0	0
Other specified carcinomas	135	4	5	0	2	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0
Carcinoma, unspecified	76	115	0	4	1	0	0	0	0	0	2	0	0	0	0	0	4	2	0	1	0	0
Malignant thymoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	616	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	17	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Leiomyosarcoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	21	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	72	1	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignat fibroepithelial tumors	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	40	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	73	0	1	0	0	0	0	0	0	0	0	0	70	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	28	0	0	0	0	0	0	0	0	0	0	0	26	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	11	0	0	0	0	0	0	0	0	0	0	0	10	0	0	0	0	0	0	0	0	0
Malignant gliomas	130	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	426	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	58	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	126	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	115	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	151	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	123	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	94	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	5	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C67		C68		C69		C70		C71		C72		C73		C74		C75		C76	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	13699	638	342	14	3	0	20	0	2	0	127	0	6	0	192	10	10	0	1	0	7	2
Small cell carcinoma	192	59	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	71	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1459	68	5	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Basal cell carcinoma	2446	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	383	7	332	6	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6724	274	3	0	0	0	0	0	0	0	0	0	0	0	187	5	7	0	0	0	5	2
Other specified carcinomas	135	4	1	0	0	0	1	0	0	0	0	0	0	0	4	3	0	0	0	0	0	0
Carcinoma, unspecified	76	115	1	7	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Malignant thymoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0
Malignant melanoma	616	7	0	0	0	0	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Rhabdomyosarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	21	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	72	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignat fibroepithelial tumors	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	40	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	28	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	130	0	0	0	0	0	0	0	0	0	124	0	6	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	6	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0	1	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	426	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	58	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	126	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	115	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	151	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	123	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	94	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Malignant tumor, unspecified	5	6	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C77		C78		C79		C80		C81		C82		C83		C84		C85		C88	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	13699	638	28	6	27	20	17	2	71	32	58	1	114	3	257	24	35	0	12	2	8	0
Small cell carcinoma	192	59	0	0	2	0	1	0	4	2	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	71	24	0	0	0	0	1	0	2	1	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1459	68	15	4	0	0	2	1	4	0	0	0	0	0	0	0	0	0	0	0	0	0
Basal cell carcinoma	2446	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	383	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6724	274	6	1	20	10	9	0	39	14	0	0	0	0	0	0	0	0	0	0	0	0
Other specified carcinomas	135	4	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0
Carcinoma, unspecified	76	115	2	1	4	9	0	1	10	8	0	0	0	0	0	0	0	0	0	0	0	0
Malignant thymoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	616	7	3	0	1	0	3	0	7	4	0	0	0	0	0	0	0	0	0	0	0	0
Fibrosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	5	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	21	1	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	72	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignat fibroepithelial tumors	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	40	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	73	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	11	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	130	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	426	29	0	0	0	0	0	0	0	0	0	0	114	3	257	24	35	0	12	2	8	0
Hodgkin lymphoma	58	1	0	0	0	0	0	0	0	0	58	1	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	126	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	115	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	151	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	123	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	94	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	5	6	1	0	0	1	0	0	1	2	0	0	0	0	0	0	0	0	0	0	0	0

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)													
	C00–C96		C90		C91		C92		C93		C94		C95		C96	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	13699	638	126	3	145	2	114	3	6	0	31	0	1	0	189	1
Small cell carcinoma	192	59	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	71	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1459	68	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Basal cell carcinoma	2446	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	383	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6724	274	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified carcinomas	135	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Carcinoma, unspecified	76	115	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant thymoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	616	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	21	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	72	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignat fibroepithelial tumors	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	40	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	130	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	426	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	58	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	126	3	126	3	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	115	2	0	0	115	2	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	151	3	0	0	30	0	114	3	6	0	0	0	1	0	0	0
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0
Chronic myeloproliferative diseases	123	0	0	0	0	0	0	0	0	0	31	0	0	0	92	0
Myelodysplastic syndromes	94	1	0	0	0	0	0	0	0	0	0	0	0	0	94	1
Other specified malignant tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	5	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Tabela 8: Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2016.

Table 8: Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2016.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
				Number	%*	Number	%*	Number	%*	Number	%*
C00 – C80	Vse lokacije All sites	M+Ž	13904	7774	55,9	3542	25,5	2403	17,3	185	1,3
		M	7491	4134	55,2	1921	25,6	1334	17,8	102	1,4
		Ž	6413	3640	56,7	1621	25,3	1069	16,7	83	1,3
C00	Ustnica Lip	M	15	14	93,3	1	6,7	0	0	0	0
		Ž	10	9	–	1	–	0	–	0	–
C01	Baza jezika Base of tongue	M	22	2	9,1	19	86,4	1	4,5	0	0
		Ž	7	1	–	6	–	0	–	0	–
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	13	8	–	5	–	0	–	0	–
		Ž	17	11	64,7	6	35,3	0	0	0	0
C03	Dlesen Gum	M	6	1	–	5	–	0	–	0	–
		Ž	10	2	–	8	–	0	–	0	–
C04	Ustno dno Floor of mouth	M	24	4	16,7	20	83,3	0	0	0	0
		Ž	8	4	–	4	–	0	–	0	–
C05	Nebo Palate	M	10	5	–	4	–	1	–	0	–
		Ž	7	2	–	5	–	0	–	0	–
C06	Usta, drugi deli Mouth, other & unspecified parts	M	13	4	–	8	–	1	–	0	–
		Ž	7	3	–	4	–	0	–	0	–
C07	Parotidna žleza Parotid gland	M	11	7	–	3	–	1	–	0	–
		Ž	8	7	–	1	–	0	–	0	–
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0	0	–	0	–	0	–	0	–
		Ž	2	0	–	2	–	0	–	0	–
C09	Tonzila Tonsil	M	41	9	22,0	29	70,7	3	7,3	0	0
		Ž	13	3	–	10	–	0	–	0	–
C10	Orofarinks Oropharynx	M	40	2	5,0	37	92,5	1	2,5	0	0
		Ž	4	0	–	4	–	0	–	0	–
C11	Nazofarinks Nasopharynx	M	8	0	–	6	–	2	–	0	–
		Ž	1	0	–	1	–	0	–	0	–
C12	Piriformni sinus Pyriform sinus	M	32	2	6,3	29	90,6	1	3,1	0	0
		Ž	1	0	–	1	–	0	–	0	–
C13	Hipofarinks Hypopharynx	M	20	1	5,0	17	85,0	2	10,0	0	0
		Ž	3	0	–	3	–	0	–	0	–
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	–	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–	0	–
C15	Požiralnik Oesophagus	M	50	7	14,0	22	44,0	19	38,0	2	4,0
		Ž	14	2	–	5	–	5	–	2	–
C16	Želodec Stomach	M	272	52	19,1	111	40,8	103	37,9	6	2,2
		Ž	170	37	21,8	76	44,7	49	28,8	8	4,7
C17	Tanko črevo Small intestine	M	25	10	40,0	7	28,0	8	32,0	0	0
		Ž	19	7	36,8	9	47,4	3	15,8	0	0
C18	Debelo črevo Colon	M	514	131	25,5	268	52,1	109	21,2	6	1,2
		Ž	390	87	22,3	218	55,9	80	20,5	5	1,3
C19	Rektosigmoidna zveza Rectosigmoid junction	M	64	13	20,3	30	46,9	20	31,3	1	1,6
		Ž	40	7	17,5	28	70,0	5	12,5	0	0
C20	Rektum Rectum	M	293	74	25,3	167	57,0	50	17,1	2	0,7
		Ž	164	38	23,2	84	51,2	37	22,6	5	3,0
C21	Anus in analni kanal Anus and anal canal	M	10	2	–	7	–	1	–	0	–
		Ž	11	4	–	6	–	1	–	0	–
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	139	53	38,1	32	23,0	47	33,8	7	5,0
		Ž	60	20	33,3	14	23,3	21	35,0	5	8,3
C23	Žolčnik Gallbladder	M	18	3	16,7	6	33,3	9	50,0	0	0
		Ž	36	9	25,0	11	30,6	16	44,4	0	0
C24	Drugi in neopredeljeni deli biliarnega trakta Billiary tract, other and unspecified parts	M	82	16	19,5	38	46,3	25	30,5	3	3,7
		Ž	59	10	16,9	23	39,0	21	35,6	5	8,5
C25	Trebušna slinavka Pancreas	M	193	11	5,7	66	34,2	104	53,9	12	6,2
		Ž	194	9	4,6	64	33,0	108	55,7	13	6,7
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	1	0	–	1	–	0	–	0	–
		Ž	3	0	–	2	–	1	–	0	–

Nadaljevanje —>
Continued —>

Tabela 8: Nadaljevanje.
Table 8: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
				Number	%*	Number	%*	Number	%*	Number	%*
C30	Nosna votlina in srednje uho	M	2	0	–	1	–	1	–	0	–
	Nasal cavity and middle ear	Ž	5	0	–	4	–	1	–	0	–
C31	Obnosni sinusi	M	2	0	–	2	–	0	–	0	–
	Accessory sinuses	Ž	2	0	–	1	–	1	–	0	–
C32	Grlo	M	92	45	48,9	46	50,0	1	1,1	0	0
	Larynx	Ž	17	10	58,8	7	41,2	0	0	0	0
C33	Sapnik	M	0	0	–	0	–	0	–	0	–
	Trachea	Ž	0	0	–	0	–	0	–	0	–
C34	Sapnica in pljuča	M	962	178	18,5	285	29,6	484	50,3	15	1,6
	Bronchus and lung	Ž	555	106	19,1	155	27,9	288	51,9	6	1,1
C37	Timus	M	5	3	–	1	–	0	–	1	–
	Thymus	Ž	7	5	–	1	–	1	–	0	–
C38	Srce, mediastinum, plevra	M	4	2	–	2	–	0	–	0	–
	Heart, mediastinum, pleura	Ž	3	1	–	1	–	0	–	1	–
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih	M	0	0	–	0	–	0	–	0	–
	Other and ill-defined sites in the respiratory system and intrathoracic organs	Ž	0	0	–	0	–	0	–	0	–
C40	Kosti, sklepni hrustanec udov	M	5	3	–	2	–	0	–	0	–
	Bone and articular cartilage of limbs	Ž	5	1	–	2	–	1	–	1	–
C41	Kosti, sklepni hrustanec, drugje	M	5	0	–	4	–	0	–	1	–
	Bone and articular cartilage of other and unspecified parts	Ž	4	0	–	1	–	3	–	0	–
C43	Maligni melanom kože	M	304	234	77,0	58	19,1	10	3,3	2	0,7
	Malignant melanoma of skin	Ž	276	218	79,0	53	19,2	5	1,8	0	0
C44	Druge maligne neoplazme kože	M	1491	1474	98,9	16	1,1	0	0	1	0,1
	Skin, other malignomas	Ž	1459	1453	99,6	6	0,4	0	0	0	0
C45	Mezoteliom	M	29	10	34,5	19	65,5	0	0	0	0
	Mesothelioma	Ž	14	5	–	9	–	0	–	0	–
C46	Kaposijev sarkom	M	1	1	–	0	–	0	–	0	–
	Kaposi's sarcoma	Ž	1	1	–	0	–	0	–	0	–
C47	Periferni živci in avtonomno živčevje	M	2	1	–	1	–	0	–	0	–
	Peripheral nerves and autonomic nervous system	Ž	2	1	–	1	–	0	–	0	–
C48	Peritonej in retroperitonej	M	6	0	–	4	–	2	–	0	–
	Peritoneum and retroperitoneum	Ž	14	0	–	8	–	6	–	0	–
C49	Drugo vezivno in mehko tkivo	M	24	7	29,2	12	50,0	4	16,7	1	4,2
	Other connective and soft tissue	Ž	32	7	21,9	21	65,6	4	12,5	0	0
C50	Dojka	M	14	8	–	4	–	2	–	0	–
	Breast	Ž	1382	795	57,5	497	36,0	86	6,2	4	0,3
C51	Žensko zunanje spolovilo	M	–	–	–	–	–	–	–	–	–
	Vulva	Ž	57	34	59,6	17	29,8	4	7,0	2	3,5
C52	Nožnica	M	–	–	–	–	–	–	–	–	–
	Vagina	Ž	14	7	–	5	–	2	–	0	–
C53	Maternični vrat	M	–	–	–	–	–	–	–	–	–
	Cervix uteri	Ž	123	60	48,8	46	37,4	15	12,2	2	1,6
C54	Maternično telo	M	–	–	–	–	–	–	–	–	–
	Corpus uteri	Ž	361	268	74,2	63	17,5	28	7,8	2	0,6
C55	Maternica, neopredeljeno	M	–	–	–	–	–	–	–	–	–
	Uterus, unspecified	Ž	17	7	41,2	5	29,4	4	23,5	1	5,9
C56	Jajčnik	M	–	–	–	–	–	–	–	–	–
	Ovary	Ž	129	18	14,0	12	9,3	99	76,7	0	0
C57	Drugi in neopredeljeni ženski spolni organi	M	–	–	–	–	–	–	–	–	–
	Other and unspecified parts of female genital organs	Ž	19	2	10,5	4	21,1	13	68,4	0	0
C58	Posteljica	M	–	–	–	–	–	–	–	–	–
	Placenta	Ž	0	0	–	0	–	0	–	0	–
C60	Penis	M	17	9	52,9	6	35,3	1	5,9	1	5,9
	Penis	Ž	–	–	–	–	–	–	–	–	–
C61	Prostata	M	1686	1164	69,0	385	22,8	119	7,1	18	1,1
	Prostate	Ž	–	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 8: Nadaljevanje.
Table 8: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
				Number	%*	Number	%*	Number	%*	Number	%*
C62	Modo	M	107	79	73,8	20	18,7	8	7,5	0	0
	Testis	Ž	–	–	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi	M	3	3	–	0	–	0	–	0	–
	Other and unspecified male genital organs	Ž	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha	M	228	138	60,5	51	22,4	37	16,2	2	0,9
	Kidney, except renal pelvis	Ž	131	82	62,6	27	20,6	18	13,7	4	3,1
C65	Ledvični meh	M	22	8	36,4	7	31,8	7	31,8	0	0
	Renal pelvis	Ž	11	5	–	3	–	3	–	0	–
C66	Sečevod	M	15	10	66,7	2	13,3	3	20,0	0	0
	Ureter	Ž	5	3	–	1	–	0	–	1	–
C67	Sečni mehur	M	251	197	78,5	32	12,7	20	8,0	2	0,8
	Bladder	Ž	114	76	66,7	31	27,2	7	6,1	0	0
C68	Drugi in neopredeljeni sečni organi	M	2	2	–	0	–	0	–	0	–
	Other and unspecified urinary organs	Ž	1	0	–	1	–	0	–	0	–
C69	Oko in očesni adneksi	M	10	6	–	3	–	1	–	0	–
	Eye and adnexa	Ž	11	6	–	5	–	0	–	0	–
C70	Meninge	M	2	1	–	1	–	0	–	0	–
	Meninges	Ž	0	0	–	0	–	0	–	0	–
C71	Možgani	M	97	96	99,0	1	1,0	0	0	0	0
	Brain	Ž	54	54	100	0	0	0	0	0	0
C72	Hrbtni mozeg, možganski živci in drugi deli CŽS	M	3	3	–	0	–	0	–	0	–
	Spinal cord, cranial nerves and other parts of CNS	Ž	5	5	–	0	–	0	–	0	–
C73	Ščitnica	M	36	19	52,8	15	41,7	2	5,6	0	0
	Thyroid gland	Ž	166	137	82,5	21	12,7	8	4,8	0	0
C74	Nadledvična žleza	M	4	1	–	2	–	1	–	0	–
	Adrenal gland	Ž	6	1	–	3	–	2	–	0	–
C75	Druge endokrine žleze in sorodne strukture	M	1	1	–	0	–	0	–	0	–
	Other endocrine glands and related structures	Ž	0	0	–	0	–	0	–	0	–
C76	Druga in slabo opredeljena mesta	M	3	0	–	1	–	2	–	0	–
	Other and ill-defined sites	Ž	18	0	0	14	77,8	4	22,2	0	0
C77	Metastaza in neopredeljena maligna neoplazma bezgavk	M	20	0	0	0	0	1	5,0	19	95,0
	Metastasis and unspecified malignant neoplasm of lymph nodes	Ž	17	0	0	0	0	1	5,9	16	94,1
C78	Metastaze dihal in prebavil	M	36	0	0	0	0	36	100	0	0
	Metastases of respiratory and digestive organs	Ž	41	0	0	0	0	41	100	0	0
C79	Metastaze, drugje	M	15	0	0	0	0	15	100	0	0
	Metastases of other sites	Ž	13	0	–	0	–	13	–	0	–
C80	Maligna neoplazma brez opredeljenega mesta	M	69	0	0	0	0	69	100	0	0
	Malignant neoplasm without specification of site	Ž	64	0	0	0	0	64	100	0	0

Šifra MKB	Primarna lokacija	Spol Sex	Število primerov Number of new cases	Stadij (Ann–Arbor)							
				I		II		III+IV		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
ICD code	Primary site			Stage (Ann–Arbor)							
				I		II		III+IV		Unknown	
				Number	%*	Number	%*	Number	%*	Number	%*
C81	Hodgkinova bolezen	M	30	3	10,0	7	23,3	19	63,3	1	3,3
	Hodgkin's disease	Ž	29	0	0	11	37,9	17	58,6	1	3,4
C82–C85	Ne-Hodgkinov limfom	M	242	45	18,6	33	13,6	141	58,3	23	9,5
	Non-Hodgkin's lymphoma	Ž	205	45	22,0	22	10,7	117	57,1	21	10,2

* Odstotki niso računani, če je število novih primerov manjše od 15
* Percentages are not calculated when number of new cases is less than 15

Tabela 9: Incidenca ne-Hodgkinovih limfomov* po lokaciji, spolu in starosti, Slovenija 2016.

Table 9: Incidence of non-Hodgkin´s malignant lymphomas* by site, by sex and by age, Slovenia 2016.

Šifra MKB–8 ICD–8 code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
	Vsi NHL	M+Ž	447	0	2	0	3	3	6	7	9	13	16	24	47	48	80	60	58	71
	All NHL	M	242	0	2	0	1	2	6	3	6	8	8	16	26	23	45	30	34	32
		Ž	205	0	0	0	2	1	0	4	3	5	8	8	21	25	35	30	24	39
142	Slinavke	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	Salivary glands	Ž	2	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
146	Orofarinks	M	8	0	0	0	0	0	0	0	1	1	1	0	2	1	0	0	1	1
	Oropharynx	Ž	10	0	0	0	1	0	0	2	0	0	0	0	1	2	0	1	1	2
147	Epifarinks	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	Epipharynx	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
151	Želodec	M	13	0	0	0	0	0	0	0	0	0	1	0	1	1	3	2	3	2
	Stomach	Ž	10	0	0	0	0	0	0	1	0	0	0	0	2	0	1	3	0	3
152	Tanko črevo	M	5	0	0	0	0	0	1	0	0	0	0	0	1	0	3	0	0	0
	Small intestine	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
153	Debelo črevo	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0
	Colon	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
155	Jetra	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Liver	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
160	Nos, obnosne votline, drugo	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Nose, sinuses, etc.	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
162	Sapnik, sapnica, pljuča	M	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0
	Trachea, bronchus, lung	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
163	Plevra, mediastinum, drugo	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Pleura, mediastinum, etc.	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
170	Kosti	M	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0
	Bone	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
171	Mehka tkiva	M	4	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	1	0
	Soft tissues	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
173	Koža, drugi malignomi	M	9	0	1	0	1	0	0	0	0	2	1	0	0	0	0	2	1	1
	Skin, other malignancies	Ž	7	0	0	0	0	0	0	0	0	0	3	0	1	0	1	0	2	0
174	Dojka	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	Breast	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
186	Modo	M	2	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0
	Testis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
190	Oko	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	Eye	Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2
191	Možgani	M	5	0	0	0	0	0	0	0	0	0	0	0	2	0	2	1	0	0
	Brain	Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1
193	Ščitnica	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	Thyroid	Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1
202	Bezgavke	M	185	0	1	0	0	2	5	3	4	5	4	13	18	20	34	25	26	25
	Lymph nodes	Ž	161	0	0	0	1	1	0	1	3	5	4	8	17	20	28	24	21	28

* Vključeni so samo citološko in histološko potrjeni primeri

* All cases included have been verified citologically and histologically

Tabela 10: Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, po spolu, Slovenija 2016.

Table 10: Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), by sex, Slovenia 2016.

Šifra ICD-O-3 ICD-O-3 code	Histološka vrsta Histology type	Spol Sex	Število Number	Incidenčna stopnja na 100.000 Incidence rate per 100,000
	Vse vrste All types	M+Ž	791	38,3
		M	440	43,0
		Ž	351	33,7
9727, 9728, 9835, 9836, 9811–9818	Neoplazme nezrelih celic B Precursor lymphoid neoplasms B	M	3	0,3
		Ž	10	1,0
9835, 9836, 9811	Limfoblastni limfom B / levkemija B, BDO B lymphoblastic lymphoma / leukaemia, NOS	M	2	0,2
		Ž	9	0,9
9812	Limfoblastni limfom B / levkemija B z rekurentnimi citogenetskimi anomalijami B lymphoblastic lymphoma / leukaemia with recurrent genetic abnormalities	M	1	0,1
		Ž	1	0,1
9729, 9837	Neoplazme nezrelih celic T Precursor lymphoid neoplasms T	M	5	0,5
		Ž	0	0,0
9729, 9837	Limfoblastni limfom T / levkemija T T Lymphoblastic lymphoma / leukaemia	M	5	0,5
		Ž	0	0,0
9591–9597, 9670–9699, 9712, 9731–9738, 9760–9764, 9823, 9826, 9833, 9940	Periferni B-celični limfom / neoplazme zrelih celic B Mature B-cell neoplasms	M	383	37,4
		Ž	293	28,2
9670, 9823	Kronična limfatična levkemija B / drobnocelični limfocitni limfom Chronic lymphocytic leukaemia / small lymphocytic lymphoma	M	73	7,1
		Ž	61	5,9
9689	Splenični limfom robne cone Splenic marginal zone lymphoma	M	4	0,4
		Ž	6	0,6
9591	Ne-Hodgkinovi limfomi, BDO; primarni vranični limfom / levkemija, nerazvrščeni; difuzni drobnocelični limfom B rdeče pulpe; posebna oblika dlakastocelične levkemije Non-Hodgkin lymphoma, NOS; splenic B-cell lymphoma / leukaemia, unclassifiable; splenic diffuse red pulp small B-cell lymphoma; hairy cell leukaemia-variant	M	3	0,3
		Ž	9	0,9
9940	Dlakastocelična levkemija Hairy cell leukaemia	M	11	1,1
		Ž	0	0,0
9671	Limfoplazmacitni limfom Lymphoplasmacytic lymphoma	M	3	0,3
		Ž	0	0,0
9761	Waldenströmova makroglobulinemija Waldenström macroglobulinemia	M	5	0,5
		Ž	3	0,3
9732, 9733	Multipli mielom Plasma cell myeloma	M	80	7,8
		Ž	46	4,4
9731, 9734	Solitarni kostni in zunajkostni plazmacitom Solitary plasmacytoma of bone and extraosseous	M	2	0,2
		Ž	1	0,1
9699, nodalni	B-celični limfom robne cone, nodalni Marginal zone B-cell lymphoma, nodal	M	20	2,0
		Ž	17	1,6
9699, ekstranodalni	B-celični limfom robne cone, ekstranodalni Marginal zone B-cell lymphoma, extranodal	M	12	1,2
		Ž	12	1,2
9690	Folikularni limfom, BDO Follicular lymphoma, NOS	M	4	0,4
		Ž	2	0,2
9691, 9695	Folikularni limfom, gradus 1 in 2 Follicular lymphoma, grade 1 and 2	M	11	1,1
		Ž	21	2,0
9698	Folikularni limfom, gradus 3 Follicular lymphoma, grade 3	M	12	1,2
		Ž	5	0,5
9597	Primarni kožni limfom folikularnih centrov Primary cutaneous follicle centre lymphoma	M	1	0,1
		Ž	0	0,0
9673	Limfom plaščnih celic Mantle cell lymphoma	M	18	1,8
		Ž	6	0,6
9735	Plazmablastni limfom Plasmablastic lymphoma	M	2	0,2
		Ž	0	0,0
9680	Difuzni velikocelični limfom B (DLBCL), BDO; primarni DLBCL CŽS; primarni kožni DLBCL, nožni tip; EBV-pozitivni DLBCL starejših; DLBCL povezan s kroničnim vnetjem; nerazvrščeni B-celični limfom, mejni primer med difuznim velikoceličnim limfomom B in Burkittovim limfomom Malignant lymphoma, large B-cell, diffuse (DLBCL), NOS; primary DLBCL of the CNS; primary cutaneous DLBCL, leg type; EBV positive DLBCL of the elderly; DLBCL associated with chronic inflammation; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma	M	111	10,8
		Ž	95	9,1
9687, 9826	Burkittov limfom / levkemija Burkitt lymphoma / leukaemia	M	8	0,8
		Ž	4	0,4

Nadaljevanje —>
Continued —>

Tabela 10: Nadaljevanje.
Table 10: Continued.

Šifra ICD-O-3 ICD-O-3 code	Histološka vrsta Histology type	Spol Sex	Število Number	Incidenčna stopnja na 100.000 Incidence rate per 100,000
9679	Primarni mediastinalni (timični) velikocelični limfom B Primary mediastinal (thymic) large B-cell lymphoma	M Ž	2 5	0,2 0,5
9596	Neopredeljivi limfom s celicami B, z lastnostmi difuznega limfoma z velikimi celicami B in klasičnega Hodgkinovega limfoma B-cell lymphoma, unclassifiable, with features between DLBCL and classical HL	M Ž	1 0	0,1 0,0
	Neoplazme zrelih celic T/NK Mature T- and NK-cell neoplasms	M Ž	19 17	1,9 1,6
9827, 9831, 9834, 9948	Levkemične neoplazme zrelih celic T/NK Leukaemic mature T- and NK-cell neoplasms	M Ž	0 1	0,0 0,1
9834	Prolimfocitna levkemija T T-cell prolymphocytic leukaemia	M Ž	0 1	0,0 0,1
9700, 9701, 9708, 9709, 9716–9719	Neoplazme zrelih (ekstranodalnih) celic T/NK Mature (extranodal) T- and NK-cell neoplasms	M Ž	4 5	0,4 0,5
9717	Limfom T z enteropatijo Enteropathy-associated T-cell lymphoma	M Ž	0 1	0,0 0,1
9700	Fungoidna mikoza Mycosis fungoides	M Ž	2 2	0,2 0,2
9718	Primarne kožne CD30+ T-celične limfoproliferativne bolezni Primary cutaneous CD30+ T-cell lymphoproliferative disorder	M Ž	0 1	0,0 0,1
9709	Primarni kožni periferni limfomi T, redki tipi Primary cutaneous T-cell lymphoma, rare types	M Ž	2 1	0,2 0,1
9702, 9705, 9714	Zrele (nodalne) neoplazme celic T/NK Mature (nodal) T- and NK-cell neoplasms	M Ž	15 11	1,5 1,1
9702	Periferni limfom T (BDO- in ALK-negativen ALCL) Peripheral T-cell lymphoma (NOS and ALK negative ALCL)	M Ž	3 4	0,3 0,4
9705	Angioimunoblastni limfom T Angioimmunoblastic T-cell lymphoma	M Ž	7 3	0,7 0,3
9714	Anaplastični velikocelični limfom, ALK-pozitivni Anaplastic large cell lymphoma, ALK positive	M Ž	5 4	0,5 0,4
9650–9667	Hodgkinov limfom (HL) Hodgkin lymphoma (HL)	M Ž	30 29	2,9 2,8
9659	HL z nodularno limfocitno predominanco Nodular lymphocyte predominant HL	M Ž	1 0	0,1 0,0
9650	Klasični HL Classical HL	M Ž	0 2	0,0 0,2
9663, 9664, 9665, 9667	Klasični HL, tip nodularne skleroze Nodular sclerosis classical HL	M Ž	14 16	1,4 1,5
9651	Z limfociti bogat klasični HL Lymphocyte-rich classical HL	M Ž	2 1	0,2 0,1
9652	Mešanocelični tip klasičnega HL Mixed cellularity classical HL	M Ž	12 9	1,2 0,9
9653, 9654	Klasični HL, tip limfocitne deplecije Lymphocyte-depleted classical HL	M Ž	1 1	0,1 0,1
9590, 9832	Neopredeljeni limfomi / levkemije Unspecified lymphoma / leukemia	M Ž	0 1	0,0 0,1
9590	Maligni limfom, BDO Malignant lymphoma, NOS	M Ž	0 1	0,0 0,1
9750–9759	Neoplazme histiocitov in dendritičnih celic Histiocytic and dendritic cell neoplasms	M Ž	0 1	0,0 0,1
9751	Histiocitoza Langerhansovih celic, NOS Langerhans cell histiocytosis, NOS	M Ž	0 1	0,0 0,1

Tabela 11a: Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2016, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemsko terapijo ali obsevani, po izbrani primarni lokaciji raka.

Table 11a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2016, that were treated by surgery, systemic therapy or radiotherapy during their first treatment by selected primary cancer site.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število kakorkoli zdravljenih* Number of all treated*		Število operiranih Number of treated by surgery		Število zdravljenih s sistemskim zdravljenjem Number of treated sistemic therapy		Število obsevanih Number of treated by radiotherapy	
			Število Number	%**	Število Number	%**	Število Number	%**	Število Number	%**
C00–C96	Vse lokacije All sites	15040	12218	81,2	9553	63,5	4150	27,6	3290	21,9
C00–C14	Usta in žrelo Mouth and pharynx	353	328	92,9	196	55,5	38	10,8	228	64,6
C15	Požiralnik Oesophagus	64	39	60,9	13	–	27	42,2	28	43,8
C16	Želodec Stomach	442	297	67,2	223	50,5	159	36,0	83	18,8
C18	Debelo črevo Colon	904	782	86,5	754	83,4	181	20,0	4	–
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	561	483	86,1	428	76,3	195	34,8	230	41,0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	199	68	34,2	24	12,1	43	21,6	1	–
C23–C24	Žolčnik in žolčevodi Gallbladder and billiary tract	195	85	43,6	80	41,0	18	9,2	4	–
C25	Trebušna slinavka Pancreas	387	158	40,8	90	23,3	102	26,4	5	–
C32	Grlo Larynx	109	95	87,2	52	47,7	4	–	69	63,3
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1517	1076	70,9	336	22,1	463	30,5	656	43,2
C43	Maligni melanom kože Malignant melanoma of skin	580	575	99,1	574	99,0	5	–	30	5,2
C44	Druge maligne neoplazme kože Skin, other malignomas	2950	2889	97,9	2746	93,1	23	0,8	122	4,1
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	76	68	89,5	58	76,3	27	35,5	28	36,8
C50	Dojka Breast	1396	1355	97,1	1222	87,5	1228	88,0	880	63,0
C53	Maternični vrat Cervix uteri	123	116	94,3	84	68,3	3	–	61	49,6
C54	Maternično telo Corpus uteri	361	340	94,2	327	90,6	51	14,1	111	30,7
C56	Jajčnik Ovary	129	109	84,5	103	79,8	79	61,2	1	–
C61	Prostata Prostate	1686	1198	71,1	874	51,8	403	23,9	187	11,1
C62	Modo Testis	107	107	100,0	107	100,0	67	62,6	0	–
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	392	309	78,8	294	75,0	22	5,6	9	–
C67	Sečni mehur Bladder	365	332	91,0	329	90,1	50	13,7	34	9,3
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	161	133	82,6	115	71,4	67	41,6	92	57,1
C73	Ščitnica Thyroid gland	202	193	95,5	185	91,6	174	86,1	111	55,0
C81	Hodgkinova bolezen Hodgkin's disease	59	58	98,3	0	–	56	94,9	28	47,5
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	447	340	76,1	52	11,6	282	63,1	114	25,5
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	129	100	77,5	4	–	92	71,3	24	18,6
C91–C95	Levkemije Leukaemias	303	130	42,9	1	–	128	42,2	9	–

* Število kakorkoli zdravljenih v okviru prvega zdravljenja, ne glede na način zdravljenja (vključno z drugimi zdravljenji, ki ne spadajo pod operacijo, sistemsko zdravljenje ali obsevanje)

* Number of all treated patients regardless of the means of treatment (including other treatments not included into surgery, systemic therapy or radiotherapy)

** Odstotki niso računani, če je število zdravljenih manjše od 15

** Percentages are not calculated for less than 15 cases

Tabela 11b: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2016, ki so bili v okviru prvega zdravljenja operirani*, po izbrani primarni lokaciji raka in bolnici posega.

Table 11b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2016, that were treated by surgery during their first treatment* by selected primary cancer site and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število operiranih Number of treated by surgery	Splošna bolnišnica Celje	Splošna bolnišnica Jesenice	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Slovenj Gradec	Splošna bolnišnica Trbovlje	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	15040	9553	751	275	173	2569	1392	1563	382	358	448	615	33	869	125
C00–C14	Usta in žrelo Mouth and pharynx	353	196	3	0	0	130	2	54	2	3	1	1	0	0	0
C15	Požiralnik Oesophagus	64	13	0	0	0	12	0	1	0	0	0	0	0	0	0
C16	Želodec Stomach	442	223	8	8	2	104	9	73	7	3	3	5	0	1	0
C18	Debelo črevo Colon	904	754	56	60	48	229	41	116	23	41	40	31	17	33	19
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	561	428	23	22	25	93	90	70	23	4	19	16	5	31	7
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	199	24	0	0	0	18	1	5	0	0	0	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and billiary tract	195	80	1	2	7	34	0	29	1	0	1	0	0	3	2
C25	Trebušna slinavka Pancreas	387	90	0	0	5	60	0	25	0	0	0	0	0	0	0
C32	Grlo Larynx	109	52	1	0	0	39	0	11	0	0	0	0	0	0	1
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1517	336	2	1	0	103	1	71	0	0	0	0	0	158	0
C43	Maligni melanom kože Malignant melanoma of skin	580	574	54	32	9	138	34	81	25	14	33	22	0	89	43
C44	Druge maligne neoplazme kože Skin, other malignomas	2950	2746	326	136	8	583	30	505	176	120	220	137	3	486	16
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	76	58	1	0	2	19	27	2	1	0	3	1	0	0	2
C50	Dojka Breast	1396	1222	24	0	24	1	903	167	2	72	0	27	0	1	1
C53	Maternični vrat Cervix uteri	123	84	2	0	1	51	2	8	5	1	1	4	1	0	8
C54	Maternično telo Corpus uteri	361	327	10	8	7	156	38	51	18	10	9	10	4	0	6
C56	Jajčnik Ovary	129	103	9	2	2	42	24	16	2	1	1	2	0	0	2
C61	Prostata Prostate	1686	874	157	0	8	154	0	95	40	49	49	286	0	31	5
C62	Modo Testis	107	107	9	0	4	51	0	13	10	4	8	5	0	0	3
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	392	294	29	0	3	103	1	34	17	15	32	42	0	18	0
C67	Sečni mehur Bladder	365	329	17	0	12	167	0	49	22	15	24	21	0	0	2
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	161	115	2	0	0	77	0	33	0	0	0	0	0	0	3
C73	Ščitnica Thyroid gland	202	185	6	0	0	25	135	9	0	0	0	0	0	10	0
C81	Hodgkinova bolezen Hodgkin's disease	59	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	447	52	4	0	3	25	7	9	1	2	0	1	0	0	0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	129	4	1	0	0	3	0	0	0	0	0	0	0	0	0
C91–C95	Levkemije Leukaemias	303	1	0	0	0	1	0	0	0	0	0	0	0	0	0

* Bolniki, ki so bili v okviru prvega zdravljenja operirani več kot enkrat, so vključeni le s prvo operacijo

* Patients that underwent multiple surgery procedures in the course of first treatment were included with the first procedure only

** V posamezni ustanovi so operirali manj kot 30 bolnikov

** Less then 30 patients were treated by surgery in individual institution

Tabela 11c: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2016, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje*, po izbrani primarni lokaciji raka in bolnici zdravljenja.

Table 11c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2016, that were treated by systemic therapy during their first treatment* by selected primary cancer site and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število zdravljenih s sistemskim zdravljenjem Number of treated sistemic therapy	Splošna bolnišnica Celje	Bolnišnica Golnik	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	15040	4150	86	147	23	399	2665	581	37	76	23	75	24	14
C00–C14	Usta in žrelo Mouth and pharynx	353	38	0	0	0	0	38	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	64	27	0	0	0	0	23	4	0	0	0	0	0	0
C16	Želodec Stomach	442	159	3	0	0	14	102	37	0	2	0	1	0	0
C18	Debelo črevo Colon	904	181	3	0	0	5	123	38	1	1	0	10	0	0
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	561	195	2	0	0	3	178	11	0	0	0	1	0	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	199	43	0	0	0	32	2	9	0	0	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and billiary tract	195	18	1	0	0	4	5	6	0	0	0	1	0	1
C25	Trebušna slinavka Pancreas	387	102	1	0	0	38	40	20	0	0	0	0	0	3
C32	Grlo Larynx	109	4	0	0	0	0	4	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1517	463	0	139	1	0	229	93	0	0	0	0	0	1
C43	Maligni melanom kože Malignant melanoma of skin	580	5	0	0	0	0	5	0	0	0	0	0	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	2950	23	1	0	0	2	0	18	1	0	0	0	1	0
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	76	27	0	0	0	9	18	0	0	0	0	0	0	0
C50	Dojka Breast	1396	1228	34	0	13	0	910	208	0	46	0	17	0	0
C53	Maternični vrat Cervix uteri	123	3	0	0	0	0	3	0	0	0	0	0	0	0
C54	Maternično telo Corpus uteri	361	51	0	0	0	0	41	8	1	1	0	0	0	0
C56	Jajčnik Ovary	129	79	0	0	0	0	64	14	0	1	0	0	0	0
C61	Prostata Prostate	1686	403	20	0	8	62	171	43	13	13	20	36	15	2
C62	Modo Testis	107	67	0	0	0	2	65	0	0	0	0	0	0	0
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	392	22	0	0	0	0	19	3	0	0	0	0	0	0
C67	Sečni mehur Bladder	365	50	0	0	0	2	38	0	9	0	0	1	0	0
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	161	67	0	0	0	6	61	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	202	174	5	0	1	17	137	6	0	0	0	0	8	0
C81	Hodgkinova bolezen Hodgkin's disease	59	56	0	0	0	8	48	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	447	282	1	0	0	15	250	9	1	1	0	0	0	5
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	129	92	6	0	0	53	0	13	7	7	3	3	0	0
C91–C95	Levkemije Leukaemias	303	128	8	0	0	87	4	17	3	4	0	5	0	0

* Bolniki, ki so v okviru prvega zdravljenja prejeli več kot eno vrsto sistemskega zdravljenja, so vključeni le enkrat

* Patients that underwent multiple systemic treatments in the course of first treatment were included with the first treatment only

** V posamezni ustanovi so zdravili manj kot 10 bolnikov

** Less then 10 patients were treated in indivdual institution

Tabela 12: Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2016.

Table 12: Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2016.

Šifra MKB ICD code	Primarna lokacija* Primary site*	Spol Sex	Leta po diagnozi Years after diagnosis				Celotna prevalenca Lifetime prevalence
			<1	1–4	5–9	10+	Vsi / All
C00–C96	Vse lokacije All sites	M+Ž	12377	33912	28905	39035	107093
		M	6532	17438	14219	14297	48641
		Ž	5845	16474	14686	24738	58452
C00–C14	Usta in žrelo	M	220	569	420	470	1679
	Mouth and pharynx	Ž	89	194	164	265	712
C15	Požiralnik	M	35	44	14	25	118
	Oesophagus	Ž	7	11	9	10	37
C16	Želodec	M	185	378	247	381	1191
	Stomach	Ž	108	213	190	342	853
C18	Debelo črevo	M	430	1155	1060	962	3607
	Colon	Ž	317	843	880	1049	3089
C19–C20	Rektum in rektosigmoidna zveza	M	307	928	845	818	2898
	Rectum and rectosigmoid junction	Ž	181	493	571	730	1975
C22	Jetra in intrahepatični vodi	M	64	99	20	18	201
	Liver and intrahepatic bile ducts	Ž	27	28	6	11	72
C23–C24	Žolčnik in žolčevodi	M	56	56	32	31	175
	Gallbladder and billiary tract	Ž	45	66	37	32	180
C25	Trebušna slinavka	M	100	66	30	16	212
	Pancreas	Ž	89	68	29	23	209
C32	Grlo	M	84	225	234	327	870
	Larynx	Ž	16	25	32	54	127
C33–C34	Sapnik, sapnici in pljuča	M	577	718	341	367	2003
	Trachea, bronchus and lung	Ž	371	515	221	177	1284
C43	Maligni melanom kože	M	298	944	752	833	2827
	Malignant melanoma of skin	Ž	269	892	932	1392	3485
C44	Druge maligne neoplazme kože	M	1464	4547	3531	3835	13377
	Skin, other malignomas	Ž	1434	4570	3872	4833	14709
C48–C49	Vezivno in mehko tkivo	M	25	81	63	193	362
	Connective and soft tissue	Ž	41	102	64	203	410
C50	Dojka	M	11	38	28	31	108
	Breast	Ž	1337	4535	4134	7189	17195
C53	Maternični vrat	M	–	–	–	–	–
	Cervix uteri	Ž	114	340	446	2623	3523
C54	Maternično telo	M	–	–	–	–	–
	Corpus uteri	Ž	341	1082	987	2277	4687
C56	Jajčnik	M	–	–	–	–	–
	Ovary	Ž	107	330	285	866	1588
C61	Prostata	M	1598	5076	4444	2106	13224
	Prostate	Ž	–	–	–	–	–
C62	Modo	M	107	445	479	1392	2423
	Testis	Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehom	M	203	604	574	606	1987
	Kidney with renal pelvis	Ž	117	332	282	452	1183
C67	Sečni mehur	M	209	513	370	404	1496
	Bladder	Ž	94	165	109	145	513
C70–C72	Centralni in avtonomni živčni sistem	M	70	103	75	191	439
	Central and autonomic nervous system	Ž	38	69	64	148	319
C73	Ščitnica	M	31	154	136	228	549
	Thyroid gland	Ž	158	483	530	955	2126
C81	Hodgkinova bolezen	M	29	80	97	347	553
	Hodgkin's disease	Ž	27	81	103	322	533
C82–C85	Ne-Hodgkinovi limfomi	M	196	493	375	509	1573
	Non-Hodgkin's lymphoma	Ž	170	474	387	535	1566
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov	M	68	135	83	49	335
	Multiple myeloma and malignant plasma cell neoplasms	Ž	41	127	70	44	282
C91–C95	Levkemije	M	123	337	266	378	1104
	Leukaemias	Ž	110	281	182	336	909

* Pri posameznih lokacijah je pri prikazu prevalence oseba z več raki vključena pri vsaki lokaciji, pri vseh lokacijah skupaj pa se v prevalenci tudi oseba z več raki šteje le enkrat

* For persons with more than one cancer the person is included as a prevalent cancer in each cancer site, but in the all sites group each person is counted once only

Tabela 13: Umrljivost* za rakom po lokaciji, spolu in starosti, Slovenija 2016.

Table 13: Cancer mortality* by site, by sex and by age, Slovenia 2016.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C00 – C97	Vse lokacije All sites	M+Ž	6247	3	1	2	5	2	6	14	18	49	102	246	413	659	818	841	927	2141
		M	3522	2	1	2	1	1	2	6	8	15	54	142	260	412	524	515	549	1028
		Ž	2725	1	0	0	4	1	4	8	10	34	48	104	153	247	294	326	378	1113
C00	Ustnica Lip	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C01	Baza jezika Base of tongue	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	7	0	0	0	0	0	0	0	0	0	2	0	0	1	3	1	0	0
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	2
C03	Dlesen Gum	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C04	Ustno dno Floor of mouth	M	7	0	0	0	0	0	0	0	0	0	0	1	2	1	1	1	1	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
C05	Nebo Palate	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	14	0	0	0	0	0	0	0	0	0	1	0	3	8	0	2	0	0
		Ž	6	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	1	2
C07	Parotidna žleza Parotid gland	M	5	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	2
		Ž	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C09	Tonzila Tonsil	M	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1
		Ž	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
C10	Orofarinks Oropharynx	M	52	0	0	0	0	0	0	0	1	1	1	6	8	14	8	9	3	1
		Ž	10	0	0	0	0	0	0	0	0	0	0	1	1	1	2	3	0	2
C11	Nazofarinks Nasopharynx	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C12	Piriformni sinus Pyriform sinus	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C13	Hipofarinks Hypopharynx	M	35	0	0	0	0	0	0	0	0	0	3	2	5	6	8	5	2	4
		Ž	4	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	1	0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	7	0	0	0	0	0	0	0	0	0	1	0	0	1	4	0	1	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	M	74	0	0	0	0	0	0	0	0	1	1	2	11	10	18	10	10	11
		Ž	21	0	0	0	0	0	0	0	0	0	0	1	2	2	1	4	3	8
C16	Želodec Stomach	M	206	0	0	0	0	0	0	0	1	0	4	13	8	25	33	31	31	60
		Ž	121	0	0	0	0	0	0	0	0	1	0	3	4	8	10	12	19	64
C17	Tanko črevo Small intestine	M	7	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	2	3
		Ž	8	0	0	0	0	0	0	0	0	0	0	0	1	0	0	3	3	1
C18	Debelo črevo Colon	M	242	0	0	0	0	0	0	0	1	2	4	4	15	26	26	32	37	95
		Ž	226	0	0	0	0	0	0	1	0	3	4	4	7	15	16	25	41	110
C19	Rektosigmoidna zveza Rectosigmoid junction	M	34	0	0	0	0	0	0	0	0	0	0	1	2	1	5	3	6	16
		Ž	24	0	0	0	0	0	0	0	0	0	0	0	0	1	2	3	4	14
C20	Rektum Rectum	M	157	0	0	0	0	0	0	0	1	1	1	6	11	18	27	28	22	42
		Ž	97	0	0	0	0	0	0	1	0	2	1	5	6	2	7	11	13	49
C21	Anus in analni kanal Anus and anal canal	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	185	0	0	0	0	0	0	0	0	0	2	8	14	21	40	32	30	38
		Ž	86	0	0	0	0	0	1	0	0	0	2	0	4	7	11	12	19	30
C23	Žolčnik Gallbladder	M	17	0	0	0	0	0	0	0	0	0	0	0	1	5	2	3	2	4
		Ž	30	0	0	0	0	0	0	0	0	0	1	0	1	1	3	3	4	17
C24	Drugi in neopredeljeni deli biliarnega trakta Billiary tract, other and unspecified parts	M	27	0	0	0	0	0	0	0	0	1	0	1	0	1	1	3	8	12
		Ž	29	0	0	0	0	0	0	0	0	1	0	1	2	1	3	0	5	16
C25	Trebušna slinavka Pancreas	M	181	0	0	0	0	0	0	0	0	0	3	10	12	21	31	31	30	43
		Ž	199	0	0	0	0	0	0	0	1	3	2	6	7	16	23	31	33	77
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	8	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	3	3
		Ž	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	13
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
C31	Obnosni sinusi Accessory sinuses	M	5	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	3
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0

Nadaljevanje —>
Continued —>

Tabela 13: Nadaljevanje.
Table 13: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C32	Grlo	M	42	0	0	0	0	0	0	0	0	0	1	1	4	8	9	7	6	6
	Larynx	Ž	7	0	0	0	0	0	0	0	0	0	0	0	1	2	1	1	0	2
C33	Sapnik	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0
	Trachea	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C34	Sapnica in pljuča	M	814	0	0	0	0	0	0	0	0	1	11	43	88	131	162	127	105	146
	Bronchus and lung	Ž	392	0	0	0	0	0	0	0	0	1	7	19	38	69	60	51	48	99
C37	Timus	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Thymus	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C38	Srce, mediastinum, plevra	M	5	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	2
	Heart, mediastinum, pleura	Ž	6	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	1	2
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Other and ill-defined sites in the respiratory system and intrathoracic organs	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C40	Kosti, sklepni hrustanec udov	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	Bone and articular cartilage of limbs	Ž	7	0	0	0	2	1	0	0	0	0	0	0	0	0	0	1	1	2
C41	Kosti, sklepni hrustanec, drugje	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	Bone and articular cartilage of other and unspecified parts	Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1
C43	Maligni melanom kože	M	79	0	0	0	0	0	0	0	1	3	5	4	9	6	13	10	13	15
	Malignant melanoma of skin	Ž	49	0	0	0	0	0	2	0	1	3	2	1	5	3	5	4	4	19
C44	Druge maligne neoplazme kože	M	13	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	0	9
	Skin, other malignomas	Ž	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	17
C45	Mezoteliom	M	31	0	0	0	0	0	0	0	0	0	2	0	3	3	6	2	12	3
	Mesothelioma	Ž	9	0	0	0	0	0	0	0	0	0	0	0	2	2	0	1	3	1
C46	Kaposijev sarkom	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Kaposi's sarcoma	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
C47	Periferni živci in avtonomno živčevje	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Peripheral nerves and autonomic nervous system	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C48	Peritonej in retroperitonej	M	6	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	3	1
	Peritoneum and retroperitoneum	Ž	14	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	3	8
C49	Drugo vezivno in mehko tkivo	M	12	0	0	0	0	0	0	0	0	0	2	0	0	2	0	1	3	4
	Other connective and soft tissue	Ž	10	1	0	0	0	0	0	1	0	1	0	2	2	0	1	1	0	1
C50	Dojka	M	8	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	3	1
	Breast	Ž	384	0	0	0	0	0	1	3	3	8	8	24	22	33	46	46	45	145
C51	Žensko zunanje spolovilo	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Vulva	Ž	24	0	0	0	0	0	0	0	0	0	1	0	2	1	1	1	4	14
C52	Nožnica	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Vagina	Ž	7	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	3
C53	Maternični vrat	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Cervix uteri	Ž	41	0	0	0	0	0	0	0	0	3	0	4	5	6	6	2	4	11
C54	Maternično telo	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Corpus uteri	Ž	50	0	0	0	0	0	0	0	0	0	0	0	0	5	14	8	10	13
C55	Maternica, neopredeljeno	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Uterus, unspecified	Ž	42	0	0	0	0	0	0	0	0	0	2	5	2	1	6	4	2	20
C56	Jajčnik	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Ovary	Ž	147	0	0	0	0	0	0	2	1	2	8	15	18	19	16	17	13	36
C57	Drugi in neopredeljeni ženski spolni organi	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Other and unspecified parts of female genital organs	Ž	15	0	0	0	0	0	0	0	0	0	1	1	1	0	2	1	2	7
C58	Posteljica	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Placenta	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C60	Penis	M	10	0	0	0	0	0	0	0	0	0	1	1	1	0	3	2	1	1
	Penis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C61	Prostata	M	404	0	0	0	0	0	0	0	0	0	1	4	10	22	27	51	81	208
	Prostate	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C62	Modo	M	4	0	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0	1
	Testis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
	Other and unspecified male genital organs	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha	M	97	0	0	0	0	0	0	0	0	1	2	3	7	12	11	12	20	29
	Kidney, except renal pelvis	Ž	64	0	0	0	0	0	0	0	0	0	0	0	1	6	4	6	7	40
C65	Ledvični meh	M	5	0	0	0	0	0	0	0	1	0	0	0	0	0	2	0	2	0
	Renal pelvis	Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2

Nadaljevanje —>
Continued —>

Tabela 13: Nadaljevanje.
Table 13: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C66	Sečevod	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	Ureter	Ž	5	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	2
C67	Sečni mehur	M	145	0	0	0	0	0	0	0	0	1	0	1	5	12	11	25	21	69
	Bladder	Ž	62	0	0	0	0	0	0	0	1	1	0	2	1	2	5	3	6	41
C68	Drugi in neopredeljeni sečni organi	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Other and unspecified urinary organs	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C69	Oko in očesni adneksi	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Eye and adnexa	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
C70	Meninge	M	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0
	Meninges	Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0
C71	Možgani	M	109	1	1	2	1	1	1	3	1	2	3	11	15	10	11	15	14	17
	Brain	Ž	74	0	0	0	0	0	0	0	2	2	2	3	3	8	9	13	12	20
C72	Hrbtni mozeg, možganski živci in drugi deli CŽS	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
	Spinal cord, cranial nerves and other parts of CNS	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C73	Ščitnica	M	8	0	0	0	0	0	0	0	0	0	1	1	2	1	1	0	2	0
	Thyroid gland	Ž	18	0	0	0	0	0	0	0	0	0	1	0	0	1	1	4	4	7
C74	Nadledvična žleza	M	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2
	Adrenal gland	Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
C75	Druge endokrine žleze in sorodne strukture	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Other endocrine glands and related structures	Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
C76	Druga in slabo opredeljena mesta	M	2	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
	Other and ill-defined sites	Ž	3	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1
C77	Metastaza in neopredeljena maligna neoplazma bezgavk	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
	Metastasis and unspecified malignant neoplasm of lymph nodes	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C78	Metastaze dihal in prebavil	M	19	0	0	0	0	0	0	0	0	0	0	1	0	2	3	4	3	6
	Metastases of respiratory and digestive organs	Ž	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	9
C79	Metastaze, drugje	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	Metastases of other sites	Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0
C80	Maligna neoplazma brez opredeljenega mesta	M	46	0	0	0	0	0	0	0	0	0	0	5	4	9	2	7	3	16
	Malignant neoplasm without specification of site	Ž	68	0	0	0	0	0	0	0	0	0	2	2	5	7	9	6	3	34
C81	Hodgkinova bolezen	M	4	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1	0	1
	Hodgkin's disease	Ž	7	0	0	0	0	0	0	0	0	0	0	1	0	1	0	3	1	1
C82	Folikularni ne-Hodgkinov limfom	M	4	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	1	1
	Follicular non-Hodgkin's lymphoma	Ž	7	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	4
C83	Difuzni ne-Hodgkinov limfom	M	36	0	0	0	0	0	0	0	0	0	0	0	5	2	5	4	12	8
	Diffuse non-Hodgkin's lymphoma	Ž	31	0	0	0	1	0	0	0	0	0	0	0	1	3	2	4	7	13
C84	Limfomi celic T in kožni limfom celic T	M	9	0	0	0	0	0	0	1	0	0	0	0	2	3	0	1	0	2
	Peripheral and cutaneous T-cell lymphomas	Ž	4	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2	1
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma	M	49	0	0	0	0	0	0	0	0	0	1	1	1	1	8	10	7	20
	Other and unspecified types of non-Hodgkin's lymphoma	Ž	43	0	0	0	0	0	0	0	0	0	0	0	1	2	4	7	10	19
C88	Maligne imunoproliferativne bolezni	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
	Malignant immunoproliferative diseases	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov	M	53	0	0	0	0	0	0	0	0	0	1	1	3	4	8	15	6	15
	Multiple myeloma and malignant plasma cell neoplasms	Ž	46	0	0	0	0	0	0	0	0	0	0	0	3	3	1	7	8	24
C91	Limfatična levkemija	M	46	0	0	0	0	0	0	1	1	0	0	0	3	4	6	0	10	21
	Lymphoid leukaemia	Ž	33	0	0	0	0	0	0	0	0	0	1	0	3	0	3	3	4	19
C92	Mieloična levkemija	M	53	1	0	0	0	0	0	0	0	0	0	3	1	2	6	9	11	20
	Myeloid leukaemia	Ž	46	0	0	0	0	0	0	0	0	1	2	0	0	6	5	9	4	19
C93	Monocitna levkemija	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	Monocytic leukaemia	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C94	Druge opredeljene levkemije	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
	Other leukaemias of specified cells	Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2
C95	Levkemija z neopredeljenim celičnim tipom	M	11	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	2	6
	Leukaemia, unspecified cell type	Ž	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	4
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva	M	41	0	0	0	0	0	0	0	0	0	0	0	0	2	2	6	7	24
	Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	Ž	33	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	3	27

Nadaljevanje —>
Continued —>

Tabela 13: Nadaljevanje.
Table 13: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C97	Maligne neoplazme na več neodvisnih (primarnih) mestih Malignant neoplasms of independant (primary) multiple sites	M	55	0	0	0	0	0	0	0	0	0	0	1	1	6	5	5	10	27
		Ž	21	0	0	0	0	0	0	0	0	0	0	0	0	1	3	2	2	13
	Zgoraj neupoštevani Not included above																			
D32	Meninge, benigna neoplazma Benign neoplasm of meninges	M	7	0	0	0	0	0	0	0	0	0	0	0	0	2	1	1	1	2
		Ž	16	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	2	11
D33	CŽS, benigna neoplazma Benign neoplasm of brain and other parts of CNS	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
D43	CŽS, neopredeljeno CNS, uncertain or unknown	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
D45	Policitemija vera (Prava policitemija) Polycythaemia vera	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
D47	Limfatičo, krvotvorno in sorodno tkivo, neopredeljeno Lymphoid, haematopoietic and related tissue, uncertain or unknown	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2

* Vir: Nacionalni inštitut za javno zdravje
* Source: National Institute of Public Health

Tabela 14: Eno-, tro- in pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2012–2016 po spolu.

Table 14: One-, three- and five-year net survival (with 95% confidence interval) of patients diagnosed with selected cancers in period 2012–2016 by sex.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Eno-letno preživetje (95 % interval zaupanja) One-year survival (95% confidence interval)		Tro-letno preživetje (95 % interval zaupanja) Three-year survival (95% confidence interval)		Pet-letno preživetje (95 % interval zaupanja) Five-year survival (95% confidence interval)	
C00–C96 brez C44**	Vse lokacije All sites	M+Ž	73,7	73,3–74,1	62,1	61,7–62,6	58,0	57,5–58,5
		M	72,0	71,5–72,6	59,9	59,3–60,6	56,3	55,5–57,0
		Ž	75,8	75,2–76,3	64,8	64,1–65,4	60,1	59,4–60,9
C00–C14	Usta in žrelo Mouth and pharynx	M	72,3	69,9–74,8	51,0	48,3–54,0	43,7	40,7–46,9
		Ž	85,0	81,3–88,9	72,5	67,6–77,9	65,9	59,0–73,6
C15	Požiralnik Oesophagus	M	41,2	36,3–46,8	14,7	11,3–19,2	10,5	7,4–14,8
		Ž	39,0	29,4–51,7	13,7	7,7–24,2	14,2	8,0–25,1
C16	Želodec Stomach	M	52,9	50,2–55,7	34,6	32,0–37,5	31,6	28,7–34,7
		Ž	48,6	45,2–52,2	34,2	30,9–37,8	30,7	27,2–34,7
C18	Debelo črevo Colon	M	79,7	77,9–81,5	67,3	65,1–69,6	62,0	59,2–64,8
		Ž	75,2	73,2–77,4	64,0	61,5–66,5	61,0	58,1–64,1
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	85,0	83,2–86,8	70,6	68,2–73,2	66,2	63,2–69,4
		Ž	79,0	76,4–81,8	64,3	61,0–67,9	57,7	53,9–61,9
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	33,0	29,7–36,7	16,6	13,9–19,7	11,7	9,2–14,9
		Ž	31,8	26,5–38,1	12,9	9,3–17,9	8,0	4,8–13,2
C23–C24	Žolčnik in žolčevodi Gallbladder and billiary tract	M	36,0	31,5–41,1	18,6	15,0–23,1	14,7	11,2–19,3
		Ž	30,5	26,7–34,9	16,3	13,2–20,1	13,6	10,5–17,7
C25	Trebušna slinavka Pancreas	M	22,1	19,6–24,9	7,4	5,8–9,3	4,8	3,4–6,7
		Ž	23,8	21,1–26,8	9,1	7,4–11,3	6,0	4,5–8,1
C32	Grlo Larynx	M	86,3	82,8–90,0	69,8	65,0–75,0	62,3	56,4–68,7
		Ž	*		*		*	
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	40,7	39,2–42,2	20,0	18,8–21,3	15,4	14,2–16,8
		Ž	49,6	47,5–51,7	28,3	26,5–30,3	22,0	20,2–24,1
C43	Maligni melanom kože Malignant melanoma of skin	M	97,9	96,7–99,1	91,9	89,7–94,1	90,5	87,5–93,7
		Ž	97,8	96,6–98,9	93,7	91,7–95,8	91,0	88,2–93,9
C44	Druge maligne neoplazme kože Skin, other malignomas	M	**		**		**	
		Ž	**		**		**	
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	78,6	72,1–85,7	61,8	53,8–70,8	57,2	48,2–67,8
		Ž	79,4	74,0–85,2	60,9	54,3–68,4	53,8	46,6–62,1
C50	Dojka Breast	M	*		*		*	
		Ž	97,0	96,4–97,5	92,3	91,4–93,2	87,7	86,4–89,0
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–
		Ž	86,3	83,4–89,2	73,4	69,7–77,3	68,9	64,5–73,7
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–
		Ž	92,2	90,8–93,7	84,3	82,3–86,5	80,8	78,2–83,6
C56	Jajčnik Ovary	M	–	–	–	–	–	–
		Ž	75,0	71,9–78,2	52,5	48,9–56,3	40,2	36,5–44,3
C61	Prostata Prostate	M	96,9	96,3–97,5	93,8	92,8–94,7	92,8	91,5–94,2
		Ž	–	–	–	–	–	–
C62	Modo Testis	M	98,6	97,5–99,6	98,2	96,9–99,5	97,5	95,8–99,2
		Ž	–	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	M	78,6	76,2–81,2	68,8	65,8–71,9	64,9	61,4–68,7
		Ž	78,5	75,2–81,9	71,0	67,1–75,2	69,7	65,2–74,5
C67	Sečni mehur Bladder	M	74,8	72,2–77,5	61,4	58,2–64,8	55,7	51,6–60,0
		Ž	69,8	65,4–74,5	52,9	47,8–58,4	44,4	38,4–51,4
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	48,1	43,7–53,0	23,8	20,2–28,1	19,9	16,3–24,2
		Ž	41,8	36,8–47,4	22,2	18,2–27,1	19,1	15,2–24,1
C73	Ščitnica Thyroid gland	M	93,5	89,9–97,3	90,3	85,6–95,4	90,6	85,2–96,4
		Ž	96,7	95,3–98,2	95,9	94,0–97,9	95,6	93,1–98,1
C81	Hodgkinova bolezen Hodgkin's disease	M	92,8	88,1–97,7	85,8	79,2–92,8	82,0	74,1–90,7
		Ž	92,2	87,3–97,4	90,0	83,7–96,7	87,8	80,3–96,0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	77,3	74,6–80,1	69,3	66,1–72,7	66,7	62,9–70,8
		Ž	75,9	73,2–78,8	65,5	62,3–69,0	61,5	57,7–65,4
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	72,1	67,3–77,4	55,6	50,0–62,0	39,2	32,7–46,9
		Ž	73,4	68,4–78,8	53,8	47,9–60,5	44,1	37,6–51,7
C91–C95	Levkemije Leukaemias	M	64,4	61,1–67,9	53,7	50,0–57,6	48,0	43,9–52,6
		Ž	68,1	64,4–71,9	58,0	53,9–62,4	50,3	45,3–56,0

* Število v analizo vključenih bolnikov je manjše od 15 povprečno letno

* Average number of patients included in the analysis is less than 15 yearly

** Preživetje bolnikov z nemelanomskim kožnim rakom se ne razlikuje v primerjavi s splošno populacijo

** Survival of patients with non-melanoma skin cancer does not differ in comparison with the general population

IZBOR PUBLIKACIJ, ki so jih sodelavci Epidemiologije in Registra raka objavili v zadnjih petih letih (tudi v sodelovanju z drugimi raziskovalci)

SELECTED PUBLICATIONS, published by the members of Epidemiology and Cancer Registry in the last five years (also in cooperation with other researchers)

2014

- Arnold M, Holterhues C, Hollestein LM, Coebergh JW, Nijsten T, Primic-Žakelj M, et al. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. J Eur Acad Dermatol Venereol 2014; 28: 1170–8.
- Gutnik H, Matišć JP, Primic-Žakelj M, Strojan Fležar M. Microinvasive cervical squamous cell carcinoma in Slovenia during the period 2001–2007. Radiol Oncol 2014; 48: 282–8.
- Ivanuš U, Primic-Žakelj M. Učinkovitost triažnega testa HPV pri ženskah s presejalno diagnozo APC-N in rezultati triažnega testiranja na HPV v 2013. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 45–52.
- Ivanuš U, Primic-Žakelj M. Obravnava žensk z indikacijo za triažni test HPV. In: Smrkolj Š, ed. Obnovitveni kolposkopski tečaj. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2014: 48–69.
- Jarm K, Ivanuš U, Krajc M, Primic-Žakelj M. Državna presejalna programa za raka materničnega vratu in dojke. In: Grmek-Košnik I, Hvalič Touzery S, Skela-Savič B, eds. Kronične bolezni sodobne družbe: od zgodnjega odkrivanja do paliativne oskrbe: zbornik prispevkov z recenzijo. Jesenice: Fakulteta za zdravstvo, 2014: 99–106.
- Kadivec M, Krajc M, Hertl K, Jarm K, Primic-Žakelj M, Šval C. Državni presejalni program za raka dojke Dora - program zgodnjega odkrivanja raka dojke = Slovenian breast cancer screening programme Dora - programme for early breast cancer detection. In: Završnik J, ed. Bolezni dojke: [simpozij, Maribor 2014]. Maribor: Zdravstveni dom dr. Adolfa Drolca, 2014: 221–8.
- Kloboves-Prevodnik V, Uhan Kastelic S, Pohar-Marinšek Ž, Žagar T, Ivanuš U. Atipične žlezne celice, neopredeljene: rezultati revizije citoloških preparatov in tveganje CIN2+. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 64–72.
- Krajc M, Zadnik V, Novaković S, Stegel V, Teugels E, Bešić N et al. Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening. Clinical genetics 2014; 85: 59–63.
- Pogačnik A, Kloboves-Prevodnik V, Nolde N, Novaković S, Ivanuš U, Primic-Žakelj M, et al. Nove triažne metode pri HPV-pozitivnih ženskah. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 36–40.
- Primic-Žakelj M. Current situation and prospects of cancer in the Balkan area: what can we do together?. In: Book of abstracts = international scientific conference. Tirana: Academy of Sciences of Albania, 2014: 6–7.
- Primic-Žakelj M, Ivanuš U. Državni presejalni program za raka materničnega vratu Zora: zgodba o uspehu. In: Petrovec M, Golle A, eds. Okužbe spolovil in spolno prenosljive bolezni: [zbornik predavanj], (Medicinski razgledi, ISSN 0353-3484, Supplement, letn. 53, 6). Ljubljana: Medicinski razgledi, 2014: 249–55.

– Primic-Žakelj M, Ivanuš U. Pregled dela in novosti v DP ZORA - 2013/2014. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 7–11.
– Primic-Žakelj M, Ivanuš U. Presejalni programi za raka materničnega vratu - trenutno stanje in prihodnost. In: Smrkolj Š, ed. Obnovitveni kolposkopski tečaj. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2014: 27–36.
– Primic-Žakelj M, Jarm K, Žagar T. Epidemiološke značilnosti raka prebavil v Sloveniji v zadnjem desetletju. In: Ivanecz A, Krebs B, Potrč S, eds. Simpozij z mednarodno udeležbo na temo Smernice in problemi zdravljenja malignomov želodca, trebušne slinavke in debelega črevesa ter danke. Zbornik predavanj. Maribor: Oddelek za abdominalno in splošno kirurgijo, Kirurška klinika UKC, 2014: 1–4.
– Primic-Žakelj M, Žagar T, Jarm K. Zbolevnost za rakom dojke in preživetje = Breast cancer incidence and survival rate. In: Završnik J, ed. Bolezni dojke [simpozij, Maribor 2014]. Maribor: Zdravstveni dom dr. Adolfa Drolca, 2014: 115–24.
– Primic-Žakelj M, Žagar T, Zadnik V. Epidemiološke značilnosti malignomov krvotvornega in limfatičnega tkiva. In: Primic-Žakelj M ed. XXII. seminar In memoriam dr. Dušana Reje. Malignomi krvotvornega in limfatičnega tkiva. Ljubljana: Zveza slovenskih društev za boj proti raku, 2014: 7–34.
– Primic-Žakelj M, Žagar T, Zadnik V, Škrlec F. Linkage of the Slovenian Cancer Registry data to other state databases and to screening registries. In: European Union and European Network of Cancer Registries (ENCR). Towards a harmonised cancer information system in Europe, 2014: 71.
– Strojan P, Zadnik V, Šifrer R, Lanišnik B, Didanovič V, Jereb S, et al. Incidence trends in head and neck squamous cell carcinoma in Slovenia, 1983–2009: role of human papillomavirus infection. Eur Arch Otorhinolaryngol 2014: 1–7.
– Šeruga B, Zadnik V, Grašič-Kuhar C, Marinko T, Čufer T, Zakotnik B, et al. Association of aromatase inhibitors with coronary heart disease in women with early breast cancer. Cancer investigation 2014; 32: 99–104.
– Škulj P, Babuder B, Zadnik V. Slora - Slovenija in rak, interaktivni spletni portal = Slora - Slovenia and cancer, an interactive web portal. In: Štemberger Kolnik T, ed. Zdravstvena nega v javnem zdravju = Nursing in public health : druga znanstvena konferenca z mednarodno udeležbo, Izola, 31. Januar 2014 = Second scientific conference with international participation. Zbornik prispevkov = Proceedings. Koper: Založba Univerze na Primorskem, 2014: 67–73.
– Zadnik V. Rak debelega črevesa in danke: epidemiološke značilnosti in nevarnostni dejavniki. In: Ocvirk J, ed. Sodobna obravnava raka debelega črevesa in danke. Ljubljana: Europacolon Slovenija,združenje za boj proti raku debelega črevesa in danke, 2014: 22–4.
– Zadnik V, Žagar T, Primic-Žakelj M. Nizkofrekvenčna polja in rak. In: Gajšek P, ed. Strokovni seminar Daljnovodi in zdravje, Ljubljana, 25. 9. 2014. Zbornik predavanj. Ljubljana: Inštitut za neionizirana sevanja, 2014: 19–21.
– Zanetti R, Sacchetto L, Calvia M, Bordoni A, Hakulinen T, Primic-Žakelj M, et al. Economic evaluation of cancer registration in Europe. J Registry Manag 2014; 41: 31–7.
– Žagar T, Primic-Žakelj M, Zadnik V, Škrlec F, Jarm K. Completeness of the cancer registry of the Republic of Slovenia using qualitative methods. In: International Association of Cancer Registries (IACR), 36th annual conference 2014. Ottawa, Canada, 26-28 June 2014. Ottawa: The National Cancer Institute, 2014: 109.

2015

- Allemani C, Weir HK, Carreira H, Harewood R, Primic-Žakelj M, Žagar T, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015; 385: 977-1010.
- Borras JM, Barton M, Grau C, Corral J, Verhoeven R, Primic-Žakelj M, et al. The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project. Radiother Oncol 2015; 116: 45-50.

- Borras JM, Lievens Y, Dunscombe P, Coffey M, Malicki J, Primic-Žakelj M, et al. The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. Radiother Oncol 2015; 116: 38-44.
- Ivanuš U, Primic-Žakelj M. Test HPV doma za neodzivnice programa Zora: preliminarni rezultati. In: Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj, 6 izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 6 november 2015. Ljubljana: Onkološki inštitut Ljubljana; 2015: 49-55.
- Ivanuš U, Primic-Žakelj M. Vloga triažnega testa HPV in kolposkopije v programu ZORA. In: Smrkolj Š, ed. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD in Onkološki inštitut, 2015: 35-52.
- Ivanuš U, Učakar V. Okužbam pripisljivi raki in preprečevanje s cepljenjem. In: Novaković S, Zakotnik B, Žgajnar J, eds. Preprečevanje raka: dejstva, ki jih mora vedeti zdravstveni delavec: zbornik. Ljubljana: Kancerološko združenje Slovenskega zdravniškega društva: Onkološki inštitut, 2015: 89-102.
- Jarm K, Krajc M, Primic-Žakelj M, Šval C, Purić F, Kadivec M, et al. Presejanje za raka dojk: program Dora. In: Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj, 6 izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 6 november 2015. Ljubljana: Onkološki inštitut Ljubljana, 2015: 70-5.
- Karalexi MA, Papathoma P, Thomopoulos TP, Ryzhov A, Zborovskaya A, Žagar T, et al. Childhood central nervous system tumour mortality and survival in Southern and Eastern Europe (1983-2014): Gaps persist across 14 cancer registries. Eur J Cancer 2015; 51: 2665-77.
- Krajc M, Primic-Žakelj M. Dojenje, hormonska zdravila in drugi dejavniki, vpleteni v nastanek raka dojk. In: Primic-Žakelj M, ed. Kaj sporoča prenovljeni evropski kodeks proti raku. Ljubljana: Zveza slovenskih društev za boj proti raku, 2015: 77-86.
- Papathoma P, Thomopoulos TP, Karalexi MA, Ryzhov A, Zborovskaya A, Žagar T, et al. Childhood central nervous system tumours: Incidence and time trends in 13 Southern and Eastern European cancer registries. Eur J Cancer 2015; 51: 1444-55.
- Primic-Žakelj M. Redke rakave bolezni. In: Modic K, ed. Redke bolezni: 28 februar 2015. Ljubljana: Društvo BKB, 2015: 35-40.
- Primic-Žakelj M. Kaj je evropski kodeks proti raku. In: Primic-Žakelj M, ed. Kaj sporoča prenovljeni evropski kodeks proti raku. Ljubljana: Zveza slovenskih društev za boj proti raku, 2015: 7-9.
- Primic-Žakelj M, Čeh F. Najpogostejši raki pri moških2015. Zveza slovenskih društev za boj proti raku, 2015.
- Primic-Žakelj M, Čeh F. 12 nasvetov proti raku : Evropski kodeks proti raku 2014-2015. Zveza slovenskih društev za boj proti raku, 2015.
- Primic-Žakelj M, Ivanuš U. Pregled dela in novosti v DP Zora - 2014/2015. In: Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj, 6 izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 6 november 2015. Ljubljana: Onkološki inštitut Ljubljana, 2015: 7-10.
- Primic-Žakelj M, Žagar T. Preprečevanje raka v ustni votlini. In: Artnik B, Premik M, Jovanovič K, eds. Zbornik člankov in izvlečkov, Kongres ob 40-letnici strokovnih srečanj stomatologov Slovenije [tudi] 40 srečanje stomatologov Slovenije "Iz prakse za prakso" in pridruženi 10 Cvahtetovi dnevi javnega zdravja "Skrb za ustno zdravje", Portorož, 4 do 6 junij 2015. Ljubljana: Stomatološka sekcija Slovenskega zdravniškega društva, 2015: 22-9.
- Rems M, Jarm K, Zadnik V, Primic-Žakelj M. Lokalna ponovitev bolezni pri bolnikih, operiranih zaradi nemetastatskega raka danke, zbolelih v obdobju 2003-2005 = Local recurence of rectal cancer in patients with nonmetastatic disease, diagnosed in 2003-2005. Zdrav vest 2015; 84: 277-86.
- Sant M, Chirlaque Lopez MD, Agresti R, Sanchez Perez MJ, Holleczek B, Primic-Žakelj M, et al. Survival of women with cancers of breast and genital organs in Europe 1999-2007: results of the EUROCARE-5 study. Eur J Cancer 2015; 51: 2191–205.
- Sant M, Minicozzi P, Primic-Zakelj M, Otter R, Francisci S, et al. Cancer survival in Europe, 2000-2007: Doing better, feeling worse? Eur J Cancer 2015; 51: 2101–3.
- Schuz J, Espina C, Villain P, Herrero R, Leon ME, Primic-Žakelj M, et al. European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer epidemiol 2015; 39 Suppl 1: S1-10.

- Strojan P, Zadnik V, Sifrer R, Lanisnik B, Didanovic V, Jereb S, et al. Incidence trends in head and neck squamous cell carcinoma in Slovenia, 1983-2009: role of human papillomavirus infection. Eur Arch Otorhinolaryngol 2015; 272: 3805-14.
- Zadnik V. Epidemiologija raka jajčnika. In: Smrkolj S, Zobec Logar H, Šešek M, eds. Rak jajčnikov: zbornik. Ljubljana: Slovensko zdravniško društvo, Združenje za radioterapijo in onkologijo, 2015: 6-9.
- Zadnik V. Epidemiološki trendi hormonsko odvisnih rakov = Epidemiological trends of hormon related-cancers. In: Černe K, ed. Kemijski povzročitelji hormonskih motenj od molekule do človeka = Endocrine disrupting chemicals - from molecule to man. Ljubljana: Slovensko toksikološko društvo, 2015: 22.
- Zanetti R, Schmidtmann I, Sacchetto L, Binder-Foucard F, Bordoni A, Zadnik V, et al. Completeness and timeliness: Cancer registries could/should improve their performance. European journal of cancer. 2015; 51: 1091-8.
- Zwitter M, Žagar T. Zdravljenje pljučnega raka: perspektiva dveh desetletij. In: Kovač V, Rajer M, eds. Prva šola pljučnega raka. Ljubljana: Slovensko zdravniško društvo, 2015: 116-20.

2016

- Avbelj M, Zupanc D, Žagar T, Kotnik P, Jakil M, Pirnat E, et al. Rak ščitnice pri otrocih. In: Bešič N, Zaletel K, eds. Dan ščitnice. Ljubljana: Slovenska sekcija za onkološko kirurgijo SZD, 2016: 27.
- Barbaric J, Sekerija M, Agius D, Coza D, Dimitrova N, Primic Žakelj M, et al. Disparities in melanoma incidence and mortality in South-Eastern Europe: Increasing incidence and divergent mortality patterns. Is progress around the corner? Eur J Cancer. 2016; 55: 47-55.
- de Leede EM, Sibinga Mulder BG, Bastiaannet E, Poston GJ, Sahora K, Primic Žakelj M, et al. Common variables in European pancreatic cancer registries: The introduction of the EURECCA pancreatic cancer project. Eur J Surg Oncol. 2016; 42: 1414-9.
- Deandrea S, Molina-Barcelo A, Uluturk A, Primic Žakelj M, Jarm K, Krajc M, et al. Presence, characteristics and equity of access to breast cancer screening programmes in 27 European countries in 2010 and 2014. Results from an international survey. Prev Med. 2016; 91: 250-63.
- Ivanuš U, Primic Žakelj M, Jerman T, Florjančič M, Kuster M, Takac I, et al. HPV self-sampling response rate in randomised study among Slovenian non-responders to the organised cervical cancer screening program. In: EUROGIN 2016 abstracts: part I - main conference program. Salzburg: EUROGIN, 2016: 333-4.
- Ivanuš U, Učakar V. Okužbam pripisljivi raki: novi pristopi v primarni in sekundarni preventivi. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 106-7.
- Karalexi MA, Baka M, Ryzhov A, Zborovskaya A, Dimitrova N, Žagar T, et al. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America. Eur J Cancer. 2016; 67: 183-90.
- Karalexi MA, Georgakis MK, Dessypris N, Ryzhov A, Zborovskaya A, Žagar T, et al. Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data. Hematol Oncol. Epub ahead of print.
- Kokalj M, Zadnik V, Ančin A, Plavc G, Didanović V, Šifrer R, et al. Ploščatocelični karcinom neznanega izvora z zasevki v bezgavkah na vratu: vloga elektivnega obsevanja sluznice v področju glave in vratu = Squamous cell carcinoma of unknown primary tumor metastatic to neck nodes : the role of elective irradiation of mucosal sites. Med Razgl. 2016; 55(S1): 297-301.
- Krajc M, Zadnik V. Razvoj in implementacija orodja za določanje individualne ogroženosti z rakom dojk v slovenski populaciji. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 116-7.

- Mandelj N, Zadnik V. Breme želodčnega raka v Sloveniji z oceno pripisljivih deležev zaradi prekomernega vnosa soli ter prenizkega vnosa sadja in zelenjave. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 119-20.
- Primic Žakelj M. Prenovljen evropski kodeks proti raku = New edition of European code against cancer. Gastroenterolog. 2016; 20(S2): 5-11.
- Primic Žakelj M, Ivanuš U. Zgodnje odkrivanje raka materničnega vratu - program Zora = Screening for cervical cancer in Slovenia - programme Zora. Gastroenterolog. 2016; 20(S2): 72-7.
- Primic Žakelj M, Ivanuš U. Presejalni programi za raka. In: Novaković S, editor. Razvojni trendi v onkologiji - onkologija čez desetletje: izbrana poglavja in državni program obvladovanja raka 2017-2021: zbornik. Ljubljana: Kancerološko združenje Slovenskega zdravniškega društva: Onkološki inštitut; 2016. p. 14-23.
- Primic Žakelj M, Jarm K, Novak Mlakar D, Ivanuš U. Presejanje za raka: krhko ravnovesje med koristmi in škodo. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 110-1.
- Primic Žakelj M, Žagar T. Epidemiologija raka dojk. In: Borštnar S, Duratović Konjević A, Grašič-Kuhar C, eds. Zbornik prispevkov, Šola raka dojk. Ljubljana: Združenje za senologijo, SZD, 2016: 6-11.
- Strojan P, Kokalj M, Zadnik V, Anicin A, Plavc G, Didanovic V, et al. Squamous cell carcinoma of unknown primary tumor metastatic to neck nodes: role of elective irradiation. Eur Arch Otorhinolaryngol. 2016; 273: 4561-9.
- Zadnik V. Onkološka epidemiologija čez desetletje. In: Novaković S, editor. Razvojni trendi v onkologiji - onkologija čez desetletje: izbrana poglavja in državni program obvladovanja raka 2017-2021: zbornik. Ljubljana: Kancerološko združenje Slovenskega zdravniškega društva: Onkološki inštitut, 2016: 9-13.
- Zadnik V. Raziskovanje vpliva okolja na zbolevanje za rakom in ocenjevanje tveganja. In: Belovič B, Čemažar M, Perharič L, Primic Žakelj M, Zadnik V, Zdešar A, eds. Kemikalije v okolju in rak. Ljubljana: Zveza slovenskih društev za boj proti raku, 2016: 7-18.
- Zadnik V, Ivanuš U. Epidemiologija raka materničnega telesa. In: Merlo S, Smrkolj Š, Šegedin B, eds. Rak materničnega telesa: zbornik. Ljubljana: Združenje za radioterapijo in onkologijo SZD: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD, 2016: 15-9.
- Zadnik V, Krajc M. Epidemiological trends of hormone-related cancers in Slovenia. Arh Hig Rada Toksikol. 2016; 67: 83-92.
- Zadnik V, Žagar T, Jarm K, Primic Žakelj M. Time trends and spatial patterns in the mesothelioma incidence in Slovenia, 1961-2013. In: Joining forces for better cancer registration in Europe. Luxembourg: Publication Office of the European Union, 2016: 32.
- Zadnik V, Žagar T, Primic Žakelj M. Linkage to supplementary registration sources: key lessons learned in the last 30 years in Slovenia. In: Benider A, Zanetti R, Siesling S, Bray F, eds. The 38th Annual IACR Conference. Marrakech: IACR, 2016: 63.
- Zadnik V, Žagar T, Primic Žakelj M. Cancer Patients' Survival: Standard Calculation Methods And Some Considerations Regarding Their Interpretation. Zdrav Varst. 2016; 55: 134-41.
- Žagar T, Zadnik V, Jarm K, Ivanuš U, Primic Žakelj M. Redki raki. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 115.

2017

- Bonaventure A, Harewood R, Stiller CA, Gatta G, Primic-Žakelj M, Žagar T et al. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. Lancet Haematol; 2017: 4: e202-17.

- Dimitrova N, Znaor A, Agius D, Eser S, Sekerija M, Primic-Žakelj M, et al. Breast cancer in South-Eastern European countries since 2000: Rising incidence and decreasing mortality at young and middle ages. Eur J Cancer; 2017: 83: 43-55.
- Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Primic-Žakelj M et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. The Lancet Oncology. 2017 Aug;18(8):1022-39. PubMed PMID: 28687376.
- Georgakis MK, Karalexi MA, Kalogirou EI, Ryzhov A, Zborovskaya A, Žagar T et al. Incidence, time trends and survival patterns of childhood pilocytic astrocytomas in Southern-Eastern Europe and SEER, US. J Neurooncol; 2017: 131: 163-75.
- Georgakis MK, Panagopoulou P, Papathoma P, Tragiannidis A, Ryzhov A, Žagar T et al. Central nervous system tumours among adolescents and young adults (15-39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US. Eur J Cancer; 2017: 86: 46-58.
- Georgakis MK, Papathoma P, Ryzhov A, Zivkovic-Perisic S, Eser S, Žagar T et al. Malignant central nervous system tumors among adolescents and young adults (15-39 years old) in 14 Southern-Eastern European registries and the US Surveillance, Epidemiology, and End Results program: Mortality and survival patterns. Cancer; 2017: 123: 4458-71.
- Horvat M, Potočnik U, Repnik K, Kavalar R, Zadnik V, Potrč S et al. Single Nucleotide Polymorphisms in Genes MACC1, RAD18, MMP7 and SDF-1a As Prognostic Factors in Resectable Colorectal Cancer. Radiol Oncol; 2017: 51: 151-9.
- Huang L, Jansen L, Balavarca Y, Molina-Montes E, Primic-Žakelj M, Zadnik V et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut; 2017: Epub ahead of print.
- Karalexi MA, Georgakis MK, Dessypris N, Ryzhov A, Zborovskaya A, Žagar T et al. Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data. Hematol Oncol. 2017; 35: 608-18.
- Matz M, Coleman MP, Carreira H, Salmeron D, Primic-Žakelj M, Žagar T et al. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecol Oncol. 2017; 144: 396-404.
- Matz M, Coleman MP, Sant M, Chirlaque MD, Primic-Žakelj M, Žagar T et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol. 2017; 144: 405-13.
- Perharič L, Martinčič M, Uršič S, Kukec A, Zadnik V, Mazej D et al. Poglobljena ocena tveganja za zdravje otrok zaradi izpostavljenosti arzenu v občini Zagorje ob Savi. Ljubljana: Nacionalni inštitut za javno zdravje; 2017.
- Ponti A, Anttila A, Ronco G, Primic-Žakelj M, Ivanuš U, Jarm K et al. Against cancer: cancer screening in the European Union. Lyon: International Agency for Research on Cancer; 2017.
- Primic-Žakelj M. Program dela Zveze slovenskih društev za boj proti raku v letu 2017. Ljubljana: Zveza slovenskih društev in regijskih društev za boj proti raku; 2017: 34-38.
- Primic-Žakelj M, Ivanuš U, eds. Zbornik predavanj, 7. izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 17. maj 2017. Ljubljana: Onkološki inštitut; 2017.
- Ranfl M, Zadnik V. Epidemiologija rakov glave in vratu v Sloveniji 1983-2012 = Epidemiology of head and neck cancer in Slovenia 1983-2012. Medicinski razgledi 2017; 56: 277-91.
- Rotovnik Kozjek N, Kompan L, Žagar T, Mrevlje Ž. Influence of enteral glutamine on inflammatory and hormonal response in patients with rectal cancer during preoperative radiochemotherapy. Eur J Clin Nutr. 2017; 71: 671-3.
- Skopec B, Škerget M, Žontar D, Zadnik V, Zver S. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients. Wien Klin Wochenschr. 2017; 129: 545-51.
- Velenik V, Šečerov-Ermenc A, But-Hadžić J, Zadnik V. Health-related Quality of Life Assessed by the EORTC QLQ-C30 Questionnaire in the General Slovenian Population. Radiol Oncol.

- Zadnik V. Epidemiologija raka zunanjega spolovila. In: Merlo S, Šegedin B, eds. Rak zunanjega spolovila: zbornik znanstvenih prispevkov. Ljubljana: Združenje za radioterapijo in onkologijo SZD, Sekcija internistične onkologije SZD, Onkološki inštitut; 2017: 10-3.
- Zadnik V. Epidemiologija RDČD: breme raka debelega črevesa in danke. In: Sodobna obravnava raka debelega črevesa in danke: zbornik prezentacij: simpozij za strokovno javnost, 31. marec 2017, Maribor. Maribor: Medicinska fakulteta; 2017: 5-16.
- Zadnik V. Rak in druge zdravstvene posledice kajenja. In: Belović B, Primic-Žakelj M, Zdešar A, eds. Kajenje in zdravje - nikoli končana zgodba. Ljubljana: Zveza slovenskih društev za boj proti raku; 2017: 67-77.
- Zadnik V. Vzpostavitev kliničnega registra melanom Registra raka Republike Slovenije. In: Boc M, Reberšek M, eds. 13. šola malignega melanoma, 10. marec 2017, Ljubljana. Ljubljana: Onkološki inštitut; 2017: 11-2.
- Zadnik V, Primic-Žakelj M, Jarm K, Žagar T. Time trends and spatial patterns in the mesothelioma incidence in Slovenia, 1961-2014. Eur J Cancer Prev. 2017; 26: S191-S6.
- Zadnik V, Primic-Žakelj M, Lokar K, Jarm K, Ivanuš U, Žagar T. Cancer burden in Slovenia with the time trends analysis. Radiol Oncol. 2017; 51: 47-55.
- Zadnik V, Primic-Žakelj M, Žagar T. Cancer survival in children and adolescents in last 50 years in Slovenia. In: Grell 2017. Bruxelles: Belgian Cancer Registry; 2017: 47.
- Zadnik V, Primic-Žakelj M, Žagar T, Škrlec F, Lokar K, Čampa A. Pregled obravnave bolnikov s kožnim melanomom v Sloveniji za incidenčna leta 2011-2016. Ljubljana: Onkološki inštitut, Epidemiologija in register raka, 2017.
- Žagar T, Primic-Žakelj M, Zadnik V. Rare cancers in Slovenia. In: Ensuring quality and use of data from cancer registries in the 21st century. Utrecht: ENCR; 2017: 129.

2018

- Allemani C, Matsuda T, Di Carlo V, Harewood R, Primic Žakelj M, Žagar T, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391: 1023-75.
- Blatnik J, Zadnik V, Artnik B. 30-year time trend of oral cancer in Slovenia, 1985 - 2014. European journal of public health. 2018; 28: Suppl. 4: 395-6.
- Doganis D, Panagopoulou P, Tragiannidis A, Georgakis MK, Moschovi M, Žagar T, et al. Childhood nephroblastoma in Southern and Eastern Europe and the US: Incidence variations and temporal trends by human development index. Cancer epidemiology. 2018; 54: 75-81.
- Doganis D, Panagopoulou P, Tragiannidis A, Vichos T, Moschovi M, Žagar T, et al. Survival and mortality rates of Wilms tumour in Southern and Eastern European countries: Socioeconomic differentials compared with the United States of America. European journal of cancer. 2018; 101: 38-46.
- Georgakis MK, Dessypris N, Baka M, Moschovi M, Papadakis V, Žagar T, et al. Neuroblastoma among children in Southern and Eastern European cancer registries: Variations in incidence and temporal trends compared to US. International journal of cancer. 2018; 142: 1977-85.
- Grašič Kuhar C, Strojan P, Zadnik V, Zakotnik B. Importance of magnesium sulfate supplementation in the prevention of hypomagnesemia and hypocalcemia during chemoradiation in head and neck cancer. Journal of trace elements in medicine and biology. 2018; 50: 327-31.
- Horvat M, Zadnik V, Južnič Šetina T, Boltežar L, Pahole Goličnik J, Novaković S, et al. Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone. Oncology letters. 2018; 15: 3602-9.
- Huang L, Jansen L, Balavarca Y, Babaei M, Primic Žakelj M, Zadnik V, et al. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study. BMC Med. 2018; 16: 125.

- Huang L, Jansen L, Balavarca Y, van der Geest L, Primic Žakelj M, Zadnik V, et al. Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014: a large international population-based study. International journal of cancer. 2018; 143: 3227-39.
- Moltara ME, Novaković S, Boc M, Bucic M, Reberšek M, Zadnik V, et al. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma. Radiol Oncol. 2018; 52: 289-95.
- Panagopoulou P, Georgakis MK, Baka M, Moschovi M, Papadakis V, Žagar t, et al. Persisting inequalities in survival patterns of childhood neuroblastoma in Southern and Eastern Europe and the effect of socio-economic development compared with those of the US. European journal of cancer. 2018; 96: 44-53.
- Perharič L, Kukec A, Martinčič M, Šlejkovec Z, Mazej D, Uršič S, Zadnik V. Risk assessment for children health from environmental exposure to inorganic arsenic. European journal of public health. 2018; 28: Suppl. 4: 109.
- Primic-Žakelj M, Zadnik V, Žagar T. Register raka Republike Slovenije. Arhivi, 2018; 1: 171-83.
- Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Žagar T, et al. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocrine-related cancer. 2018; 25: 607-18.
- Sacchetto L, Zanetti R, Comber H, Bouchardy C, Brewster DH, Zadnik V, et al. Trends in incidence of thick, thin and in situ melanoma in Europe. European journal of cancer. 2018; 92: 108-18.
- Škerget M, Skopec B, Zadnik V, Žontar D, Podgornik H, Reberšek K, et al. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction. Acta haematologica. 2018; 139: 228-34.
- Tomšič S, Zadnik V. Epidemiologija rakov, povezanih s čezmernim pitjem alkoholnih pijač. In: Belović B, Primic Žakelj M, Zdešar A, eds. Alkohol in rak. Ljubljana: Zveza slovenskih društev za boj proti raku. 2018, str. 99-112.
- Tomšič S, Zadnik V, Žagar T. Epidemiologija raka trebušne slinavke. In: Ivanecz A, Krebs B, eds. Simpozij z mednarodno udeležbo na temo Rak trebušne slinavke, rak debelega črevesa in danke, jetrni zasevki. Maribor: Oddelek za abdominalno in splošno kirurgijo, Kirurška klinika UKC. 2018, str. 3-11.
- Weberpals J, Jansen L, Silversmit G, Verbeeck J, van der Geest L, Zadnik V, et al. Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients. Clin Epidemiol. 2018; 10: 1109-25.
- Zadnik V. Monitoring inequalities in the cancer burden in Europe. European journal of public health. 2018; 28: Suppl. 4: 212-3.
- Zadnik V, Guillaume E, Lokar K, Žagar T, Primic Žakelj M, Launoy G, et al. Slovenian Version of The European Deprivation Index at Municipal Level. Zdravstveno varstvo. 2018; 57: 47-54.
- Zadnik V, Krajc M. Razvoj in implementacija orodja za določanje individualne ogroženosti z rakom dojk v slovenski populaciji. Onkologija. 2018; 2: 6-10.
- Zadnik V, Lokar K. Register raka Republike Slovenije kot podlaga za spremljanje bremena ginekoloških rakov. In: Istenič A. Ženske in ginekološki raki. Sekcija medicinskih sester in zdravstvenih tehnikov v onkologiji pri Zbornici zdravstvene in babiške nege - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije. 2018, str. 9-17.
- Zadnik V, Lokar K, Tomšič S, Škrlec F, Žagar T. Estimating fractions of cancers attributable to socioeconomic inequalities in Slovenia. In: Data linkage and cancer registries. Ispra: European Commission. 2018, str. 35.
- Zadnik V, Lokar K, Žagar T. Bayesian spatial modelling of socioeconomic environment and cancer incidence in Slovenia. In: IACR 2018: 40th annual scientific conference. Arequipa: IACR. 2018, str. 37.
- Zadnik V, Žagar T. Population-based cancer registries: monitoring the cancer burden within and between countries: a case of Slovenian Cancer Registry. European journal of public health. 2018; 28: Suppl. 4: 213.

POROČILO RR št. 58
REPORT No. 58
Ljubljana 2019
ISSN 1318-5845